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Spinal Muscular Atrophy (SMA) is a childhood form of motor neuron disease (MND). 
It is monogenic, caused by loss of Smn1. Although Smn is ubiquitously expressed in 
all cells, and acts in a housekeeping function to correctly assemble the spliceosome, 
motor neurons are specifically vulnerable to loss of Smn. This leads to degeneration 
of the motor neurons. Mounting evidence shows that this degeneration starts at the 
neuromuscular junction and then proceeds to the motor axon. Studies have identified 
chondrolectin as a downstream gene adversely affected by the Smn deficiency. 
Chondrolectin is mis-spliced pre-symptomatically in mouse models of SMA. The 
protein is required for motor axon outgrowth in zebrafish, and over-expression of 
chondrolectin partially rescues smn knockdown.  
In this project, I generated a CRISPR/Cas9 knockout of chondrolectin in the zebrafish. 
The mutant is homozygous viable and has no gross morphological defects, but the 
primary motor axons phenocopy previously published morpholino knockdown. The 
axons are stalled at a choice point called the horizontal myoseptum, which is known 
to be rich in ECM proteins such as collagens. Using both acute manipulation and a 
stable transgenic line, I demonstrate that only full-length chondrolectin is able to 
rescue the axon length, and loss of any of its protein domains leaves the protein non-
functional. From this, we hypothesise a mechanism of action for this protein where it 
binds an ECM molecule on the axon surface and transduces a signal via 
phosphorylation of its intracellular domain. We suggest the binding partner for 
chondrolectin to be collagenXIXa1.  
SMA has been linked to synaptic defects, therefore, I analysed the synaptic 
compartments of the axons in the chondrolectin mutant at embryonic and larval 
stages. At embryonic stages, the pre-synaptic compartment is enlarged around the 
horizontal myoseptum in the mutant compared to wild-types, and fully rescued in a 
stable chondrolectin-FLAG line. When the secondary motor neurons have also 
extended axons to innervate the myotome, there are fewer synaptic puncta in the 
mutant compared to wild-type. This synapse phenotype is partially rescued in the 




Due to the stereotypical phenotype of the chondrolectin mutant, and its relationship 
with SMA, we developed a drug screening protocol to discover molecules that improve 
axon growth. We identified two hits after screening a 40-compound library. 
Developing this protocol allows refinement of potentially useful compounds   from 
larger libraries to use in other models of SMA. 
Overall, this project offers new insight into the mechanism and function of 
chondrolectin, a gene linked to SMA. Novel findings include the domain analysis 
demonstrating that all protein domains are required for its function in zebrafish. We 
also found that loss of chondrolectin leads to synaptic defects, with embryonic 
synapse puncta enlarged in the mutant, and a loss of synaptic puncta in the larval 
stage. Finally, we have demonstrated potential translational uses for this mutant by 
























Motor neuron disease is an umbrella term for multiple diseases related by their effect 
on the motor neurons (the nerve cells which carry movement signals from the brain 
and spinal cord to the muscle). When these cells are damaged in the course of the 
disease, it leads to an inability to move, swallow, or talk, as the movement signals can 
no longer travel to the muscle. Spinal Muscular Atrophy (SMA) is a form of motor 
neuron disease which mostly affects children, and its most severe form is fatal by the 
age of 2. As well as studying the disease directly, it is also vital to understand how 
these motor neuron cells function normally, and how they develop. During my PhD 
project I studied the development of motor neurons, and specifically the axon portion 
of these cells. An axon is the long ‘cable’ part of the neuron which extends out of the 
spinal cord and forms connections onto the muscle. However, due to the difficulty in 
observing these cells directly in humans, I used embryonic zebrafish as my 
experimental subjects instead. These small zebrafish develop motor neurons and 
axons very rapidly and are transparent, so their spinal cords and nerve growth can be 
imaged under a microscope. It is also possible to test drugs on them easily, as they 
can be dissolved into the water that the embryos develop in.  
My PhD project focused specifically on a gene called chondrolectin. Very little is 
known about how this gene affects the cell’s function, but it has previously been 
shown that it is required for the motor neurons to extend from the spinal cord properly. 
It has also been linked to the disease Spinal Muscular Atrophy and is disrupted in 
mice that have SMA. I created a zebrafish mutant that did not have a functional 
chondrolectin gene, and further investigated the effect this had on the motor neurons. 
As well as affecting the growth of the axons, the mutant also failed to develop proper 
synapses (the junction points between the nerve and the muscle). These changes 
affect the behaviour of the zebrafish, and the mutant cannot turn away from touch to 
escape as well as a normal zebrafish would. 
As previously mentioned, the zebrafish is an excellent animal to use in biological 
studies as it can be easily treated with drugs and the effects observed. As part of my 
project, I designed a screening tool to test with 40 drugs, looking for an improvement 
in the nerve growth. I found one drug which improved the growth of the motor axons 
in the chondrolectin mutant zebrafish. We hope to take this drug forward into other 
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models of SMA such as human cells or mice to discover if they can alleviate the 
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Chapter One - General introduction 
1.1 – Zebrafish as a model organism 
1.1.1 – Zebrafish in biological and biomedical research 
 
Zebrafish (Danio rerio) have been used as a model organism in biomedical studies 
for approximately 30 years. Although mammalian systems such as mice and rats have 
traditionally been the most widely used in research, zebrafish are increasingly 
important. Their large clutch sizes and ex utero development of embryos give them a 
sampling advantage over rodents. The have modest husbandry requirements, and 
the adults become sexually mature at 3 months of age (Kimmel, 1989; Lawrence, 
2007). The zebrafish has been classically used as a developmental model due to the 
advantages its embryonic and larval form offers, toxicological studies due to its 
aqueous environment, and large genetic screens (Lele and Krone, 1996; Lawson and 
Wolfe, 2011). 
Zebrafish are excellent models for neuronal development. The developmental stages 
of the zebrafish have been well characterised, and zebrafish rapidly develop, with 
motor neuron differentiation starting just 9 hours post-fertilisation (hpf) (Myers, Eisen 
and Westerfield, 1986; Kimmel et al., 1995). The motor system is extremely well 
characterised, with individually identified axons with stereotyped pathfinding 
(Westerfield and Eisen, 1988; Pike, Melancon and Eisen, 1992; Lewis and Eisen, 
2003). The embryos are optically transparent during their development, meaning that 
zebrafish larvae are incredibly easy to image in wholemount preparations. 
Furthermore, fluorescent cell-reporter transgenic lines are widely available for a 
variety of cell types, allowing live time-lapse imaging. 
Their genetic tractability make zebrafish an excellent biomedical model. Multiple 
models of motor neuron diseases (MNDs) are available (Babin, Goizet and Raldúa, 
2014; Patten et al., 2014). This includes Amyotrophic Lateral Sclerosis (ALS), with 
mutant SOD1 over-expression (Lemmens et al., 2007; Ramesh et al., 2010), 
C9ORF72 knockdown (Ciura et al., 2013), and Spinal Muscular Atrophy (McWhorter 






1.1.2 – Mutagenesis, transgenesis, and gene expression 
manipulations in zebrafish 
 
Zebrafish are teleosts (bony fish, and thus vertebrates) and have an almost fully 
annotated genome, with 70% of human genes having a direct orthologue in the 
zebrafish (Howe et al., 2013). Their genetic tractability and the wide range of mutants 
generated is one of the key features of the zebrafish system. The earliest papers 
published using the zebrafish focus on generating mutants, using γ-radiation to 
mutagenise fertilised eggs (Walker and Streisinger, 1983), and breeding strategies to 
generate homozygous mutants (Streisinger et al., 1981). Large-scale forward 
genetics screens, such as the Tübingen ENU screen from 1993-1996, identified 
mutants for multiple genes involved in development (Mullins et al., 1994; Driever et 
al., 1996; Furutani-Seiki et al., 1996). Overall, zebrafish are extremely amenable to 
genetic manipulation, and many tools are available. (Lawson and Wolfe, 2011; Auer 
and Del Bene, 2014) 
A wealth of techniques are available in zebrafish to generate both stable transgenic 
lines as well as acute manipulations. Complete knockout, over-expression, and 
knockdown are achievable. Tissue-specific expression, or temporal induction via 
chemical or heat treatment may also be performed (Akerberg, Stewart and 
Stankunas, 2014).Traditional transgenesis, used to generate cell reporter lines, is 
straightforward in zebrafish as microinjection of linear DNA into single-cell eggs can 
randomly integrate into the genome. For example, generation of the Tg:mnx1:GFP 
line (HB9:GFP) was achieved by injecting DNA fragments containing the mnx1 
promoter fused to the GFP sequence (Flanagan-Steet et al., 2005). However, 
integration rates are random and may be very low.  
 
1.1.2.1 – Acute genetic manipulations in embryonic and larval stages - 
Injection of mRNA allows gene over-expression, while morpholino allows gene 
knockdown 
 
Injection of mRNA into single-cell eggs is a widely used technique to induce acute 




commercial kits, this has been used extensively to investigate proteins of interest. For 
example, over-expression of Delta in zebrafish embryos caused a reduction in Islet-1 
positive cells (i.e. neurons), showing that Delta is involved in neuron differentiation 
(Dornseifer, Takke and Campos-Ortega, 1997). As well as investigating the effect of 
gene over-expression, this technique can also be used to confirm that knockdown or 
knockout of the putative gene are specific, as the mRNA should rescue the 
phenotype. However, this technique contains some caveats. For example, the mRNA 
is not tissue-specific, and so aberrant expression in non-specific tissue may have its 
own phenotype. Furthermore, given that mRNA must be injected at the single-cell 
stage, the protein may be translated and thus present during developmental stages 
when it is not normally expressed. For certain proteins, this may induce a phenotype 
or be toxic because of this aberrant expression (Beis and Stainier, 2006). 
Morpholinos (MOs) have been extensively used to acutely knock down gene 
expression in the embryo and larval stages. Morpholinos are RNA analogues, around 
25 bp in length, and achieve knockdown in a similar mechanism to siRNA, where the 
MO binds to mRNA and sterically prevent access by the cellular machinery during 
translation or RNA processing. The morpholino backbone, an uncharged morpholine 
ring, is resistant to degradation in the cell, allowing the morpholino and thus 
knockdown effect to persist until approximately 3 days post fertilisation (dpf) (Bill et 
al., 2009). Design of morpholinos for use in zebrafish embryos are quite 
straightforward as long as the sequence of the gene of interest is known. Morpholinos 
can be designed to bind to the start site, blocking translation via steric inhibition of the 
ribosome. Splice-site morpholinos can also be designed to bind an intron-exon 
boundary, preventing the correct splicing and leading to intron inclusion or exon 
skipping (Eisen and Smith, 2008; Bill et al., 2009). 
Like with all techniques, several flaws to morpholino use have been documented, and 
experiments using them must be tightly controlled to ensure that the phenotype is 
specific. Firstly, the effective window for morpholino knockdown is from 0-3 dpf, and 
so phenotypes expected at later stages may not be possible to observe. A control of 
specificity might be to compare the knockdown to a known mutant and look for 
phenocopy. However, morpholinos may bind to maternally deposited mRNA present 
in the eggs, leading to a phenotype that may be different to a mutant produced from 
heterozygote incrosses. This was observed in smn mutants compared to the smn MO, 




effects may also lead to misleading phenotypes. It has been shown that some 
morpholino effects attributed to the gene knockdown, most notably developmental 
delays and excessive cell death, may be due to activation of p53 (Robu et al., 2007). 
Controls have been suggested, such as use of multiple morpholinos which phenocopy 
each other and can act synergistically, as well as knockdown confirmation using 
Western blot or RT-PCR. Rescue of the phenotype by mRNA injection (i.e. a 
combined knockdown and over-expression of the same gene) is also recommended 
to confirm a specific phenotype (Eisen and Smith, 2008; Stainier et al., 2017). With 
the advent of CRISPR/Cas9 to generate targeted mutants, there have been reported 
discrepancies between MO knockdown and mutant phenotypes, which do not 
phenocopy each other, suggesting a mechanism of compensation in mutants (Place 
and Smith, 2017). For example, (Rossi et al., 2015) demonstrates that egfl7 mutants 
do not recapitulate vascular defects observed in the morphants, due to upregulation 
of vegfab. 
 
1.1.2.2 – The Tol2 system allows integration of large cassettes into the 
zebrafish genome to generate stable transgenic lines 
 
The Tol2 system allows transgenesis of almost any cassette into the zebrafish 
genome with a higher integration rate than injection of linear DNA only. The Tol2 
mechanism acts via transposable elements, and was first identified in medaka (Koga 
et al., 1996). Cassettes containing a promoter region and protein of interest, flanked 
on each side by Tol2 motifs. By co-injecting mRNA of the transposase enzyme, these 
cassettes are cleaved and integrated at high efficiency into the genome using these 
transposable element motifs (Kawakami, 2005). The Tol2 system has been further 
refined, allowing integration of cassettes over 10 kb, and the minimal sequence 
required for efficient integration found (MiniTol2), (Balciunas et al., 2006). A gateway-
based Tol2Kit to increase the ease of cloning such constructs has also been 
developed (Kwan et al., 2007). As well as generating reporter lines, the Tol2 system 
has been used to generate GAL4-UAS lines with higher efficiency than was previously 





1.1.2.3 Genome editing – The CRISPR/Cas9 system offers better efficiency 
than previous methods such as TALENs and zinc finger nucleases 
 
To perform targeted genome editing, several methods have been developed in 
zebrafish. Protein-based targeting and nuclease techniques include transcription 
activator-like effect nucleases (TALENs) and zinc finger nucleases (ZFNs). With each 
tool, the mechanism by which mutations are induced is via double-strand breaks 
(DSBs) in the DNA, which is improperly repaired by non-homologous end joining 
(NHEJ) (Rodgers and Mcvey, 2016). This error-prone repair may lead to small 
insertions or deletions (indels) which can cause frame-shift mutations and premature 
stop codons, leading to nonsense-mediated decay of the mRNA and a lack of protein 
translation (Pelley, 2007; Popp and Maquat, 2016). 
Zinc finger nucleases (ZFNs) act as chimeric proteins to target and cleave DNA. The 
DNA recognition and binding domains are zinc finger transcription factors, combined 
with a FokI nuclease which causes the DNA lesion (Urnov et al., 2010). Adaptations 
to ZFNs for use in zebrafish genome editing represents the first time that targeted 
mutations were performed (Meng et al., 2008). However, ZFNs are difficult to 
generate and screen for efficient cleavage. As each zinc finger motif recognises only 
3 bp, multiple motifs must be assembled together to generate a targeting sequence 
that is unique in the genome. This can be difficult to achieve due to the complexity of 
the zinc finger assembly (Ramirez et al., 2008). Commercial companies which 
assemble and screen ZFNs means that the price point to achieve genome editing is 
very high (Huang et al., 2012; Sertori et al., 2016; Simone et al., 2018). TALENs 
function in a similar way to ZFNs, except instead of zinc fingers as the DNA 
recognition motif, transcription activator like effector (TALE) sequences are used (Y. 
Liu et al., 2014). TALE sequences are protein-based, with 35aa sequences 
recognising a single DNA base. TALENs were demonstrated to generate germline 
transmission of indel mutations in zebrafish (Huang et al., 2011; Sander et al., 2011). 
TALEN targeting sequences are easier to design than ZFNs, with PCR-based 
gateway cloning systems available (Y. Liu et al., 2014). However, similarly to ZFNs 
their efficiency is variable, and so to generate the chondrolectin mutant we chose to 
use CRISPR/Cas9. As CRISPR/Cas9 targeting is RNA-based rather than protein-
based, it is less complex to design targets than ZFNs or TALENs and cheaper than 




The CRISPR/Cas9 system has rapidly expanded in the last few years as a method 
for targeted gene knockout and knock-in with high efficiency. Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) / CRISPR associated system (Cas) 
(CRISPR/Cas9) naturally occurs in prokaryotes and archaea as an immune response 
against viral infection. When foreign DNA integrates into the genome, it disrupts the 
CRISPR locus and RNA transcribed from this locus becomes processed into short 
RNAs. The Cas protein binds these short RNAs and recognise the disrupted CRISPR 
locus, cleaving the foreign DNA to destroy it (Wiedenheft, Sternberg and Doudna, 
2012). 
CRISPR/Cas9 was adapted for eukaryotic systems to generate mutants, as by 
artificially designing the guidance RNAs and injecting Cas9, theoretically any gene 
could be targeted for cleavage by the RNA-Cas9 complex.  
Like ZFNs and TALENs, CRISPR/Cas9 mediates gene knockout by generating DSBs 
which are improperly repaired by non-homologous end-joining. As well as gene 
knockout using these indels, gene knock-in can also be performed by introducing 
homologous sequences for use as an artificial template during homology-directed 
repair (Auer and Del Bene, 2014). This allows integration of mutagenised sequences 
during the knock-in, to generate inactive or constituently active forms of the protein, 
or to knock-in tags to generate fusion proteins directly in the genome (Auer and Del 
Bene, 2014; Gonzales and Joanna Yeh, 2014).  
By modifying the Cas9 and guidance RNAs (gRNAs) for the zebrafish, highly efficient 
gene disruption can be achieved. For example, cloning a Cas9 optimised for zebrafish 
codon usage, and containing a nuclear-localisation sequence to improve the 
efficiency of the Cas9 cleavage enzyme is presented in Jao, Wente and Chen, 2013. 
Online-based tools for gRNA design based on the sequence of interest have also 
been produced (Hsu et al., 2013; Hwang et al., 2013). This allows simultaneous 
searches for the PAM motif and thus putative gRNA targets, with genomic cross-
reference for off-target binding. The tool thereby generates a score and ranks all 
potential gRNAs according to sequence similarity to other genomic regions, allowing 





1.2 – Motor axon development and 
synaptogenesis in zebrafish and other 
organisms 
1.2.1 – The zebrafish primary motor neuron system 
 
In zebrafish, the motor neurons develop as two subtypes, differentiating at different 
stages and with different morphology. The primary motor system is simple and 
excellently characterised, allowing easy phenotypic characterisation after genetic 
manipulation (discussed in next section) (Lewis and Eisen, 2003; Goldsmith and 
Jobin, 2012).  
The primary motor neurons begin to differentiate at ~9 hpf, and each somite contains 
three cell bodies which begin to extend axons from ~16 hpf, the caudal primary (CaP), 
middle primary (MiP) and rostral primary (RoP) (Myers, Eisen and Westerfield, 1986; 
Seredick et al., 2012). Motor neuron differentiation and axon growth develops rostral 
to caudal, and so exact developmental timings vary. Motor neurons at the anterior 
sections of the trunk will have already begun to extend axons when the posterior 
motor neurons differentiate. Each axon from the primary motor neurons follows a 
shared pathway until a pathfinding choice point at the horizontal myoseptum (HM). 
The HM region is rich in ECM proteins, including Tenascin-C and collagens 
(Schweitzer et al., 2005; Bader et al., 2009). After pausing at the horizontal 
myoseptum, the axons then diverge in their paths. The CaP axon continues on a 
ventral path along the vertical myoseptum, the MiP extends dorsally, and the RoP 
axon extends along the lateral line of the trunk (Shown below, Figure 1.1, adapted 











1.2.2 – The primary motor axon morphology is a classic 
readout for identifying crucial proteins for axonal growth 
 
The CaP axon of the primary motor neurons have a stereotypical appearance, as well 
as well-characterised development over time (Myers, Eisen and Westerfield, 1986; 
Grunwald et al., 1988; Lewis and Eisen, 2003). Because of this, the morphology of 
the CaP axons has been used as a readout for aberrant gene expression linked to 
motor neuron development or maintenance, as well as disease models.  
Pathfinding by the primary motor axons requires interaction between muscle-derived 
proteins and axon-expressed proteins. For example, the muscle specific kinase 
(MuSK) mutant zebrafish unplugged exhibit pathfinding errors in the primary axons, 
demonstrating its necessity for axonal growth (Zhang et al., 2004). Knockdown of 
Figure 1.1: The primary motor system in zebrafish embryos at 25 hpf. 
A: Illustration of a zebrafish embryo at 25 hpf, in lateral orientation. The red 
circle indicates the chevron-shaped somites which each contains three primary 
motor neurons. B: A single somite is shown. The RoP (red), MiP (blue) and CaP 
(green) extend axons along a common path as they exit the spinal cord, until the 
horizontal myoseptum choice point (dashed yellow line). The primary axons then 





collagen15 leads to branched CaP axons, and the collagen19a1 mutant stumpy 
exhibits axon stalling at the HM choice point (Pagnon-Minot et al., 2008; Hilario, Wang 
and Beattie, 2010) (Figure 1.2 F, G). Knockdown of notum2, a hydroxylase that can 
cleave GPI-anchored cell signalling proteins and is expressed in the horizontal 
myoseptum, by morpholino also causes CaP axons to stall at the HM, preventing the 
axons from exiting the choice point (Cantu, Flowers and Topczewski, 2013). These 
observations suggest the key contribution of ECM molecules during axon growth, 
especially at the horizontal myoseptum. Knockdown of axon-expressed proteins also 
causes morphological changes to the CaP axon, such as morpholino-mediated 
knockdown of agrin, which causes truncated axons (Kim et al., 2007). Axonal RNA 
transport and local translation in the growth cone is also vital for correct axon growth, 
and RNA transport is impaired in SMA (discussed in Section 1.3.2). Knockout mutants 
of the splicing factor SFPQ have widespread axonal defects, with axons unable to exit 
the spinal cord, which is rescued when human SFPQ is re-expressed without its 
nuclear localisation signal (Thomas-Jinu et al., 2017). This paper demonstrates not 
only the cell-autonomous function of the splicing factor, but also the importance of 
subcellular localisation. 
Changes to the CaP axon morphology have been used as phenotypes for motor 
neurons diseases including Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular 
Atrophy (SMA). Over-expression of mutant SOD1, modelling familial ALS, causes 
branching and shortening of the primary motor axons (Lemmens et al., 2007) (Figure 
1.2 A, B). Knockdown of C9ORF72, associated with ALS, also causes branching of 
the CaP axons (Ciura et al., 2013). Knockdown of smn expression, the causative gene 
of SMA, also leads to truncated, branching, or missing axons (McWhorter et al., 2003) 
(Figure 1.2 C, D, E). 
Overall, changes to the CaP axon morphology have been used as a readout for 












Figure 1.2: Examples of morphological changes to the CaP axon after genetic 
manipulation. Lateral trunk views of embryos between 24-30 hpf are shown. 
Axons are labelled with HB9:RFP (A, B) or znp-1 (C-G). 
A: Injection of wild-type SOD1 mRNA does not affect the CaP axon. B: Injection 
of mutant SOD1A4V causes bifurcation and branching of the CaP axon. (From 
Lemmens et al., 2007). C: Wild-type embryos show normal CaP axon 
morphology (White arrowhead). D, E: Injection of smn morpholino causes 
shortened (black arrowhead) or branched (black arrow) CaP axons (From 
McWhorter et al., 2003). F: Wild-type embryos show normal CaP axon 
morphology. G: In the collagen 19a1 mutant, stumpy, the CaP axons stall at the 




1.2.3 – The secondary motor system in zebrafish 
 
A secondary set of motor neurons differentiate starting at 14 hpf (Kimmel, Warga and 
Kane, 1994) and begin to extend axons from ~ 33 hpf. The secondary motor neurons 
have smaller cell bodies and are more numerous than the primary system, which only 
comprise 3 cells per somite (Babin, Goizet and Raldúa, 2014).  
The secondary motor axons follow the path of the primary motor neurons as pioneers, 
but this is not necessary for axonal growth. Ablation studies demonstrate that although 
the secondary axons are delayed in the absence of the pioneers, they eventually do 
extend correctly (Pike, Melancon and Eisen, 1992). After following the vertical 
myoseptum along the CaP axon trajectory, the secondary motor axons then branch 
excessively to infiltrate axons onto the myotome and innervate the musculature. The 
primary axons also branch after reaching their targets, but this is less extensive than 
secondary axon branching (Babin, Goizet and Raldúa, 2014). Similarly to the primary 
motor axons, changes to the secondary axons can be quantified after mutations or 
exposure to toxic stimuli. For example, secondary motor axon outgrowth is impaired 
after nicotine exposure (Menelaou and Svoboda, 2009). An miRNA model of SMA 
shows a reduction in axonal branching and aberrant pathfinding by the secondary 
motor axons (Laird et al., 2016).  
The zebrafish larvae hatch from their chorions between 2 and 3 dpf. At this stage, the 
zebrafish do not freely swim, but exhibit spontaneous burst movement. They can also 
perform escape behaviour in response to vibratory or touch stimuli (Budick and 
O’Malley, 2000; Bhandiwad et al., 2013). This escape response has been widely used 
to quantify functional changes to the zebrafish motor and sensory circuit. For example, 
after spinal lesion, the ability to escape from a tail stimulus is lost, but upon recovery 
of the axons across the lesion site, functional behaviour and swimming is restored 
(Wehner et al., 2017; Tsarouchas et al., 2018). Zebrafish with mutations to their 
neuromuscular junctions, such as AChR and rapsyn mutants, are also either 
completely paralysed or unable to maintain swimming when touched (Ono et al., 
2001, 2002; Fetcho, Higashijima and McLean, 2008). 
As well as the distance covered during an escape flight, larval zebrafish turn from a 
startle stimulus using a highly stereotypical C-bend, where the trunk contracts to allow 
the head to touch the tail to induce a turn of ~180° (Bhandiwad et al., 2013). The 




induce all motor neurons on the contralateral side of the trunk to contract (Kohashi 
and Oda, 2008). space cadet, a zebrafish hindbrain mutant, cannot induce this turning 
motion correctly, instead performing several C-bend turns in succession, leading to a 
spiralling swimming pattern (Lorent et al., 2001). The SMA model zebrafish described 
in Hao et al., 2013 also demonstrates motor deficits, with a reduction in the swim 
distance at 5 dpf compared to wild-types, and a reduction in body curvature during 
swimming. 
 
1.2.4 – Synaptogenesis in zebrafish and mammals 
 
1.2.4.1 – Synapse formation in zebrafish  
 
Synaptogenesis in zebrafish and mammals share many similarities in terms of 
signalling pathways and pre-and post-synaptic proteins. These include muscle-
expressed factors such a muscle-specific kinase (MuSK), acetylcholine receptors 
(AChRs) and rapsyn, and axon-expressed proteins such as agrin. 
Pre-patterns of acetylcholine receptors, which will form the post-synaptic puncta, form 
clusters in the muscle before the axons exit the spinal cord. The pre-patterns form 
from around 16 hpf onwards (Flanagan-Steet et al., 2005), while primary axons extend 
from 19 hpf (Westerfield and Eisen, 1988). The pre-patterns form along the vertical 
myoseptum, the same path that the CaP axon will extend along, (Panzer, Song and 
Balice-Gordon, 2006) (Schematic shown in Figure 1.3 A). 
The pre-patterning of AChRs in zebrafish is dependent on the muscle-specific kinase 
(MuSK). In the MuSK mutant zebrafish unplugged, the pre-patterns remain scattered 
on the muscle fibres, and do not form into a clustered pre-pattern along the middle of 
the myotome as is seen in wild-types (Jing et al., 2009). As the motor axon extends 
from the spinal cord, the growth cone filopodia are preferentially stabilised upon 
contact with AChRs on the muscle. This means that axonal pathfinding tends to follow 
these pre-patterns as pioneers (Panzer, Song and Balice-Gordon, 2006). As well as 
the axon becoming stabilised by the presence of AChRs, the AChRs are also 
stabilised by the motor axons. Aneural AChRs not contacted by axons are eventually 
dispersed, but the clusters contacted by axons become stabilised and do not (Figure 




they continue to remodel as the axons pass over them, and the co-localisation of pre- 
and post-synapse improves over time. Although initially elongated, the AChRs 
become more punctate and condensed over time (Panzer et al., 2005) (Compare 
Figure 1.3 B and C).  
The further stabilisation of the post-synapse after axonal contact, to form mature 
synapses, requires both muscle-derived and neuron-derived signal proteins, such as 
agrin in the axon (Wu, Xiong and Mei, 2010). In morpholino-mediated knockdown of 
agrin, zebrafish embryos form AChR pre-patterns, but they are not stabilised, and the 
AChR clusters disperse after axonal growth (Kim et al., 2007). However, zebrafish 
unplugged mutants still develop synapses, although the larvae have reduced 
numbers of, and smaller sized, post-synaptic puncta, showing that it is dispensable in 
zebrafish (Zhang et al., 2004). As well as stabilising the pre-patterned AChR clusters, 
zebrafish can spontaneously induce synaptic sites, (Flanagan-Steet et al., 2005; 
Panzer et al., 2005) which explains why the unplugged mutants are able to form a few 
synapses. 
There is a close relationship between axonal pathfinding and synaptogenesis in 
zebrafish. The mutant unplugged exhibits axonal pathfinding defects, including 
stalling of the CaP axon at the HM with excessive branching, and aberrant pathfinding 
of the RoP axon (Zhang et al., 2004). MuSK signalling induces expression of ECM 
molecules in axonal pathfinding choice points including the horizontal myoseptum, for 
example unplugged mutants do not express Tenascin-C, an ECM molecule important 
for the correct axonal pathfinding (Schweitzer et al., 2005). The Collagen19a1 mutant 
stumpy, whose primary axons stall at the horizontal myoseptum (Hilario, Wang and 
Beattie, 2010), exhibit reduced number of synapses in larval stages (Panzer et al., 
2005). 
In larval zebrafish, when the secondary axons have differentiated and extended motor 
axons, the axons begin to branch and innervate the myotome outside of the ventral 
axon bundle (Figure 1.3 D, E). Pathfinding of these branches does not require pre-
patterning of AChR clusters (Panzer, Song and Balice-Gordon, 2006). Further 
zebrafish mutants have indicated proteins required for correct synapse stabilisation. 
For example, the rapsyn mutant twitch once is unable to correctly initiate an escape 
swim when startled, due to diffuse AChR clusters which leads to reduced motility (Ono 
et al., 2002). Rapsyn is a scaffolding protein which stabilises the post-synaptic density 




humans (Ohno et al., 2002). Rapsyn requires acetylcholine receptors for the protein 
to be transported from the Golgi apparatus to the synapse (Ono et al., 2001; Park et 
al., 2012).   
As well as the link between pathfinding and synaptogenesis, we hypothesise that 
there is a link between motor axon branching and synaptogenesis. In Xenopus motor 
axons, pre-synaptic puncta are required to stabilise nascent motor branches, and 
branches tend to extend from synaptic sites (Javaherian and Cline, 2005).  Retinal 
ganglion cells (RGCs) in both zebrafish and Xenopus also exhibit a similar 
requirement for synapses to stabilise extending dendrites. In RGCs, pre-synaptic 
puncta are required in order to stabilise nascent dendritic arbours, which retract 
without the presence of these pre-synaptic proteins. Branches also emerge from pre-























1.2.4.2 – Similarities and differences in mammalian synaptogenesis 
 
Mammalian motor synaptogenesis share several key features with the process in 
zebrafish, but there are some key differences. Similarly to zebrafish, the muscle forms 
AChR pre-patterns on the muscle fibres before the motor axon contacts the muscle 
(Figure 1.4 A) (Wu, Xiong and Mei, 2010). These pre-patterns assemble without any 
axonal signalling, although their stabilisation requires axonal factors including agrin, 
and will dissipate if not innervated (Darabid, Perez-Gonzalez and Robitaille, 2014) 
(Figure 1.4 B).  
MuSK is necessary for post-synaptic differentiation in mammals, where it recruits 
rapsyn and AChR to the post-synaptic density after agrin signalling from the axon 
MuSK-null mice do not form neuromuscular junctions and die at birth due to an 
inability to breathe (Burden, 2002). This is dispensable in zebrafish, where MuSK 
mutants do eventually form synapses, albeit smaller and fewer in number (Zhang et 
al., 2004). Agrin-null mice do not develop NMJs and die at birth (Gautam et al., 1996). 
There is a reciprocal relationship between agrin and the neurotransmitter 
acetylcholine, as double-mutant mice for agrin and ACh develop synapses (Misgeld 
et al., 2005). Ectopic expression of MuSK in mice promotes synapse formation and 
can rescue the lack of synapses normally observed in agrin-null mice. Increased 
levels of MuSK also promote axonal growth, causing excessive axonal branching 
across the muscle (Kim and Burden, 2008). 
Figure 1.3: Synaptogenesis in the wild-type zebrafish motor system. 
At each time-point, a single somite of the trunk is shown from a lateral view, with 
a higher magnification view in the bottom box. Motor neurons are green, AChRs 
in the post-synapse are red, and co-localisation is yellow. A: Between 16-20 hpf, 
before motor axons exit the spinal cord, the AChRs form aneural pre-patterns on 
the muscle. B: Between 20-24 hpf, the AChRs contacted by axons are stabilised 
but remain larger than the pre-synapse on the axon, while the aneural clusters 
begin to disperse. C: From 24-30 hpf, the axons have grown to the edges of the 
myotome. Pre- and post-synapse proteins are being remodelled into co-localised 
synaptic puncta. D: At 48 hpf, the axons are slightly branched into the muscle 
and the synaptic compartments are tightly co-localised. E: At 120 hpf, the motor 
axons are highly branched into the myotome and have co-localised puncta of the 




Comparing Figure 1.3 and Figure 1.4 shows that there are clear similarities between 
zebrafish and mammal synapse formation, including shared pathways. The faster 
genetic manipulation and increased ability to image zebrafish larvae over mouse 









Figure 1.4: Mouse synaptogenesis and stabilisation.  
A: At early stages, the muscle fibres for small, scattered pre-patterns of 
AChRs before the arrival of the nerve growth cone. B: At later stages, after 
the muscle fibres become innervated, the AChR clusters contacted by the 
axon are stabilised and grow in size, while the aneural clusters disappear. 




1.3 – Spinal Muscular Atrophy is an inherited, 
childhood form of motor neuron disease 
1.3.1 – The genetics of Spinal Muscular Atrophy  
 
Spinal Muscular Atrophy (SMA) is an inherited form of motor neuron disease and is 
the leading cause of inherited child mortality. SMA is monogenic, in that it is caused 
by loss of function mutations in SMN1, but it exhibits a spectrum of severity due to the 
presence of a compensatory gene in humans, SMN2 (Lefebvre et al., 1995). The 
SMN2 is a duplication of SMN1 but contains a single base substitution in exon 7 (C 
to T) which causes exon 7 skipping during translation (Cartegni et al., 2006). This 
leads to 50-90% of SMN2 transcripts to be non-functional and thus quickly degraded 
in all humans, so in normal conditions the optimal cellular dosage of Smn protein is 
expressed from SMN1. Thus, in the event of SMN1 loss of function, SMN2 is unable 
to compensate with the right expression level of Smn. The reduced level of Smn 
protein leads to SMA. The severity of SMA is determined by the number of copies of 
SMN2 and thus the spectrum of SMN protein level which is able to be translated from 
the SMN2 (Lunn and Wang, 2008). Other primates including chimpanzees do not 
have SMN1/SMN2, but rather multiple copies of the same SMN gene, demonstrating 
that the divergence and C to T mutation came very late in human evolution (Rochette, 
Gilbert and Simard, 2001). Mice, zebrafish, fruit flies and yeast also have only one 
copy of SMN. 
Complete loss of function of SMN1 and SMN2 in humans is embryonically lethal, and 
complete knockout in animal models also causes embryonic lethality. For example, 
mice homozygous for SMN knockout do not develop much beyond the implantation 
stage and exhibit massive cell death within 4 days of the mouse mating (Schrank et 
al., 1997). Zebrafish homozygote knockouts have an average survival of just 12 days 
post fertilisation (Hao et al., 2013). Therefore, in animal models of SMA, either gene 
knockdown or knockout combined with low-level expression of the human form of 








1.3.2 – The functional role of SMN 
 
SMN is ubiquitously expressed in all model systems and is necessary for cell survival 
in all tissue types. SMN is involved in splicing, forming part of a complex known as 
the spliceosome (Kolb, Battle and Dreyfuss, 2007). There is also increasing evidence 
that SMN is vital for bioenergetic and protein homeostasis in the cell (Chaytow et al., 
2018). In an SMA mouse model, an increased oxidative stress and fragmented 
mitochondria were observed before the onset of motor symptoms (Miller et al., 2016), 
and changes to mitochondria and energy requirement were observed in zebrafish with 
smn knockdown (Boyd et al., 2017). SMN also has vital roles in the ubiquitin pathway, 
interacting with UBA1 (Wishart et al., 2014). 
SMN is named for survival of motor neuron, as despite its ubiquitous expression and 
function as a housekeeping protein, motor neuron cells are selectively vulnerable to 
the reduced level of SMN (Burghes and Beattie, 2009; Ling et al., 2012; Boyd and 
Gillingwater, 2016). Motor neurons may be vulnerable due to the role of SMN in RNA 
transport and local translation in the growth cones of motor neurons (Dombert et al., 
2014; Fallini et al., 2016). A tissue-specific model of SMA in zebrafish demonstrates 
that reduction in motor neuron Smn levels causes axonopathy, but reducing muscle 
expression does not (Laird et al., 2016). Widespread splicing defects have been 
reported in SMA model mice, especially in the spinal cord (Zhang et al., 2008), 
although some evidence suggests that this may be a consequence of late-stage 
disease pathology rather than a causative of the degeneration (Bäumer et al., 2009). 
However, at early stages in severe SMA mouse models, before the onset of motor 
symptoms, several genes are already dysregulated, including chondrolectin. 
Chondrolectin is down-regulated by a fold change of 1.7 at p7, and shows a shift in 
the ratio of its isoforms in SMA mice compared to wild-type (Bäumer et al., 2009). 
Given that this down-regulation is observed prior to motor symptoms, it suggests that 
chondrolectin could be a key gene affected by SMN dysfunction and thus contributes 





1.3.3 – SMA pathology is linked to neuromuscular junction 
dysfunction 
 
As previously discussed, although SMN protein is ubiquitously expressed and 
required for splicing in all cell types, the motor neurons are specifically vulnerable to 
loss of SMN. Several mechanisms have been proposed for this vulnerability, including 
defects in spliceosome and snRNP assembly (Burghes and Beattie, 2009). Other 
suggested mechanisms include failures in axonal transport of RNA (Fallini et al., 
2016), or the higher energetic requirement of motor neurons to generate 
neuromuscular signals (Lefebvre et al., 2004; Miller et al., 2016; Boyd et al., 2017). 
SMN protein has also been observed localised to the motor terminal of the axon, 
suggesting a local role in the neuromuscular junction (NMJ) (Dombert et al., 2014). In 
particular, deficits to the NMJ are a key feature of SMA pathology, both in symptomatic 
stages with degeneration to the NMJ, as well as pre-symptomatically (Kariya et al., 
2008). These pre-symptomatic defects to the NMJ are of particular interest, as they 
suggest that rather than a purely degenerative disease, SMA patients exhibit 
developmental changes to their motor neurons and so early intervention by 
therapeutics is key. As well as a putative target for further investigations into the 
disease mechanism, this also suggests potential therapeutic targets.  
In human Type I SMA patients, motor symptom onset occurs before 6 months of age, 
with the average lifespan less than two years (Lunn and Wang, 2008). In foetal tissue 
of Type I SMA patients, neurofilament accumulation is observed in the neuromuscular 
junctions, and there is a failure of the pre-synapse to fully occupy the post-synaptic 
compartment (Martínez-Hernández et al., 2013). This demonstrates that aberrant 
changes to the NMJ are quantifiable during development. This aggregation of 
neurofilament was confirmed in diaphragm muscle samples donated from human 
SMA Type I patients, as well as poor arborisation of the motor terminals (Kariya et al., 
2008). In both papers, there is also a weakening of the post-synaptic signal, 
suggestive of an instability of the post-synaptic density as it is not maintained. 
Immaturity of the post-synapse is also present in SMA patients, quantified by an 
increase in foetal forms of AChR and smaller post-synaptic density (Harding et al., 
2015). These defects suggest that in human SMA patients, there is arrest of delay in 
the maturation of the NMJ. SMN is required for the maturation of the NMJ, as an 




maturation of NMJs (p17) caused defects in the pre- and post-synapse (Kariya et al., 
2014). This study also demonstrated that inactivation of SMN after NMJ maturation 
did not cause degeneration directly but made those NMJs more vulnerable to damage 
by crush injury, as well as impaired recovery. Similarly to the foetal human tissue, 
which exhibited neurofilament accumulation (Martínez-Hernández et al., 2013), the 
same NF accumulation is observed in mouse pre-synapses (Kariya et al., 2008), 
along with bulb-like axon terminal which cannot correctly occupy the post-synaptic 
density. However, axonal growth and pathfinding does not appear to be impaired, as 
normal axon extension is observed in severe SMA mouse models (Mcgovern et al., 
2008). However, the NMJ occupancy by the axon is impaired, even though the axon 
reaches its muscle target. 
It is established that in the mid- and late-symptomatic stages of disease in mice 
models of SMA, there is NMJ pathology including withdrawal of the pre-synaptic 
terminal and shrinkage of the post-synapse, and this is also observed in early 
symptomatic stages of the most vulnerable muscle groups (Murray et al., 2008). 
Electrophysiology data in mouse models of SMA also demonstrates functional defects 
in diseased NMJs. The NMJ excitability is affected in SMA, as mouse neuronal culture 
of healthy and SMA mice demonstrate reduced Ca2+ channel clustering and reduced 
calcium transients (Jablonka et al., 2007). Impaired synaptic vesicle release is 
observed in mouse electrophysiology data (Kong et al., 2009). SMN is required for 
organisation of the active zone of the motor synapse. This includes microtubule and 
synaptic vesicle maturation, and synaptic vesicle recycling (Torres-Benito et al., 
2011). 
A zebrafish SMA model also exhibits pre-synaptic deficits, labelled with SV2 (Boon et 
al., 2009). The SV2 staining in 11 dpf larvae is reduced compared to controls, but the 
post-synaptic labelling remains intact, leading to a decrease in co-localisation of the 
two labels. This reduction is SV2-specific, with synaptotagmin labelling unchanged 
between controls and mutants. Introduction of the human SMN2 gene in these mutant 
zebrafish extended their lifespan by several days, and rescued the synaptic defects 
for these days, although the loss of SV2 staining re-emerged by the time these 
mutants died (Hao, Burghes and Beattie, 2011). This demonstrates that zebrafish 





1.3.4 – Current therapies available or in development to 
treat SMA 
 
SMA is considered a rare disease, with incidence of 1 in 10000 live births (Lunn and 
Wang, 2008), and similarly to other MNDs such as ALS has limited treatment options. 
Currently, only one therapy has been approved for use in SMA, nusinersen, which is 
an antisense oligonucleotide (ASO). 
Nusinersen, as an antisense oligonucleotide, functions by binding to the SMN2 
mRNA, preventing the skipping of exon 7 (Rigo et al., 2012). This decreases the 
proportion of SMNΔ7 and the proportion of normal SMN protein increases. After 
undergoing multiple clinical trials, nusinersen was approved for use in Type I SMA 
(Swoboda et al., 2016; Finkel et al., 2017). However, ASOs have a high production 
cost, due to the frequency of treatment and lifelong treatment requirements. 
Nusinersen must be administered 4 times in the first 2 months of treatment, followed 
by doses every 4 months, potentially for life, and long-term studies have not yet been 
performed. In its appraisal, NICE estimated a cost of approximately £450,000 per 
patient for the first year of treatment, and £225,000 for subsequent years, as the 
baseline level of nusinersen must be maintained in the spinal cord to modify the 
splicing of all transcribed SMN mRNAs. It is for these reasons NICE rejected 
nusinersen for use by the NHS in England and Wales (NICE, 2018). There is thus an 
unmet need for further compounds to treat SMA or supplement the treatment by 
nusinersen. 
Before the development of nusinersen, there were attempts to repurpose existing 
drugs for use in SMA (Calder, Androphy and Hodgetts, 2016). The splicing error in 
SMN2 leads to a high proportion of its transcript being degraded, as exon 7 is skipped. 
However, some transcripts are successfully spliced and thus produce full-length SMN 
protein (Cartegni et al., 2006). The repurposed drugs included epigenetic modulators 
such as trichostatin A or valproic acid, which are HDAC inhibitors. The rationale was 
to increase levels of SMN by increasing the expression of SMN2 despite its large 
proportion of defective transcripts. This approach is known as SMN-dependent. 
Although SMN2 transcription levels increased after HDAC inhibition in patient cell 
cultures and mice (Tsai et al., 2008; H. Liu et al., 2014), HDAC is involved in multiple 
processes and its inhibition could affect other key genes. It thus would affect SMN2 




trialled in SMA patients. Riluzole prolongs survival of ALS patients by two or three 
months (Miller, Mitchell and Moore, 2012), but in a phase I trial with SMA patients, 
mean survival increased but the sample size was too small for statistical testing 
(Russman, Iannaccone and Samaha, 2003). 
Potential treatments have been developed to specifically target SMN2; either to 
increase its transcription rate, to increase the proportion of transcripts which include 
the exon 7, or to stabilise the SMN protein to increase its lifespan in the cells (Calder, 
Androphy and Hodgetts, 2016). One example was discovered through a large-scale 
screen performed in mouse motor neuron cell culture, to determine compounds which 
increase the SMN expression (Jarecki et al., 2005). A class of hits were identified, 
2,4-Diaminoquinazolines, and derivatives of the structural family were further trialled 
(Thurmond et al., 2008). Although the best compound, RG3039, showed increased 
survival of SMA mouse models (Gogliotti et al., 2013), it has not been passed into 
clinical trials due to the acquisition of the rights by Pfizer Inc., who terminated further 
work into the compound.  
Several other potential treatments are undergoing clinical trials at different phases, 
mostly focused on SMA Type I as this is the most severe form (Shorrock, Gillingwater 
and Groen, 2018). A viral vector delivering an enhanced SMN1 through the blood-
brain barrier to neurons, AVXS-101, is currently entering a Phase 2 trial after success 
in Phase 1 (Shell et al., 2018). After a high-throughput screen to find compounds 
which caused specific increases in the SMN2 transcript, Roche identified a compound 
called RG7800 which showed promising results pre-clinically but failed in human 
trials. After extensive structure refinement, risdiplam (RG7916) has been designed 
with improved pharmacokinetics. This compound is now entering part 2 of its first 
clinical trials (Ratni et al., 2018). A neuroprotective compound, olesoxime, which 
increases the stability of the mitochondria to resist stress, has recently shown to be 









1.4 – Chondrolectin 
 
1.4.1 – Chondrolectin is a transmembrane protein 
containing a C-type lectin domain 
 
Structural domains determined from the chondrolectin sequence predicts a single-
pass type I transmembrane domain and a carbohydrate recognition domain, known 
as a C-type lectin domain (CTLDs). C-type lectin domains require Ca2+ to bind 
carbohydrates, and are often found in proteins which interact with glycoproteins 
(Zelensky and Gready, 2005; Cummings and McEver, 2017). CTLDs also have an 
important role in immunity, as leukocytes express a class of adhesion molecules 
called selectins which aid their movement around tissues during infection surveillance 
(Rini and Leffler, 2010; Mayer, Raulf and Lepenies, 2017). Dectins recognise fungal 
proteins during infection and signal to induce cytokine release (Yan, Ohno and Tsuji, 
2013; Dambuza and Brown, 2015). 
Further structural domains for chondrolectin have been predicted from their sequence 
motifs (UniProt: Q568T5, https://www.uniprot.org/). This includes an N-terminal signal 
peptide (1-20aa) followed by the C-type lectin (38-187aa). The transmembrane 
domain spans aa position 239-266, and the C-terminus contains a short, 30aa 
intracellular domain (267-296 aa). A schematic of zebrafish chondrolectin is shown 





Figure 1.5: Schematic of the protein domains of zebrafish chondrolectin.  
Chondrolectin is a 296 aa sized protein, comprising of a signal peptide 
(SP), C-type lectin domain (CTLD), transmembrane domain (TMD) and 
intracellular domain (ID). Adapted from Zhong et al., 2012 and 
www.uniprot.org, Q568T5 
 
Figure 1-1: in situ hybridisation shows the expression pattern of 
chondrolectin.  
A: At 10hpf, there is no detectable expression of chondrolectin. B-D: 
Arrows show that the trigeminal ganglion contains detectable chodl signal. 
B: At 12 hpf, arrowheads show cells in the trunk which are putative motor 
neurons. C: At 20 hpf, the chodl signal is strongly detectable in the trunk, 
both in motor neurons and dorsal of the MNs (arrowheads). D: At 24 hpf, 




Publications examining the protein interactions, or the function of each structural 
domain, are scarce for chondrolectin. Chondrolectin’s closest homologue, layilin (45% 
homology), also contains a lectin domain and functions as a cytoskeleton protein. 
Layilin was identified as a hyaluronan receptor via its lectin domain (Bono et al., 2001), 
but researchers were unable to detect any interaction between chondrolectin and 
hyaluronan (Weng et al., 2002). There is no known binding partner of the C-type lectin 
domain in chondrolectin published. A zebrafish mutant for collagen XIXaI, stumpy, 
phenocopies the morphant and mutant to chondrolectin, suggesting a functional link 
between the proteins (Hilario, Wang and Beattie, 2010). 
The transmembrane domain is a single pass, type I transmembrane domain. Although 
the transmembrane domain and C-type lectin domain are most commonly associated 
with ECM interactions at the cell surface, previous published papers show perinuclear 
signal of chondrolectin. In Weng et al., 2002, transfected cells with HA-tagged 
chondrolectin show a strong perinuclear signal using a monoclonal HA antibody, with 
further punctate signal in the cytoplasm and plasma membrane of the transfected 
cells. An anti-chondrolectin antibody was generated for Western blotting in that paper, 
and later used in Enjin et al, 2010. Chondrolectin immunohistochemistry in mouse 
motor neurons showed wide immunofluorescence in the cytoplasm and it was 
excluded from the motor neuron nuclei. However, there is no published antibody to 
chondrolectin that is validated in zebrafish, and custom antibodies to chondrolectin 
did not give any specific signal. The subcellular localisation of chondrolectin, and its 
mechanism in the cell, is thus a key unanswered question which we investigated 
during this thesis.  
The intracellular domain of chondrolectin is a short helical chain with no structural 
motifs, 30 amino acids in length. The only published study of this domain is the one 
by Claessens, Weyn and Merregaert, 2008, in which an Sos recruitment screen of 
this domain was used to pull down binding proteins. The protein isolated was Rab 
geranylgeranyl transferase β (Rabggtb), a protein that associates with Rab GTPase 
to prenylate it for its association with the plasma membrane. The paper does not 
hypothesis if the Rab geranylgeranyl transferase binds as part of the function of 
chondrolectin but posits that chondrolectin could stabilise the Ranggtb during its 
catalytic prenylation of the Rab GTPase. 12/30 (40%) of the residues are serine or 
threonine, which means a high proportion of this domain can be phosphorylated. This 




domain binds a target ligand in the ECM and a phosphorylation-dependent change 
occurs via the C-terminal intracellular domain. 
1.4.1.1 – The human and mouse chondrolectin has several isoforms, caused 
by alternative splicing, while zebrafish have only one isoform 
 
Zebrafish chondrolectin has only a single isoform and has a high homology with the 
human and mouse chondrolectin, with 92% sequence identity to the canonical 
sequences of both mouse and human chondrolectin (Zhong et al., 2012). There are 
multiple human and mouse splice isoforms of chondrolectin, however, and their 
localisation and the amount of information about their function is varied. An 
alignment across species and isoforms is shown below (generated using UniProt’s 
alignment tool, Figure 1.6). For example, Figure 1.6 A shows all 4 isoforms of 
human chondrolectin and the 3 mouse isoforms aligned with the single zebrafish 
protein sequence. However, two of the human isoforms of chondrolectin are not 
expressed in the spinal cord and so do not contribute to the function of chondrolectin 
in the motor neurons. These isoforms, known as chodl_F and chodl_FΔE, are 
instead expressed by lymphocytes and involved in the maturation of T-cells (Weng 
et al., 2003, Claessens et al., 2007), and neither isoform contains the signal peptide 
sequence. Human chodl_FΔE also lacks most of the transmembrane domain seen 
in other isoforms, demonstrating it is soluble (Claessens et al., 2007). The C-type 
lectin domain is frequently observed as a recognition domain in proteins in the 
immune system (Zelensky and Gready, 2005.), which supports the potential role of 
these isoforms in T-cells. The mouse splice isoform known as Chodl-003 is also not 
detected in the spinal cord, and its function and localisation is unknown (Sleigh et 
al., 2014).  
Focusing on the isoforms which have been detected in cells in the spinal cord, the 
alignment of these protein sequences is duplicated in Figure 1.6 B for clarity. These 
isoforms share the common protein domains of a signal peptide, C-type lectin 
domain, and transmembrane domain. Of the two mouse isoforms, Chodl-001 shows 
the most homology with both the human and zebrafish orthologues of chondrolectin 
(Sleigh et al., 2014). The two isoforms also show a differential rate of expression in 
the spinal cord, and in severe SMA model mice, RT-PCR shows downregulation of 
Chodl-001 but not Chodl-002 at p7 and p13 (Bäumer et al., 2009). The link between 
chondrolectin and SMA is discussed in more detail in Section 1.4.3. Chodl-001 and 




more amino acids in the intracellular domain than either the human or other mouse 
isoform. However, there is no published data on the potential differences in 
mechanism that these extra residues may have, or other differences between these 
two isoforms. From these alignments, there is a high degree of homology between 
the zebrafish and mammal orthologues of chondrolectin, especially in the negative- 
or positive-charged properties of the residues, or their hydrophobicity. However, the 
zebrafish protein sequence contains an extra 9 amino acids in the C-type lectin 
domain compared to all mammal isoforms, and also contains an extra 14 amino 
acids in the extracellular region between the C-type lectin domain and the 
transmembrane domain. It is not known what effects, if any, these extra residues 
have on the function of the protein, or if they are an artefact of the difference 























1.4.2 – The expression pattern of chondrolectin shows it is 
highly enriched in motor neurons 
 
Chondrolectin (chodl) was first identified during a PCR-based screening for novel 
genes expressed in neonatal mice during endochondral ossification (bone formation), 
and thus was named chondrolectin due to this link with bone (chondro-) (Weng et al., 
2002). Comparison to human expressed sequence tags (ESTs) found homologues in 
human transcripts, and Chodl was isolated from human testis muscle RNA and then 
found to be highly expressed in human skeletal muscle, heart, and spleen tissue using 
Southern and Western blotting (Weng et al., 2002; Weng, Hübner, et al., 2003). 
Further studies probed motor neuron expression arrays using in situ hybridisation in 
foetal mouse tissue. This analysis found that chondrolectin is highly expressed in 
motor neurons, and this was verified with immunostaining using a CHODL antibody, 
Figure 1.6: Protein sequence alignments for the multiple isoforms of 
chondrolectin across zebrafish, human, and mouse.  
For all alignments, the UniProt code and then the species/isoform title is 
shown. The starting and ending amino acid number for each line is shown, 
and the proteins domains are labelled above the amino acid sequence. The 
residues are coloured according to their properties (blue= hydrophobic, red= 
negatively charged, green= positively charged). The symbol under the 
alignment identifies similarity between residues across isoforms, where * 
indicates an identical, conserved residue. A : (colon) indicates a strongly 
similar properties but not complete conservation of residues, and . (period) 
indicates 
A: Alignment of all isoforms of chondrolectin. zf_chodl = zebrafish, h_chodl = 
human canonical chondrolectin, h_chodl_F = human isoform of chodl known 
as chodl_F, h_chodl_FΔE = human isoform known as chodl_FΔE, m_chodl-
001= mouse chondrolectin isoform-001, m_chodl-002= mouse isoform chodl-
002, m_chodl-003= mouse isoform chodl-003. B: Alignment of the protein 
sequences of chondrolectin isoforms known to be located in the motor 
neurons and spinal cord. zf_chodl = zebrafish, h_chodl = human canonical 
chondrolectin, m_chodl-001= mouse isoform Chodl-001, m_chodl-002= 




where staining was clustered around the perinuclear region in motor neuron cell 
bodies. Furthermore, electrophysiology of these CHODL-positive motor neurons 
suggested that these were the fast-twitch subtype of α motor neurons (Enjin et al., 
2010). 
In zebrafish, chondrolectin was identified as being highly expressed in motor neurons 
during axon outgrowth (Zhong et al., 2012). Preventing axon exit from the spinal cord 
using a dominant-negative cofactor to the LIM homeodomain construct (transcription 
factors that regulate motor neuron development, DN-CLIM) abolishes the expression 
of genes which are necessary for axon growth. By comparing the gene expression 
between control motor neurons and those injected with the DN-CLIM, several genes 
were identified that were likely to be involved in axon growth. These included chodl, 
tac1, and calca. In situ hybridisation analysis of chondrolectin expression showed 
detectable expression exclusively in HB9:GFP-positive motor neurons. This ISH 
expression was detectable from ~12 hpf and was strongly detectable in the spinal 
cord until at least 60 hpf, which correlates with motor neuron development stages 
(Figure 1.7). There is also detectable signal in several regions of the brain, including 





















Figure 1.7: in situ hybridisation shows the expression pattern of chondrolectin.  
A: At 10hpf, there is no detectable expression of chondrolectin. B-D: Arrows show 
that the trigeminal ganglion contains detectable chodl signal. B: At 12 hpf, 
arrowheads show cells in the trunk which are putative motor neurons. C: At 20 hpf, 
the chodl signal is strongly detectable in the trunk, both in motor neurons and 
dorsal of the MNs (arrowheads). D: At 24 hpf, the ISH signal is strongly enriched in 
motor neurons (arrowheads). (Adapted from Zhong et al., 2012). E: Representative 
images of chodl ISH are shown between 48-60hpf, as a lateral view and a dorsal 
view. Between 48-60 hpf, there is detectable expression of chodl mRNA in the 
olfactory bulb (red arrow), diencephalon (black arrow) tectal neurons (red 
arrowhead), and hindbrain (black arrowhead), as well as in the trunk. F: Lateral 
and dorsal views of a 5 dpf larvae after chodl ISH. Detectable signal is observed in 
the olfactory bulb (red arrow), diencephalon (black arrow) tectal neurons (red 







Morpholino (MO) knockdown of chondrolectin caused stalled motor axons at 24 hpf, 
confirming its importance during axon growth. In particular, the axons stalled at the 
horizontal myoseptum (HM), an important choice point during the primary axon growth 
in zebrafish (Zhong et al., 2012). During normal motor axon growth, all three primary 
axons extend to the HM, before diverging paths. In wild-type embryos, the CaP axons 
pause at the HM for around 1 hour, between 21.5 and 22.5 hpf, before extending 
further (Myers, Eisen and Westerfield, 1986; Westerfield and Eisen, 1988). In the 
published MO knockdown of chodl (Zhong et al., 2012), the CaP axons stall around 
the horizontal myoseptum (HM) for several hours, and although their growth rate is 
unchanged from controls, this delay means that many axons are still shorter than 




Over-expression of chondrolectin using mRNA injection rescued the morpholino-
mediated knockdown, although over-expression alone also resulted in a shorter axon 
phenotype (Figure 1.9). This suggests that the gene dosage of chondrolectin is tightly 
Figure 1.8: Morpholino knockdown of chondrolectin causes stalled CaP axons. 
A: At 24 hpf, the CaP axons have extended past the HM, while chondrolectin 
morphants show CaP axons stalled at the HM (arrowheads). B: At 33 hpf, the CaP 
axons are shorter than in controls (arrowheads), and some MiP axons have failed 
to extend (MiPs shown with arrows). Axons were labelled with znp-1 antibody. 





regulated to maintain its correct function in zebrafish motor axons. This technique 
contains the caveat that mRNA injection is not tissue-specific, and so ectopic 
expression of chondrolectin in muscle or other tissues could cause the aberrant 
morphology. 
Overall, although Zhong et al., 2012 demonstrated that chondrolectin has a key role 
in axonal growth, localises mostly to motor neurons, and its expression level in the 
embryo must be tightly controlled, there are still unanswered questions. The study 
does not offer any functional data and only speculates on the potential mechanism by 
which chondrolectin regulates axonal growth, namely that as a transmembrane 
protein it likely traffics to the cell surface, and its C-type lectin domain may be used in 
ligand interactions. Functional assays form a key aspect of this thesis, to attempt to 
address this gap in knowledge. Due to the temporal limit of morpholino of around 3 
dpf, there is no behavioural test performed to investigate if the motor axon deficit 
affects the larval swimming activity. There was also no way to speculate on 
phenotypes in the adult stage. Another unanswered question that this thesis 
addresses is any potential effect of chondrolectin knockdown in synapse formation. 
This is related to the relationship between NMJ defects and Spinal Muscular Atrophy. 
There are also links between chondrolectin and Spinal Muscular Atrophy, discussed 








1.4.3 – Chondrolectin is a key downstream target of Smn 
dysfunction seen in SMA models 
 
Due to the complexing of SMN in the spliceosome, and its role in mRNA processing, 
SMA was hypothesised to lead to splicing defects, and the potentially toxic mis-spliced 
proteins could contribute to the pathology (Kolb, Battle and Dreyfuss, 2007). Splicing 
defects are widespread particularly in the brain and spinal cord of SMN-deficient mice, 
at both the onset of motor symptoms (p6) and at the end-stage of the disease (p11) 
(Zhang et al., 2008). One of the down-regulated genes in the spinal cord is 
chondrolectin, suggesting a link between SMN dysfunction and changes to 
chondrolectin expression. Another study investigated splicing defects before the 
onset of motor symptoms in the SMA model mice, to investigate if the splicing defects 
may be causative and contributing to the SMA pathology, or are a consequence of 
already-degenerating cells (Bäumer et al., 2009). This study demonstrated that most 
mis-spliced products were late onset, although several transcripts were mis-spliced 
before the onset of motor symptoms, including confirming chondrolectin mis-splicing 
and downregulation at p7. Overall, this indicates a potential link between 
chondrolectin and Spinal Muscular Atrophy. 
The link between SMA and dysregulation of chondrolectin has also been observed in 
a study of miRNAs and their contribution to SMA disease pathology (Wertz et al., 
2016). miRNAs are involved in post-transcriptional modification of mRNAs. Profiling 
mRNA and miRNA expression profiles in SMN knockdown, including human SMA 
Figure 1.9: Injection of chodl mRNA causes aberrant axons in wild-type 
embryos and rescues the morpholino knockdown phenotype.  
A: In wild-type embryos at 26 hpf, injection of scrambled control mRNA 
does not change the axon phenotype, but over-expression of chodl mRNA 
causes shortened axons (arrowheads). B: Co-injection of control mRNA 
and morpholino leads to the morphant phenotype of stalled axons, which 
co-injection of mRNA and morpholino leads to axons which are closer in 
appearance to the wild-type (shorter axons indicated with arrowheads). 




iPSC-derived motor neurons, identified several miRNAs which are significantly 
upregulated in neurons. These neurons exhibit shorter neurite lengths, and one 
miRNA which is upregulated is miRNA-431. Inhibition of miRNA-431 rescues the 
neurite length, showing its link to axonal growth, and the targets of miRNA-431 include 
chondrolectin.  
Further evidence of a relationship between chondrolectin and Smn comes from the 
zebrafish. Knockdown of Smn by morpholino leads to aberrations in the primary motor 
axon, including truncations, branching, and missing axons (McWhorter et al., 2003). 
This morpholino data is phenocopied in several mutant lines, including one  which is 
smn -/- but has human SMN2 expressed as a transgene (Hao, Burghes and Beattie, 
2011), and an smn -/- mutant which expresses a low level of Smn due to a leaky 
hsp70:smn-RFP transgene (Hao et al., 2013). Crucially, over-expression of 
chondrolectin by injection of chodl mRNA in smn knockdown embryos partially 
rescues the axonal phenotype observed in smn knockdown alone (Figure 1.10, 
below) (Sleigh et al., 2014). This suggests that in smn knockdown, at least part of the 
axonal phenotype may be due to reduction in, or mis-splicing of, the chondrolectin 
protein. This paper also demonstrates that in vitro culture of mouse neuronal cells 
with SMN knockdown exhibited shorter neurites, and transfection with chodl rescues 
the neurite length. Overall, this validates chondrolectin as a potentially important 















Figure 1.10: Over-expression of chondrolectin in Smn morpholino embryos 
partially rescues the axonal phenotype in zebrafish.  
A: Embryos injected with control morpholino do not exhibit morphological 
changes to the CaP axons. B: Injection of smn morpholino leads to excessive 
branching (arrowheads), shortened (arrows) or missing axons (asterisk). C: Co-
injection of smn morpholino and chodl mRNA partially rescues the axonal 
phenotype, although some branching is still observed (arrowhead). Scale bar= 




1.5 – Zebrafish are highly amenable for use in 
drug screens 
 
Zebrafish are an increasingly popular model system for modelling motor neuron 
diseases (MNDs). With approximately 70% gene orthology between human and 
zebrafish (Howe et al., 2013), multiple disease models have been generated in 
zebrafish, including for SMA and other MNDs (reviewed in Patten et al., 2014), and 
so utilisation of the zebrafish for translational approaches is also increasing. Due to 
the large clutch sizes, ease of drug incubation in the aqueous medium, and 
physiological relevance of analysing the whole organism, zebrafish are an excellent 
model for medium- to high-throughput drug screening (Langheinrich, 2003; Tamplin 
et al., 2012; Phillips and Westerfield, 2014). 
Zebrafish have been traditionally used in phenotypic screens to identify biologically 
active compounds (MacRae and Peterson, 2015). This is because of their biological 
accessibility during embryonic and larval stages, and their optical transparency for 
imaging studies. There are a wide array of both forward-genetics mutants (extensively 
generated for example in the Tübingen/Harvard ENU mutagenesis screen and 
published in Development in 1996, (e.g. Driever et al., 1996; Furutani-Seiki et al., 
1996)) and targeted genomic editing tools such as CRISPR/Cas9. Comparison 
between the drug phenotype and phenocopied mutants helps to rapidly identify the 
protein target of the compound. 
There are two general strategies for phenotypic screens in zebrafish. Wild-type larvae 
may be treated with drugs, and any aberrant phenotype identified to find similarity with 
an expected mutant or tissue target. For example, drugs which altered the gross 
morphology were identified as phenocopying hedgehog-null mutants. Further study 
into the compound target showed that it bound to other proteins than the canonical 
Hedgehog / Patched / Smoothened pathway (Williams et al., 2015). An increased 
motor response to light was used to find compounds which activate sensory neurons 
in the embryo (Kokel et al., 2013).  
The other strategy used in zebrafish screens is to identify compounds which rescue 
a mutant or injury model. For example, cessation of a seizure response in mutant 




(Baraban, Dinday and Hortopan, 2013). Ephrin4A was identified as a disease-
modifying protein in ALS using a morpholino-based screen. A SOD1 overexpression 
model was screened for axonal rescue after injection by a library of morpholino. 
Knockdown of Ephrin4A rescued the axons, demonstrating that inhibition of its 
expression could be a therapeutic target (Van Hoecke et al., 2012). A screen to 
identify regenerative pathways used a fin amputation model and looked for 
compounds which abolished regeneration. From this, glucocorticoids were identified 
as necessary for the regeneration, offering insight into the regenerative mechanisms 
(Mathew et al., 2007). 
 
1.6 – Statement of Aims 
 
Overall, in this thesis I developed our understanding of the role and mechanism of 
chondrolectin during motor axon development. It has already been established that 
chondrolectin is required for motor axon growth in zebrafish, and that there is a link 
between chondrolectin and SMA, observed in zebrafish, mouse, and rat models of 
the disease. However, little was known about the mechanism by which chondrolectin 
acts in the motor axon to induce axon growth. There was also very limited information 
about how loss of chondrolectin function could impact later developmental stages in 
the larvae or adult, including behaviour. 
My overarching hypothesis is that there is a link between chondrolectin, SMA, 
synapse deficits, and motor axon growth. Therefore, I speculate that chondrolectin is 
required for motor axon growth due to facilitating synapse stabilisation, and 
synaptogenesis is required for correct axonal growth. Thus, chondrolectin dysfunction 
is involved in SMA pathology by contributing to synaptic defects. 
The main aims of this thesis are as such: 
1. Generate and characterise a knockout zebrafish mutant for chondrolectin, 
detailed in Chapter Three. 
2. Investigate the mechanism of the chondrolectin protein to perform its function 
in zebrafish, described in Chapter Three. 
3. Analyse any changes to the motor synapses in the chondrolectin knockout, 




4. Design a drug screening protocol using the chondrolectin mutant to find axon-










2.1 – Zebrafish husbandry and techniques 
 
2.1.1 - Zebrafish husbandry 
 
All fish were kept and bred in our laboratory fish facility according to standard 
procedures (Westerfield, 2000). The adults were kept on a 14-hour light/10hour dark 
cycle at 26.5 °c. The embryos were raised at 27.5°c in E3 medium with 0.00001% 
methylene blue. All embryonic and larval experiments were performed under the 5 
dpf developmental stage (the time-point that the animals become regulated under the 
Animals in Scientific Procedures Act (1986)). Generation and maintenance of 
genetically-modified animals as adults were approved by the British Home Office 
(project license no.: 70/8805).   
Fish lines used were the WIK wild-type strain of zebrafish and the HB9:GFP 
transgenic line (Tg:mnx1:GFP) (Flanagan-Steet et al., 2005). Further transgenic lines 
and mutants were generated using CRISPR/Cas9 and Tol2 transgenesis as 
described below. These lines are chodl -/-, and chodl-/-;HB9:Chodl-FLAG.  
 
Line name Background 
strain 
Method  Specific 
mutation 
Phenotype 









within 9 aa of 
the start site 
Short CaP motor 






Tol2  Insertion of the 
HB9 promoter 
Axonal rescue of 










in motor neurons 
 
 
2.1.2 - Microinjection of eggs 
 
Thin-walled glass capillaries containing an internal filament (World Precision 
Instruments) were prepared as microinjection needles. The glass capillary tubes were 
pulled using a P-97 Sutter needle puller and stored in petri dishes containing blu-tack 
to prop the tips up until use. The needle-pulling settings are tabled below: 
 
Ramp – 598 Pull – 100 Velocity – 150  
Heat – 410  Time – 200   
 
 
Prepared injection solutions were backfilled into the glass needles using long-tailed 
pipette tips (Eppendorf). The needles were loaded into a micromanipulator attached 
to a microinjector (Narishige IM-300) and the tips broken using tweezers. The injection 
volume was calibrated by injecting a bolus into mineral oil on a slide marked with a 
µm scale bar. Adjusting the pressure and injection duration manually, we calibrated 
the bolus to total 1 nl. 
Freshly-laid eggs at the single cell stage were arrayed in a line against a microscope 
slide in a petri dish and the majority of liquid removed. Using a fine pipette tip, the 
eggs were each oriented with the cell in view and injected into the single cell. 
Approximately every 8 eggs the needle was rinsed in the medium and checked for 
volume injection, to ensure no blockages of the needle-tip. Injected eggs were rinsed 







2.1.3 - Zebrafish DNA extraction & genotyping 
 
Embryos were digested whole using a solution containing 2.5µl Proteinase K 
(Invitrogen), 10µl Taq polymerase buffer (New England Biolabs) and 90µl dH2O and 
heating to 65° for 20 minutes, vortexing, and then heating to 95’ for 15mins. The 
solution was then vortexed again, spun down and 40ul of supernatant removed for 
storage at -20° for use as a PCR template. 
Adult zebrafish fins were cut by first anaesthetising the fish in 1:500 MS-222 (Sigma) 
and cutting off a small portion of fin (approximately 2 mm from the fin edge) using a 
clean scalpel blade. The fish were then returned immediately to water in single tanks 
and monitored for recovery. The fin piece was digested in the same buffer as the 
embryos above and heated in the same sequence as the embryo DNA extraction. 
The DNA was amplified using genotyping primers which span a ~300bp region around 
the gRNA target sequence. The amplicons were digested with the restriction enzyme 
for each target and run on a 2% agarose gel with the undigested amplicon for 
comparison. An undigested band demonstrates destruction of the restriction site via 
indel mutations by the Cas9. For gRNA1, which generated the chodl mutant line, the 
primers are (forward 5’GAC TGG AGC AAG TCT GTG 3’ and reverse 5’ CTG CAC 
GAG ACC AGA AAA 3’, with BspCNI as the restriction site). gRNA2 genotyping 
primers are (forward 5’ GTT CTG GGA GGC TCT GC 3’ and reverse 5’ AAA CGC 
AGA GCC TCC CAG AAC G 3’, with PstI as the restriction enzyme). gRNA3 
genotyping primers are (forward 5’ TAG GTC CTG TCC CAA TCT GTA C 3’ and 
reverse 5’ AAA CGT ACA GAT TGG GAC AGG A 3’, with BsrGI as the restriction 
enzyme site). The full list of primers arranged in a table are available in Section 2.3. 
 
2.1.4 - Generation of a chodl -/- mutant zebrafish using CRISPR/Cas9 
 
Three gRNAs targeting Exon 1 of the chondrolectin gene were designed using 
http://crispr.mit.edu/. (Hsu et al., 2013). The top guides were selected for estimated 
cutting efficiency and fewest off-target sites, and for a restriction site to use in 
genotyping. Oligos for these gRNA sequences were generated using 




annealed and ligated into the pT7 vector as described (Jao, Wente and Chen, 2013). 
The pT7-gRNA plasmid maps are shown in Figure 2.1, Figure 2.2, and Figure 2.3. 
The gRNAs and Cas9 mRNA were transcribed and purified before being stored at -
80°c (described in the next section, 2.1.6). Each gRNA was co-injected with Cas9 
mRNA into single-cell HB9:GFP embryos, with an injection volume of 1nl. The injected 
gRNA concentration was 15ng/ul and the Cas9 concentration was 150ng/ul.  
At 24hpf, the embryos were checked for normal gross morphology and motor axon 
appearance. 5 embryos in each injection clutch were pooled for DNA extraction and 
genotyping to determine cutting efficiency of the gRNA target sequence. 
G0 injected fish for gRNA1 were raised and outcrossed into the HB9:GFP fish line. 
F1 adults were fin-clipped and genotyped for heterozygous mutation in the target 
sequence. Founders had deletions of ΔCTCA and ΔACACT in Exon1 of 
chondrolectin, leading to frameshift mutations and premature stops in Exon 2. The 
ΔCTCA founder was then crossed into both the HB9:GFP and WIK lines to generate 
mutant lines with and without GFP in the motor neurons. These adults were then 
incrossed. In the HB9:GFP line, 25% of the clutch showed a shortened axon 
phenotype. These phenotypic embryos were selected and raised to generate 
homozygous mutant stocks, and some were used to sequence the DNA and confirm 
homozygosity of the indel. For the WIK mutant line, homozygous adults were selected 
by genotyping through fin-clipping. The shortened axon phenotype in these fish were 
later confirmed by SV2 staining in their offspring. 
 
2.1.5 - Generation of a chodl -/-;HB9:chodl-FLAG zebrafish line using Tol2 
transgenesis 
 
chodl -/- embryos were injected at the single-cell stage with 1nl of a mixture of 
transposase mRNA (50ng/µl) and tol2-HB9:chodl-FLAG (25ng/µl) dissolved in 
RNAse-free water. At 24hpf, embryos were selected which showed a mosaic rescue 
of axon length. These fish were raised and backcrossed into the chodl -/- line, with F1 
embryos selected which showed rescue of all motor axons at 24hpf. Transmission of 
the HB9:chodl-FLAG expression was also confirmed using FLAG 






2.1.6 - Zebrafish larval behaviour 
 
To analyse swimming differences between wild-type and mutant larvae, 3dpf larvae 
were touched with a fire-pulled pipette on the median fin fold. The swim path of their 
escape response was recorded and analysed using a Noldus behaviour analysis set-
up and EthoVision software (v. 7). Behavioural data is shown as distance travelled 
within 15 s after touch, averaged for triplicate measures per larvae. 
To measure turning defects in the chodl mutants, we recorded larvae using a Casio 
EX-ZR1300 camera with high-speed recording set to 1000 frames/second. Larvae 
were recorded before, during, and after an escape response from a head tap using a 
fire-pulled glass pipette. The videos were manually viewed, and the angle of the initial 
escape after the C-bend recorded. The escape response was recorded in triplicate 
per larva. 
 
2.1.7 - Drug treatment of embryos 
 
24-well plates were prepared by filling each well with 699 µl of E3 medium. 1 µl of 
each drug solution (10 mM stock concentration) was added and the plate gently 
swirled to dissolve the compound in each well. A pipette tip was widened by trimming 
the tip off. At 6 hpf, once embryos had reached the shield stage and gastrulated, they 
were carefully dechorionated using insect pins. After dechorionation, 6 embryos in a 
group were carefully drawn up into the widened pipette tip in a volume of 300 µl, and 
carefully dispensed into each well, to a total volume of 1000 µl. The embryos were 










2.2.1 – Primer design 
 
Primer oligos for PCR were designed manually, by planning the binding sequences 
and calculating the GC content to be between 40-60%. The melting temperature (Tm) 
of the primers was calculated using the OligoCalc online tool 
(http://biotools.nubic.northwestern.edu/OligoCalc.html). The addition of any further 
restriction sites or tags was then added onto these oligos, without adjusting the Tm 
as these do not bind the target sequence. The oligos were ordered from and produced 
by Integrated DNA Technologies (IDT). 
 
2.2.2 – Polymerase Chain Reaction (PCR) 
 
PCRs were carried out using the Expand High Fidelity PCR System (Roche). This kit 
includes a proof-reading polymerase, allowing higher efficiency when amplifying 
larger fragments or inducing mutations via primers during the PCR. The reaction 
mixture per PCR was made as a master mix according to manufacturers’ instructions.   
 The PCR cycler was set to the following reaction protocol, with the extension time 











2.2.3 – Gel electrophoresis and extraction of DNA 
 
2.5% 
Agarose gels with 0.0001% Gel Red (Biotium) in TAE buffer were used to separate 
PCR amplicons and digested plasmid fragments using electrophoresis. Appropriately 
sized DNA ladders (NEB) were also run in adjacent columns and used to determine 
the correctly sized band. The bands were illuminated under UV light and excised using 
a clean scalpel. The DNA was extracted from the gel using the QIAquick Gel 
Extraction Kit (Qiagen). 
 
2.2.4 – Ligation of PCR fragments 
 
TA cloning was performed using either a TOPO TA Cloning Kit (Invitrogen), or 
Strataclone PCR Cloning Kit (Agilent) according to manufacturers’ instructions. This 
ligates a PCR fragment containing A base overhangs (left by the Taq polymerase 
during PCR) into a linear vector with T base overhangs. The ligated vector is then 
transformed into competent cells. TA cloning was used to amplify PCR fragments in 
plasmids for mini-prepping and sequencing. 
T4 ligation of DNA fragments into linearised vectors was performed to generate the 
final plasmids for injection into zebrafish. T4 ligase and ligase buffer (NEB) were used 
to ligate DNA fragments according to protocols available from the manufacturer.  
 
2.2.5 – Transformation of competent bacterial cells and growth on agar plates 
 
5-alpha competent cells (NEB) were stored at -80°c until use, then thawed on ice. To 
maintain an aseptic environment, bacterial work was performed adjacent to a Bunsen 
burner to generate an air stream. The cells were gently mixed with 2µl of plasmid 
solution after ligation or TA cloning mix and incubated on ice for 15 minutes. Heat-
shocking was performed at 42° for 45 seconds before returning the tubes to ice for 2 












Final elongation  5 min 68° 




mins. 200 µl of LB medium was added to the cells and incubated on a 37 ° shaking 
incubator for at least one hour before being spread onto antibiotic-treated agar plates 
and incubated overnight at 37°.   
 
2.2.6 – Picking bacterial colonies and growing bacteria in LB media 
 
After overnight incubation following bacterial transformation, agar plates were 
wrapped in parafilm to prevent drying out and stored in a 4° cold room until needed. 
To maintain an aseptic environment, bacterial work was performed adjacent to a 
Bunsen burner to generate an air stream. Bacterial colonies were prepped for mini- 
or midi- kits by first preparing antibiotic-containing LB medium in either 5ml or 50ml 
falcon tubes, depending on downstream application. The antibiotic chosen depended 
on the antibiotic resistance included in the plasmid, either ampicillin at 100 µg/ml or 
kanamycin at 50 µg/ml. A single colony at a time was carefully picked using a pipette 
tip, streaked on a fresh agar plate to generate a master plate, and then dropped into 
the falcon tube. After overnight incubation on a shaking incubator at 37°, the broth 
was then used to isolate plasmid DNA for sequencing or further applications. 
 
2.2.7 – Isolation of plasmid DNA from bacterial culture 
 
Plasmid DNA was isolated using commercial Mini- or Midi- Kits (Qiagen) according to 
manufacturers’ instructions. Glycerol stocks of the bacterial culture were generated 
for long term storage at -80° by mixing 175 µl of glycerol with 325 µl of bacterial broth. 
Determination of the DNA concentration was performed using a Nanodrop (Thermo 
Scientific) calibrated against the elution medium. DNA solutions were stored at -20° 
until needed. 
 
2.2.8 – Sanger sequencing of DNA  
 
Sequencing of plasmid DNA was performed using the commercial service from 
Source Bioscience (www.sourcebioscience.com). Sequencing primers were provided 




flanking the region of interest to be checked, and the specific primers were selected 
according to the expected sequence or the vector backbone. 
The sequences were sent from Source Bioscience as SEQ or AB1 files via email and 
viewed using ContigExpress. Sequences were compared on ContigExpress with 
reference sequences from NCBI (https://www.ncbi.nlm.nih.gov/) to determine if the 
correct sequence had been generated (e.g. when generating mutated constructs) or 
if the cassettes had been ligated correctly into the plasmids. 
 
2.2.9 – Restriction digest of DNA by restriction enzymes 
 
Restriction digest of DNA was performed using restriction enzymes (NEB) and a 
suitable buffer (NEB) according to standard protocols. Double digestion using two 
enzymes simultaneously was first checked for the most suitable buffer using the NEB 
Double Digest online tool (https://nebcloner.neb.com/#!/redigest). The following 
enzymes were used: 




BamHI (High-Fidelity) CutSmart 37° 
BglII Buffer 3.1 37° 
BspCNI CutSmart (+SAM) 25° 
BsmBI Buffer 3.1 55° 
BsrGI Buffer 2.1 37° 
ClaI CutSmart 37° 
EcoRI Buffer 2.1 / EcoRI Buffer 37° 
EcoRV Buffer 3.1 37° 
HindIII Buffer 2.1 37° 
NotI Buffer 3.1 37° 
PstI (High Fidelity) CutSmart 37° 
SalI (High Fidelity) CutSmart 37° 
XbaI CutSmart 37° 






2.2.10 - Production of capped mRNA for microinjection 
 
gRNA was transcribed using the mMessage mMachine T7 Transcription kit 
(Invitrogen) after the plasmids were linearised with BamHI. Because of the small size 
of the gRNAs, the RNA was cleaned up using the mirVana miRNA Kit (Ambion). 
The Cas9 mRNA was prepared from the pT3TS-nCas9n plasmid, linearised with XbaI 
and transcribed using the mMessage mMachine T3 Transcription Kit (Invitrogen). The 
mRNA was cleaned up using the RNeasy Mini Kit (Qiagen) and stored as aliquots at 
-80°c. 
The pT3TS-Tol2 plasmid was linearised by digestion with XbaI, and capped mRNA 
produced using the mMessage mMachine T3 Transcription kit (Invitrogen). RNA 




2.2.11 – Cloning and generated plasmids 
 
To generate the plasmids used in various experimental procedures the following 
vectors were used: The gRNA scaffold vector pT7-gRNA was a gift from Wenbiao 
Chen (Addgene plasmid # 46759), the Cas9 expression vector pCS2-nCas9n was a 
gift from Wenbiao Chen (Addgene plasmid # 47929). Tol2 transgenesis plasmids of 
transposase mRNA sequence pT3TS-Tol2 was a gift from Stephen Ekker (Addgene 
plasmid # 31831) and pminiTol2 vector (gift from Stephen Ekker, Addgene #31829). 
pCS2P+ was a gift from Marc Kirschner (Addgene # 17095). pCMV-chodl-myc was 
used in Zhong et al., 2012, generated in our group. All restriction enzymes and buffers 
used were from New England Biolabs.  
The full list of primers arrayed in a table are available in Section 2.8, as are schematics 
of the plasmids generated in Section 2.9.  
The chodl gRNA1 was generated by ordering two overlapping oligos, generated using 
http://ZiFit.partners.org/ using the target sequence. The oligos were annealed 
together using a PCR cycler and ligated into the pT7 vector as described (Jao, Wente 
and Chen, 2013). (Forward 5’ TAG GAG GAT GCG CGC GAC ACT C 3’, reverse 5’ 




same manner as gRNA1. (Forward 5’ TAG GCG TTC TGG GAG GCT CTG C 3’, 
reverse 5’ AAA CGC AGA GCC TCC CAG AAC G 3’). The chodl gRNA3 was 
generated in the same manner as gRNA1 above. (Forward 5’ TAG GTC CTG TCC 
CAA TCT GTA C 3’, reverse 5’ AAA CGT ACA GAT TGG GAC AGG A 3’).  
pCS2P-chodl-FLAG was generated by amplifying the chondrolectin coding sequence 
from pCMV-chodl-myc, adding an artificial Kozak sequence (AAC) 5’ of the start site 
and adding a Gly-Pro-Gly linker and a synthetic FLAG tag to the 3’end. (Forward 
EcoRI 5’ GCG GAA TTC AAC ATG CGC GCG ACA CTC AGG 3’, Reverse XhoI 5’ 
GCG CTC GAG TCA TTT ATC ATC ATC ATC TTT ATA ATC TGG TCC TGG GAC 
CTC CAT GCC ACT 3’). The amplified chodl-FLAG was digested and ligated into 
pCS2P+ to generate pCS2P-chodl-FLAG. The map for this plasmid is included as 
Figure 2.4.  
The pMiniTol2-HB9 plasmid was generated by Dr Ana-Maria Oprişoreanu. The 3kb 
promoter fragment of HB9 was amplified from genomic DNA using the forward primer 
(NotI) 5’- GCG GCG GCC GCC CAT TTA AAT TAG CCT GGC ATC TGG AC-3’ and 
reverse primer (EcoRI) 5’-GCG GAA TTC TCT GGC CCA CCT CAC AAA CAG-3’), 
and the fragment was cloned into the NotI-EcoRI pminiTol2 digested vector. 
The pMiniTol2-HB9:chodl-FLAG plasmid was cloned by amplifying the chodl-FLAG 
cassette and SV40 from the pCS2P-chodl-FLAG, and subcloning into the pMiniTol2-
HB9 plasmid. (Forward EcoRI 5’ GAT TCG AAT TCA ACA TGC GCG 3’, Reverse 
EcoRV 5’ CGA TGA TAT CAA AAA ACC TCC CAC ACC TCC C 3’). The map is linked 
as Figure 2.5. 
To generate the construct pMiniTol2-HB9:Chodl-FLAG (w/o ID)(1-263aa), the 
chondrolectin coding sequence until the TM domain was amplified and a linker with 
FLAG tag added, using the pCS2P-chodl-FLAG as template. (Forward EcoRI 5’ ATG 
CGA ATT CAA ACA TGC GCG CGA CAC TCA GG 3’, Reverse XhoI 5’ GCA TCT 
CGA GTT ACT TGT CGT CAT CGT CTT TGT AGT CAG GGC CAG GGA AAC AGC 
ACG TCC CTG AAG 3’). This fragment was subcloned into the pCS2P+ vector and 
used as a PCR template to add the SV40 sequence for ligation into the pMiniTol2-
HB9 plasmid (Forward EcoRI 5’ GAT TCG AAT TCA AAC ATG CGC G 3’, Reverse 
EcoRV 5’ CGA TGA TAT CAA AAA ACC TCC CAC ACC TCC C 3’).  The map is 




To generate pMiniTol2-HB9:Chodl-FLAG (w/o CTLD) (1-29Δ188-296aa), two 
intermediate chodl fragments were generated 5’ and 3’ of the C-type Lectin domain 
sequence (Cassette 1 Forward EcoRI 5’ ATG CGA ATT  CAA ACA TGC GCG CGA 
CAC TCA GG 3, Reverse XhoI 5’ GCA TCT CGA GCA CTG TCT GAC CGC TCA 
CAA 3’, Cassette 2 Forward XhoI 5’  ATG CCT CGA GTA TGA ACC AGA AAG TCA 
TCT GG 3’, Reverse XbaI 5’ GCA  TTC TAG ATT ACT TGT CGT CAT CGT CTT TGT 
AGT CAG GGC CAG GGA CCT CCA TGC CAC 3’). These were ligated together into 
the pCS2P+ vector, and then the whole chondrolectin cassette and SV40 amplified to 
ligate into pMiniTol2-HB9. The primers for this amplification are the same as 
previously used to generate the final cassette of the chodl w/o ID. The map is available 
at Figure 2.7.  
To generate pMiniTol2-HB9:Chodl-FLAG (w/ ID S/T->A) (1-263aa, S/T-A 264-296aa), 
the intracellular sequence 3’ of the transmembrane domain was mutagenised using 
PCR primers. A sequence of 4 primers were used, which first bound to the TM domain 
and added 30bp of mutagenised sequence, then bound to the last 20bp of each 
successive mutagenised sequence and added another 30bp. The final primer also 
contained the Gly-Pro-Gly linker and FLAG tag. In each case, the forward primer was 
the same. (Forward EcoRI 5’ ATG CGA ATT CAA ACA TGC GCG CGA CAC TCA 
GG 3’, Reverse 1 5’ AGC TTT AGC CCG TGG TTT AGC CTT AGC CAA CAT CTG 
GAA ACA GCA CGT CCC TGA AG 3’, Reverse 2 5’ CGT CTT AGC GAT CCA GAG 
AGC AGC TTG GTT GAC AGC AGC TTT AGC CCG TGG TTT AGC 3’, Reverse 3 
5’ GAC CTC CAT GCC AGC GTC TAT CTT AGC CGT CTT AGC GAT CCA GAG 
AG 3’, Reverse 4 5’ GCA TCT CGA GTT ACT TGT CGT CAT CGT CTT TGT AGT 
CAG GGC CAG GGA CCT CCA TGC CAG CGT C 3’). As described for the other 
truncated constructs, the cassette was ligated into the pCS2P+ vector and re-
amplified with the SV40 sequence, and ligated into the pMiniTol2-HB9 plasmid. The 









2.3 – Histology, staining, imaging, and analysis 
 
2.3.1 - Zebrafish wholemount immunohistochemistry 
 
2.3.1.1 – Immunohistochemistry at 28 and 31 hpf 
 
Between 24 and 30hpf, the zebrafish embryos were dechorionated and fixed for 45 
minutes at RT in 4%PFA/1%DMSO. This under-fixation is necessary for the low signal 
in the synapse preparations and the injected FLAG constructs. The embryos are then 
rinsed 3x5mins with PBS+0.1%Triton-X100 and blocked using blocking buffer 
containing 1% normal donkey serum (1%DMSO, 1%BSA, 0.7%Triton-X100 in PBS 
pH7.4) for 60-90minutes at RT with gentle shaking. The embryos are then incubated 
O/N at 4’ with the primary antibodies in blocking buffer with 1% NDS. Primary 
antibodies were: anti-GFP (1:400, AbCam, AB13970), anti-FLAG (1:100, Sigma, 
F1804), anti-SV2 (1:200, DSHB), and anti-AChR (1:200, DSHB, mAb35). The primary 
antibodies were washed off using PBS-Tx 6x10mins and the secondary antibody 
incubated for 4h at RT. Secondary antibodies used were: AlexaFluor488 donkey anti-
chicken (1:400, Jackson ImmunoResearch), AlexaFluor 594 donkey anti-mouse 
(1:400 Jackson ImmunoResearch), AlexaFluor 594 donkey anti-mouse with pre-
adsorbtion against rat protein (1:400, Jackson ImmunoResearch), and AlexaFluor 
488 donkey anti-rat with pre-adsorbtion against mouse protein (1:400, Jackson 
ImmunoResearch). After fully rinsing off the secondary antibody, the embryos were 
settled in 70% glycerol/30% PBS and stored wrapped in foil at 4’ until imaging.  
 
2.3.1.2 – Immunohistochemistry at 3 dpf 
 
At 3dpf, the larvae were fixed in 4% PFA/1%DMSO for 4h at 4’. After 3x10 mins rinsing 
in PBS+0.1% Triton-X100, the larvae were skinned to permeabilise the muscle to the 
synaptic antibodies. The larvae were insect-pinned to a sylgard-coated petri dish and 
most of the liquid sucked away from the larvae. Sharpened tungsten wire was used 
to gently pull the skin away from the head area, and fine forceps were then used to 
fully pull the skin off the trunk and tail. After skinning, the larvae were blocked for 60-




antibodies were used at the same concentrations and incubation time as described 
for the embryos. 
2.3.1.3 – Phalloidin staining at 30 hpf 
 
Carrying out all steps on a gentle shaker, embryos were fixed overnight at 4° in 4% 
PFA in PBS, OR 2 hours at RT. After washing 2 x 5 minutes in PBSTw (PBS+0.1% 
Tween-20) OR in PBSTx (PBS+ 0.2% Triton-X-100), embryos were inncubated for 2h 
in PBS + 2% Triton X-100 to permeabilise the tissue. Further washes were performed, 
2 x 5 mins in PBSTw or PBSTx, before 1.5h incubation in phalloidin-AlexaFluor564 
solution (dilute the stock 1:20 in PBSTw). Final washes of 6x 10 minutes in PBSTw 
or PBSTx were performed before mounting in glycerol and imaging. 
To quantify differences in myotube architecture, the average number of myotubes per 
somite were counted, and the average thickness of a myotube measured. 
Measurements were taken along the midline of the somite, and the values from 3 
somites were averaged for each embryo.  
 
2.3.2 – Microscopes and imaging 
 
All zebrafish were mounted onto glass slides using 70% glycerol, deyolked with insect 
pins, and covered with coverslips anchored with silicone gel. Several microscopes 
were used during this study.  
To sort reporter lines by their fluorescence, and to initially sort phenotypic embryos 
during establishment of transgenic lines, a fluorescent stereomicroscope (Leica) was 
used. To image axons for the initial phenotypic analysis of the chodl -/- phenotype, a 
Zeiss Apotome.2/ImagerZ1 upright microscope was used. To image the zebrafish 
after immunohistochemistry, a Zeiss LSM880 with Airyscan was used.  
To image the embryos during the drug screening, the VAST BioImager was linked to 
a custom spinning disk confocal microscope. Information on the set-up is available 
from Early et al., 2018. An Axio Examiner D1 (Carl Zeiss) microscope was fitted with 
a high- speed CSU-X1 spinning disk confocal scanner (Yokogawa, Tokyo, Japan), 
with a high-speed piezo drive to generate rapid Z-stacks. (PIFOC P-725.4CD piezo 





2.3.3 – Loading and imaging by the VAST BioImager 
 
After drug treatment, 25 hpf embryos were carefully pipetted 3 at a time in 300 µl of 
medium and transferred into 96 well plates. The vehicle-treated control groups were 
randomly arrayed in the wells to control for the development of the embryos over time 
during imaging. The 96 well plate was then fitted into the plate loading bay of the 
VAST BioImager platform.  
The VAST BioImager (Union Biometrica) was combined with a spinning disk confocal 
microscope (SDCM, Zeiss) (further described in Early et al., 2018). Following an 
adapted protocol from this publication, optimised for 26-30 hpf embryos (described in 
detail during Chapter Five), the embryos from each well were automatically loaded, 
rotated in the imaging chamber to the lateral view, and imaged with both brightfield 
and GFP channels. During imaging, a CSV format file was generated giving each 
image set a number and well location. After imaging, this CSV and the images were 
loaded into a Zen macro (Early et al., 2018) which generated maximal intensity 
projections of each stack. The MIPs were then stitched together using an ImageJ 
macro (Early et al., 2018) and these stitched images were scored. After scoring, the 
experiments were unblinded using the image number and well location from the CSV 
file to determine the treatment. 
 
2.3.4 – Body length and eye diameter measurements 
 
For both body length and eye measurement, ImageJ and its straight line tool was 
used to measure the diameter of the eyes and the body length from nose to tail tip, 
from HB9:GFP and chodl-/- embryos at 30hpf. When using the VAST BioImager to 
sort and image embryos, the VAST platform generates a brightfield image of the 
capillary chamber containing the embryo. These images are BMP files without 







2.3.5 – Analysis of axon score and axon length 
 
Axons scoring was performed by loading maximum intensity projections (MIPs) into 
Image J. The axons were scored if they were at the position of the horizontal 
myoseptum (HM) or if they had grown past that point (HM+). The horizontal 
myoseptum location is visible due to the slight morphological thickening of the axon 
at this choice point. For the axonal scoring, 8 axons from somite 7-15 per embryo 
were scored and the mean percentage of HM+ axons calculated.  
Axon length measurements were performed using ImageJ. The images were loaded 
containing the metadata for pixel-µm scale. Using the segmented line feature, axons 
were traced from the border between the axon and cell body, to the tip of the axon. If 
the axon was branched at the tip, the longest branch was followed. Upon completing 
the axon trace, the length of the segmented line was measured. For all experiments 
which recorded CaP axon length, unless otherwise stated, 8 axons per embryo were 
measured.  
To quantify branching of the axons at 48 hpf and 72 hpf, maximum intensity 
projections of the trunk were generated, with both wild-type and chodl -/- larvae 
expressing the HB9:GFP transgene. Branching from 8 axons (from somite 7-15) were 
quantified for each larva. The number of branches were counted by tracing lines from 
the spinal cord ventrally, at a distance 10 µm (48 hpf) or 15 µm (72 hpf) anterior and 
posterior from the main axon. Branches that crossed each line were counted. This 
counted the number of branches but discarded small filopodia or very minor branches 
coming from the axon. Branches on both sides of the axon were added together and 
then averaged for each larva.  
 
2.3.6 – Quantification of chodl -/- rescue by injection of truncated chondrolectin 
constructs 
 
Truncated constructs of chondrolectin-FLAG were generated and subcloned into the 
pMiniTol2-HB9 plasmid. These constructs are: chondrolectin without the 3’ sequence 
after the predicted transmembrane domain, removing its intracellular domain (chodl 




and chondrolectin with the serine and threonine residues converted to alanine 
residues in the intracellular domain (chodl w/ ST->A ID).  
These truncated constructs, or the empty pMiniTol2-HB9 plasmid, or full-length 
pMiniTol2-HB9:Chodl-FLAG, were injected into chodl -/- embryos at the single-cell 
stage, with a volume of 1nl. Transposase mRNA was co-injected at 50 ng/µl, and the 
plasmid concentration was 25 ng/µl.  
At 28hpf, the embryos were dechorionated, fixed, and immunohistochemistry of GFP 
and FLAG was performed. The embryos were imaged, and the axon length measured 
using ImageJ, as well as the presence or not of FLAG expression. Axons were only 
considered FLAG positive if the FLAG staining was visible along the full length of the 
axon, and if the FLAG-positive cell body matched the morphology of the CaP axon, 
as published in Meyer, Eisen, & Westerfield (1986). This prevented the measurement 
of RoP or MiP axons, which partially share the path of the CaP axon.  
 
 
2.3.7 - Synapse puncta quantification 
 
The pre- and post-synapses of zebrafish were labelled using α-SV2 and α-AChR 
labelling and imaged using a confocal microscope as described above. All 
measurement of the synaptic puncta was performed in ImageJ. For analysis, a 20 x 
20 µm2 square was drawn around the horizontal myoseptum in 28hpf embryos, with 
4 axons measured and the values averaged for each embryo. To determine synaptic 
measurements in the axonal branches at 3dpf, a 40 x 40 µm2 square was drawn in 
the dorsal region of the myotome, with 3 myotomes averaged per larva.  
In each square, synaptic puncta were analysed with the following analysis pipeline, 
performed in ImageJ. First, the background in each image was reduced by performing 
background subtraction of the images, using a rolling ball subtraction with a radius of 
33% of the square’s length in pixels. The maximum grey value was measured after 
smoothing function was applied for each image, and used to calculate a 20% 
threshold. This had to be calculated for each image due to biological variation in the 
intensity of staining and thus intensity of the signal captured by the confocal. The 20% 
threshold was then applied to the non-smoothed image to remove the lowest 20% of 




Application of a 20% threshold was qualitatively determined to remove much of the 
noise in the image without removing any true synaptic staining. After application of 
the threshold, the Analyse Puncta function was used to count puncta number and 
area. The minimum area defined as a punctum for the Analyse Particle function was 
set as 0.5µm2. Again, this was qualitatively determined as the minimum size to not 
quantify any remaining background noise and only measure true puncta. 
 
2.3.8 - Statistical analysis 
 
For all experiments, the person performing the analysis was blinded to the condition 
or group until after all measurements were concluded. Data is shown as mean ± 
standard error of mean (SEM), and all N numbers refer to number of embryos unless 
otherwise stated. All statistical tests and graphs were produced using GraphPad 7 
software. All data was checked for Gaussian distribution via a D’Agostino-Pearson 
omnibus normality test before further statistical tests were performed. The statistical 
test between two groups was either a student’s t-test or Mann-Whitney test, 
depending on whether the data set followed Gaussian distribution or not. The 
student’s t-test also had Welch’s correction applied if the variances between groups 
differed significantly. The statistical test between three or more groups was either a 
one-way ANOVA or Kruskal-Wallis test, depending on if the data set was normally 
distributed or not. Comparison tests between groups after a one-way ANOVA was 
Bonferroni’s multiple comparison test and after Kruskal-Wallis was Dunn’s multiple 
comparison test. Multiple comparison tests were always performed to compare all 
groups to every other group. Post-hoc power calculations were performed on 
statistically significant data using GPower 3.1. 
 
2.3.9 – Software 
 
Data was collected on Microsoft Excel before being transferred to GraphPad Prism 
for statistical testing and generation of graphs. All images were analysed using Fiji 
(ImageJ). Image macros for Zeiss Zen software and ImageJ, used to process the 
VAST BioImager data, are published in Early et al., 2018. Figures were generated 




VectorNTI and SnapGene Viewer. The content of this thesis was written using 
Microsoft Word 2016 and the bibliography managed by Mendeley desktop and its 













Agarose Sigma-Aldrich (BPE1356) 
Aminobenzoic acid ethylmethylester 
(MS-222) 
Sigma-Aldrich (A5040) 
Ampicillin sodium salt Sigma-Aldrich (A9518) 
Bovine serum albumin (BSA) Sigma-Aldrich (A3912) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (D8418) 
Ethanol VWR International (64-17-15) 
6x Gel loading dye New England Bioscience (B7025S) 
Glycerol Sigma-Aldrich (G5516) 
Glycine Sigma-Aldrich (G8898) 
Hydrochloric acid (HCl) Sigma-Aldrich (320331) 
IOX1 Cayman Chemicals (11572) 
Kanamycin  Fisher Scientific (BPE906-5) 
Methanol Fischer Chemicals (67-56-1) 
Methylene blue VWR International (370.0025) 
Normal donkey serum Millipore (S30) 
Paraformaldehyde Sigma-Aldrich (P6148) 
Potassium chloride, KCl Sigma-Aldrich (P9541) 
Potassium dihydrogen orthophosphate 
(KH2PO4) 
Scientific Laboratory Supplies 
(CHE2948) 
Quickload 100 bp DNA ladder New England Bioscience (N0468S) 
Quickload 1 kbp DNA ladder New England Bioscience (N0551S) 
Sodium chloride (NaCl) Sigma-Aldrich (S7653) 
Sodium phosphate dibasic (Na2HPO4) Sigma-Aldrich (S0876) 
Sodium hydroxide (NaOH) Sigma-Aldrich (30620) 
Triton-X-100 Acros Organics (327372500) 
Trizma Base Sigma-Aldrich (93362) 
Tween-20 Sigma-Aldrich (P1379) 

















1% Normal donkey serum (NDS) 
0.7% Triton-X-100 




16 g Paraformaldehyde 
40ml 10x PBS 
complete using dH2O up to 400 ml 
 
10x Phosphate-buffered saline (PBS) 
 
160 g NaCl 
28.3 g Ma2HPO4 
4 g KCl 
4.8g KH2PO4 
Complete with dH2O to 2l 
 
 
50 x TAE Buffer 
 
484 g Tris base 
114.2 ml Acetic acid 
1000 ml EDTA, pH 8 
Adjust pH to 7.5 using HCl 
make up to 2 l using dH2O 
 
 












anti-GFP - 1:300 GFP 
 
Chicken AbCam ab13970 
 






anti-SV2 - 1:200 SV2 (isoforms 
a,b,c) 
 




mAb 35 1:200 alpha-subunit 
of AChR 
Rat DSHB mAb 35 
Phalloidin 
 
Alexa Fluor 568 
Phalloidin 
 














Fluorophore Company Product 
# 



















Alexa Fluor® 594 
AffiniPure 
Donkey Anti-















Alexa Fluor® 594 
AffiniPure 
Donkey Anti-







































Alexa Fluor® 647 
AffiniPure 
Donkey Anti-
















































5-alpha Competent E. coli (High Efficiency) 
 
New England Biolabs 
(C287H) 
Expand High-Fidelity PCR System 
 
Roche (11732641001) 
mirVana miRNA Isolation Kit, without phenol 
 
Ambion (AM1561) 
mMESSAGE mMACHINE SP6 Transcription Kit 
 
Invitrogen (AM1340) 
mMESSAGE mMACHINE T3 Transcription Kit 
 
Invitrogen (AM1348) 
mMESSAGE mMACHINE T7 Transcription Kit 
 
Invitrogen (AM1344) 
QIAPrep Spin Mini Kit 
 
Qiagen (27106) 
Qiagen Plasmid Plus Midi Kit 
 
Qiagen (12943) 
QIAQuick Gel Extraction Kit 
 
Qiagen (28706) 
RNeasy Mini Kit 
 
Qiagen (74106) 
StrataClone PCR Cloning Kit, with competent cells 
 
Agilent (240205) 






2.8 - Primers 
 




Sequence (5’ – 3’) Tm (°) 
1 chodl gRNA 1 
  
Fwd - 2 TAGGAGGATGCGCGCGACACTC 67.9 
2 chodl gRNA 1 
 
Rev - 1 AAACGAGTGTCGCGCGCATCCT 65.8 
3 chodl gRNA 2 
  
Fwd - 4 TAGGCGTTCTGGGAGGCTCTGC 67.9 
4 chodl gRNA 2 
 
Rev - 3 AAACGCAGAGCCTCCCAGAACG 65.8 
5 chodl gRNA 3 
 
Fwd - 6 TAGGTCCTGTCCCAATCTGTAC 62.1 
6 chodl gRNA 3 
 
Rev - 5 AAACGTACAGATTGGGACAGGA 60.1 




7 Genotyping for 
gRNA 1 
 
Fwd – 8 GACTGGAGCAAGTCTGTG 56.3 
 
8 Genotyping for 
gRNA 1 
 
Rev – 7 CTGCACGAGACCAGAAAA 53.8 
 
9 Genotyping for 
gRNA 2 
 
Fwd – 10 AAGACGTGTCGAGTCGTG 56.3 
 
10 Genotyping for 
gRNA 2 
 
Rev – 9 CTCTCGCAGAAGGTGTTC 56.3 
 
11 Genotyping for 
gRNA 3 
 
Fwd – 12 GACGGAGACTTCTGGATC 56.3 
 
12 Genotyping for 
gRNA 3 
 
Rev - 11 GAACAGCGAGACACTTCC 56.3 
 
     




































     




Fwd – 20, 





20 chodl w/o ID. + 
FLAG (1-266aa) 





21 addition of SV40 to 
Chodl-FLAG 
Fwd - 22 GATTCGAATTCAAACATGCGCG 60.1 
22 addition of SV40 to 
Chodl-FLAG 
Rev – 21 CGATGATATCAAAAAACCTCCCACA
CCTCCC 
61.2 
23 Chodl w/o CTLD (1-
29aa fragment) 




24 Chodl w/o CTLD 
(188-293aa 
fragment) 


















26 Chodl w/ ID (S/T-
>A) #1 
 





27 Chodl w/ ID (S/T-
>A) #2 
 





28 Chodl w/ ID (S/T-
>A) #3 
 
Rev - 19 GACCTCCATGCCAGCGTCTATCTTA
GCCGTCTTAGCGATCCAGAGAG 
60.5* 
29 Chodl w/ ID (S/T-
>A) #4 





     
 
• Please note that the Tm listed are calculated from the portion of primer binding 
to the target sequence. Addition of tags or restriction sites via primer do not 
contribute to the binding during the first stages of the PCR and thus are not 


















Figure 2.1: The pT7.chodl.gRNA1 map. The gRNA1 target sequence was 
annealed via paired oligos and subcloned into the pT7.gRNA scaffold vector 
(Addgene # # 46759, from Wenbiao Chen). BamHI was used to linearise the 














Figure 2.2 The pT7.chodl.gRNA2 map. The gRNA1 target sequence was 
annealed via paired oligos and subcloned into the pT7.gRNA scaffold vector 
(Addgene # # 46759, from Wenbiao Chen). BamHI was used to linearise the 
plasmid for mRNA transcription. 
 
Figure 2-1: The pT7.chodl.gRNA2 map. The gRNA1 target sequence was 
annealed via paired oligos and subcloned into the pT7.gRNA scaffold vector 
(Addgene # # 46759, from Wenbiao Chen). BamHI was used to linearise the 
plasmid for mRNA transcription.Figure 2-2: The pT7.chodl.gRNA2 map. The 
gRNA1 target sequence was annealed via paired oligos and subcloned into the 
pT7.gRNA scaffold vector (Addgene # # 46759, from Wenbiao Chen). BamHI 














Figure 2.3: The pT7.chodl.gRNA2 map. The gRNA1 target sequence was 
annealed via paired oligos and subcloned into the pT7.gRNA scaffold vector 
(Addgene #  46759, from Wenbiao Chen). BamHI was used to linearise the 
plasmid for mRNA transcription. 
 
Figure 2-3: The pCS2P-Chodl-FLAG plasmid map. The chodl coding sequence 
without stop and with a linker and FLAG tag added was amplified and subcloned 
into the pCS2P+ plasmid. Figure 2-4: The pT7.chodl.gRNA2 map. The gRNA1 
target sequence was annealed via paired oligos and subcloned into the 
pT7.gRNA scaffold vector (Addgene # # 46759, from Wenbiao Chen). BamHI 












Figure 2.4: The pCS2P-Chodl-FLAG plasmid map. The chodl coding sequence 
without stop and with a linker and FLAG tag added was amplified and subcloned 
into the pCS2P+ plasmid.  
 
Figure 2-5: The pMiniTol2-HB9:Chodl-FLAG plasmid map. The chodl-FLAG 
sequence and SV40 were amplified from pCS2P-Chodl-FLAG (Error! Not a valid 
bookmark self-reference.) and subcloned into the pMiniTol2-HB9 plasmid.Figure 
2-6: The pCS2P-Chodl-FLAG plasmid map. The chodl coding sequence without 
stop and with a linker and FLAG tag added was amplified and subcloned into the 













Figure 2.5: The pMiniTol2-HB9:Chodl-FLAG plasmid map. The chodl-FLAG 
sequence and SV40 were amplified from pCS2P-Chodl-FLAG (Figure 2.5) and 
subcloned into the pMiniTol2-HB9 plasmid. 
 
Figure 2-7: The pMiniTol2-HB9:Chodl-FLAG (w/o ID) map. The chodl sequence 
without intracellular domain and with a linker and FLAG tag were amplified and 
subcloned into the pMiniTol2-Hb9 plasmid.Figure 2-8: The pMiniTol2-
HB9:Chodl-FLAG plasmid map. The chodl-FLAG sequence and SV40 were 
amplified from pCS2P-Chodl-FLAG (Figure 2.4: The pCS2P-Chodl-FLAG 
plasmid map. The chodl coding sequence without stop and with a linker and 
FLAG tag added was amplified and subcloned into the pCS2P+ plasmid.  
 
Figure 2-5: The pMiniTol2-HB9:Chodl-FLAG plasmid map. The chodl-FLAG 
sequence and SV40 were amplified from pCS2P-Chodl-FLAG (Error! Not a 
valid bookmark self-reference.) and subcloned into the pMiniTol2-HB9 
plasmid.Figure 2-6: The pCS2P-Chodl-FLAG plasmid map. The chodl coding 
sequence without stop and with a linker and FLAG tag added was amplified and 










Figure 2.6: The pMiniTol2-HB9:Chodl-FLAG (w/o ID) map. The chodl sequence 
without intracellular domain and with a linker and FLAG tag were amplified and 
subcloned into the pMiniTol2-Hb9 plasmid. 
 
Figure 2-9: The pMiniTol2-HB9:Chodl-FLAG (w/o CTLD) map. The chondrolectin 
coding sequence, excluding the CTLD domain, and a linker, FLAG tag, and SV40 
was amplified and subcloned into the pMiniTol2-HB9 plasmid.Figure 2-10: The 
pMiniTol2-HB9:Chodl-FLAG (w/o ID) map. The chodl sequence without 
intracellular domain and with a linker and FLAG tag were amplified and 













Figure 2.7: The pMiniTol2-HB9:Chodl-FLAG (w/o CTLD) map. The chondrolectin 
coding sequence, excluding the CTLD domain, and a linker, FLAG tag, and SV40 
was amplified and subcloned into the pMiniTol2-HB9 plasmid. 
. 
 
Figure 2-11: The pMiniTol2-HB9:Chodl-FLAG (w/ ID S/T->A) map. The 
chondrolectin cloning sequence, with the intracellular domain Ser and Thr 
residues mutagenised to Ala, a linker, FLAG tag, and SV40 were amplified and 
subcloned into the pMiniTol2-HB9 plasmid.Figure 2-12: The pMiniTol2-
HB9:Chodl-FLAG (w/o CTLD) map. The chondrolectin coding sequence, 
excluding the CTLD domain, and a linker, FLAG tag, and SV40 was amplified 









Figure 2.8: The pMiniTol2-HB9:Chodl-FLAG (w/ ID S/T->A) map. The 
chondrolectin cloning sequence, with the intracellular domain Ser and Thr 
residues mutagenised to Ala, a linker, FLAG tag, and SV40 were amplified and 




Chapter Three - Chondrolectin acts 
cell-autonomously in motor neurons 
and is necessary for timely axon 
growth 
 
3.1 – Introduction 
 
3.1.1 – Chondrolectin is expressed in motor neurons and 
is required for correct timing of motor axon outgrowth in 
zebrafish 
 
As was introduced in Chapter One, chondrolectin (chodl) shows enriched expression 
in motor neurons. Chondrolectin was first isolated from the mouse tail muscle (Weng 
et al., 2002), and shows strong expression in the brain, spinal cord, smooth muscle, 
and spleen (Weng, Hübner, et al., 2003). In the mouse, staining for CHODL showed 
immunoreactivity in the fast-twitch motor neurons (Enjin et al., 2010). In zebrafish, in 
situ hybridisation demonstrated detectable expression in the motor neurons and 
trigeminal ganglion, from ~12 hpf onwards (Zhong et al., 2012) (Shown in Chapter 
One, Figure 1.6). Co-labelling of the chondrolectin ISH and HB9:GFP fluorescence, 
which labels motor neurons, demonstrates that chondrolectin expression is detectable 
before axons begin to extend from the spinal cord and remain detectable in the spinal 
during axon outgrowth, until at least 3 dpf (Zhong et al., 2012, Thisse et al., 2004). 
Morpholino-mediated knockdown of chodl in zebrafish showed that the CaP axon is 
shorter at 24 hpf, and the CaP axon tended to stall at the horizontal myoseptum choice 
point. This stalling of the CaP axon persists until at least 33 hpf, and MiP axons also 
fail to grow. This demonstrated that chondrolectin is required for motor axon growth 







Chondrolectin mRNA injection into the morphants rescued the axonal length, 
demonstrating the specificity of chondrolectin expression level in the axon growth. 
However, over-expression by chondrolectin mRNA injection into wild-type embryos 
also caused shorter CaP axons (Chapter One, Section 1.4.2). This suggests that the 
expression level of chondrolectin must be tightly controlled, as both over-expression 
and knockdown of chondrolectin leads to changes in the axon length compared to 
wild-type controls. 
From the findings published in Zhong et al., 2012, it is clear that chondrolectin is 
necessary for axonal growth in zebrafish. This is supported by the findings in Enjin et 
al., 2010, where chondrolectin is highly expressed in mouse fast-twitch α motor 
neurons. Primary motor neurons in zebrafish also exclusively innervate fast twitch 
muscle fibres (Menelaou and McLean, 2012; Babin, Goizet and Raldúa, 2014). As 
well as being a key gene during the development of motor axons, chondrolectin has 
also been linked to a form of motor neuron disease, Spinal Muscular Atrophy. 
Chondrolectin expression is down-regulated and mis-spliced in mouse models of 
SMA both before the onset of motor symptoms (Bäumer et al., 2009) and into later 
stages of disease progression (Zhang et al., 2008). Over-expression of chondrolectin 
also partially rescues the axonal phenotype in zebrafish with smn knockdown, further 
suggesting the link between SMA pathology and chondrolectin function (Sleigh et al., 
2014). 
Chondrolectin is therefore a key gene for further investigation, important both due to 
its requirement for motor axon development and the translational aspect of its links 
with SMA. Given the temporal limitation of morpholino, limited to the first 3-5 days 
post fertilisation (Bill et al., 2009), this chapter details the generation of a stable 
knockout of chondrolectin for characterisation. 
  
 
3.1.2 - Chondrolectin is a transmembrane protein 
containing a C-type lectin domain 
 
The sequence homology between the zebrafish and the human or mouse gene is 




(Zhong et al., 2012). The amino acid sequence of chondrolectin predicts several 
protein domains, according to Uniprot (www.uniprot.org, Uniprot ID Q568T5). The 
protein domains include an N-terminal signal peptide, a C-type lectin domain, 
transmembrane domain, and short C-terminal helix (intracellular domain). A 
schematic representation is shown in Chapter One, Figure 1.5.  
However, the mechanism by which chondrolectin performs its function is unknown. 
Chondrolectin does not have any close homologue, its closest related gene being 
layilin, with 45 % homology. Layilin has been identified as a hyaluronan receptor, but 
there is no detectable interaction between chondrolectin and hyaluronan (Bono et al., 
2001; Weng et al., 2002). Although C-type lectin domains are usually ligand-binding 
domains, there are no published binding partners for the CTLD of chondrolectin. 
Chondrolectin also contains a single pass, type I transmembrane domain. Together, 
the transmembrane domain and C-type lectin domain suggest that chondrolectin acts 
as a cell-surface protein, interacting with the ECM. We hypothesise in this thesis that 
Collagen XIXa1 is a binding partner to chondrolectin, and this is discussed in Detail 
in Section 3.3.3 of this thesis. A zebrafish mutant for collagen XIXaI, stumpy, 
phenocopies the morphant and mutant to chondrolectin, suggesting a functional link 
between the proteins (Hilario, Wang and Beattie, 2010). 
The intracellular domain of chondrolectin is a short helical chain of 30 aa in length, 
with no structural motifs. There is one published study of this domain which used an 
Sos recruitment screen with this domain to pull down binding proteins (Claessens, 
Weyn and Merregaert, 2008). The protein isolated was Rab geranylgeranyl 
transferase β (Rabggtb), a protein that associates with Rab GTPase, isoprenylating 
the Rab GTPase for its association with the plasma membrane. There is no further 
discussion or speculation in this paper as to why Rab geranylgeranyl transferase 
binds the chondrolectin domain. The authors suggest that chondrolectin could 
stabilise the Rabggtb during its catalytic prenylation of the Rab GTPase but assume 
the domain would not be prenylated itself due to lack of the usual motifs. However, 
the chondrolectin intracellular domain contains a high proportion of serine and 
threonine residues, 12/30 (40%). This means numerous amino acids of this domain 
can be phosphorylated, suggesting that chondrolectin could act as a signalling 
molecule. Supporting this hypothesis, the C-type lectin superfamily is associated with 
signalling proteins important for immunity or cell adhesion (Zelensky and Gready, 




chondrolectin binds a target ligand in the ECM and a phosphorylation-dependent 
change occurs via the C-terminal intracellular domain. Given the largely unknown 
mechanism of chondrolectin, functional analysis of the protein domains was an 
important question posed during this thesis, and results are presented in Section 3.2.6 
of this chapter. 
 
3.1.3 - Transgenesis, expression manipulation, and 
genome editing in zebrafish 
 
A key advantage of zebrafish as a model organism is its great genetic tractability. A 
wide range of tools are available to manipulate gene expression and perform genome 
editing. 
Acute gene knockdown in zebrafish is performed using morpholino. Morpholino are 
short antisense oligos which bind to mRNA, containing a morpholine ring backbone 
which prevents degradation in the cell. These oligos are straightforward to design, 
can be commercially produced, and induce knockdown via two methods. Translation-
blocking morpholinos bind the translational start site of the mRNA and cause steric 
blockage of the ribosome. Splice-site morpholinos bind to splicing sites, leading to 
intron inclusion or exon skipping during pre-mRNA processing (Eisen and Smith, 
2008). Morpholino is particularly useful as the translation-blocking morpholinos can 
also knockdown maternally deposited mRNA present in the yolk, which may have 
compensatory effects in early development, while splice-site morpholinos do not, 
allowing comparison of these effects. However, morpholino-based approaches have 
some limitations in their use, particularly that the dosage of MO injected is diluted as 
the embryo’s cells continue to divide. Thus the effect of MO knockdown usually lasts 
for a maximum of 3-5 days (Bill et al., 2009), preventing experiments on older larvae 
or adults. Morpholino also must be carefully dosed and laboriously injected into each 
clutch to prevent over- or under-dosage of the knockdown. Although this is more 
labour-intensive, it does allow titration of the knockdown effect. Some off-target 
effects have been reported due to potential toxicity of the morpholino and poor control 
of specificity, particularly activation of p53 (Robu et al., 2007; Stainier et al., 2017). A 




investigation into the mechanism and function of chodl aside from its role in axonal 
growth.  
Acute over-expression in zebrafish is commonly performed by injection of capped 
mRNA into the single-cell embryo. Much like morpholino, there is little temporal or 
spatial control of the expression change, as all cells can take up the mRNA or 
morpholino at any point after the injection. In mRNA over-expression, this can lead to 
exogenous translation of the protein in cell types that do not normally express it, but 
the amount of mRNA can be injected can be adjusted to investigate different doses 
of protein (Simone et al., 2018).  
Classical transgenesis, used to establish fluorescent reporter lines such as HB9:GFP 
(Flanagan-Steet et al., 2005), is possible as injection of DNA can randomly integrate 
into the genome. However, there are limits to the size of cassette which can be 
integrated, the efficiency is very low, and its insertion site is random, potentially having 
deleterious effects. An improved method of transgenesis to insert fusion proteins or 
tissue reporters is the Tol2 transposon system. Utilising transposable elements, the 
integration sites and number of copies inserted are still stochastic, but the efficiency 
and size of cassette which can be inserted is improved (Kawakami et al., 2004; 
Balciunas et al., 2006). The combination of a gene’s coding sequence with a tissue-
specific promoter allows spatial control of the expression, which is advantageous over 
mRNA expression, but given the integration is mosaic, it is may be more suitable for 
generation of stable transgenic lines rather than the acute manipulation offered by 
mRNA injection.  
To generate knockout mutants, recent developments have greatly improved the ability 
to target a gene for deletion, and its efficiency. Mutants were previously generated 
using forward genetic approaches, such as ENU mutagenesis, in large genetic 
screens such as the Tübingen screen published in Development (Mullins et al., 1994; 
Driever et al., 1996; Furutani-Seiki et al., 1996; Granato et al., 1996). However, 
reverse genetic approaches for genome editing have become more feasible in the 
last decade (Huang et al., 2012). The CRISPR/Cas9 system represents a more 
streamlined method to generate indel mutants. The Cas9 nuclease is separate to the 
targeting gRNA, and can be introduced as either RNA or protein into the cell. The 
gRNA targeting each sequence is formed by the gRNA backbone and addition of the 




2013). It does not therefore require generation of large recognition sequences for 
each target like for ZFNs and TALENs.  
CRISPR/Cas9 is a modified prokaryotic immunity, where foreign DNA sequences are 
recognised and cleaved after insertion into the genome (Wiedenheft, Sternberg and 
Doudna, 2012). The Cas9 nuclease has been engineered for improved efficiency in 
zebrafish, including a zebrafish nuclear localisation sequence (Jao, Wente and Chen, 
2013). Downsides to CRISPR are that the rate of off-target effects are thought to be 
higher than in TALENs (Pattanayak, Guilinger and Liu, 2014; Anderson et al., 2015, 
2017), but protocols of screening methods to reduce this chance have been 
published. Given the ease of designing and producing a gRNA oligo over the proteins 
for TALENs and ZFNs, I chose to use CRISPR/Cas9 to generate a chondrolectin 
knockout mutant. 
In this chapter, I will present data on the design and generation of a chondrolectin 
knockout zebrafish. This chapter also characterises the chodl -/- zebrafish in its gross 
morphology and motor axon phenotype, as well as the generation of a transgenic 
chodl -/-;HB9:Chodl-FLAG line which rescues the embryonic phenotype. By limiting 
the Chodl expression to motor neurons with the HB9 promoter, this demonstrates a 
cell-autonomous function of chondrolectin. I also perform functional analysis of 
chondrolectin in the zebrafish, observing if chondrolectin constructs that have 
structural domains removed can induce acute rescue of the phenotype. 
 
3.2 – Results 
 
3.2.1 - Design of gRNAs for targeted chondrolectin 
knockout via CRISPR/Cas9 
 
As previously described, the CRISPR/Cas9 system requires both a Cas9 protein to 
cut the genomic DNA, and a guidance RNA (gRNA) to bind the targeted region and 
direct the specific site for the Cas9 to cleave. The gRNA length is between 18-23 bp 
and must contain an XGG motif called the PAM (protospacer adjacent motif), but no 
other sequence motifs are required, making potential gRNAs easy to find in a genomic 
sequence, although several factors are involved in gRNA design to maximise the 




can search the genomic sequence of interest and determine potential gRNAs, and 
then rank them according to specificity and likelihood to generate DSBs 
(http://crispr.mit.edu (Hsu et al., 2013), and 
http://zifit.partners.org/ZiFiT/Introduction.aspx (Sander et al., 2010; Hwang et al., 
2013)).  
CRISPR-mediated mutations generate frame-shifting indels which lead to premature 
stops and thus a truncated, non-functional protein. To find gRNAs for chondrolectin, I 
entered the sequence for Exon 1 and 2 into http://crispr.mit.edu to find potential 
gRNAs (Hsu et al., 2013). This tool ranks the gRNA sequences by specificity, using 
the number of potential off-target matches and the number of mis-matched bases, as 
well as if these off-targets are located in genes or intronic regions. For ease of 
genotyping mutants, the potential gRNAs were then checked for restriction sites close 
to the PAM, as the DSBs are most likely to be generated 3-4bp upstream of the PAM 
(Jinek et al., 2012). Destruction of a restriction site from indels generated at this 
position can therefore be used to screen mutants.  
I aimed to find gRNA targets as close to the 5’ start site of the coding sequence, to 
increase the likelihood that a premature stop would lead to a truncated, non-functional 
protein. However, it has been recently reported that exon-skipping and other splicing 
disruptions may be induced after CRISPR-generated indels (Sharpe and Cooper, 
2017). In zebrafish, this has been shown to potentially allow mRNA transcripts to be 
produced which escape the usual nonsense-mediated decay process, although it is 
considered to occur with low frequency (Anderson et al., 2017). In practice, this meant 
that as well as using the sequence data to predict frame-shift mutations, further 
controls were utilised such as morphant phenocopy and rescue of the mutant 
phenotype (presented later in this chapter). Three gRNAs were selected, using the 
online CRISPR tool to check that there were not potential off-targets either in genes 
or with a mismatch of fewer than 3 bases. This is because it has been shown that 
mismatches of 1 or 2 bases have a chance to bind off-target. However, mismatches 
of 3 or more bases are unlikely to bind (Ran et al., 2013; Anderson et al., 2015). I also 
cross-referenced the target sequences for restriction sites close to the PAM (Table 
3.1). After generating these gRNA sequences, there is a further tool to design primers 
that allows insertion of the gRNA target into a plasmid containing the hairpin gRNA 






The gRNA plasmids were generated and transcription of gRNA and Cas9 mRNA 
performed (see Chapter Two – Materials and Methods). Single-cell stage eggs from 
the HB9:GFP transgenic line were injected with each gRNA and Cas9. Several were 
screened for potential acute phenotypes in the g0, while the rest were raised for later 
breeding to generate founders. Several representative images from the injected 
clutches are shown below (Figure 3.1), demonstrating that all gRNAs generated 
efficient indels which led to a visible phenotype even in acute injection. These early 
mosaic phenotypes, where the CaP axon is stalled at the horizontal myoseptum, were 
also an indicator that the target was specific to chondrolectin, as this phenocopies the 




gRNA Target sequence 
(PAM bolded) 
Number of targets with 







0 (0 inside genes) 98 BspCNI 
2 GGCGTTCTGGGA
GGCTCTGCAGG 
0 (0 inside genes) 85 PstI 
3 GGTCCTGTCCCA
ATCTGTACAGG 
0 (0 inside genes) 93 BsrGI 
Table 3.1: gRNAs designed to induce knockout of chondrolectin. 
The chosen 3 gRNAs for targeted knockout of chondrolectin, the number of potential 
off-targets found by the crispr.mit.edu tool, its rating, and the restriction enzyme used 






As well as assessing the acute axon phenotype in injected embryos, genotyping was 
performed using restriction digest analysis. PCR primers were designed to amplify a 
~300 bp region flanking the gRNA target. Digestion of uninjected genomic DNA by 
the restriction enzymes listed in Table 3.1 above would result in bands of ~200 and 
~100 bp, but loss of the restriction site due to mutations in the injected clutches means 
the ~300 bp amplicon would remain undigested. By pooling the DNA of several 
Figure 3.1: All gRNAs are able to induce an acute axon phenotype into injected 
clutches. 
A: The domain structure of chondrolectin, and the locations of the chosen gRNAs. 
B: Acute phenotypes in injected HB9:GFP embryos at 26 hpf. Uninjected embryos 
show all axons have grown beyond the horizontal myoseptum. For each gRNA, at 
least 1 axon is stalled at the HM (arrowheads). Scale bars= 50 µm 
 
Figure 3-1: Restriction-based genotyping of CRISPR mutations. 
An example gel used for genotyping potential mutation efficiency by gRNA1. A 100 
bp ladder was used, with the 300 bp position marked. In the Uninjected group, the 
undigested band is ~300bp in length, and addition of BspCNI digests the band to 
two bands at ~100 and ~200 bp. In the Injected group, both the undigested and 
digested bands remain at 300 bp, suggesting a high efficiency of indels induced by 
the gRNA1 and loss of the BspCNI site.Figure 3-2: All gRNAs are able to induce an 
acute axon phenotype into injected clutches. 
A: The domain structure of chondrolectin, and the locations of the chosen gRNAs. 
B: Acute phenotypes in injected HB9:GFP embryos at 26 hpf. Uninjected embryos 
show all axons have grown beyond the horizontal myoseptum. For each gRNA, at 




embryos, the proportion of digested to undigested bands can be used as a qualitative 
measure of a gRNA’s cutting efficiency. 
An example gel from gRNA1 is shown below, (Figure 3.2). 5 embryos from uninjected 
and injected conditions were pooled at 26hpf and their genomic DNA extracted. After 
PCR amplification of the 300bp flanking region of gRNA1’s target and half of the 
reaction mixture digested with BspCNI, a restriction enzyme whose recognition site 




As can be seen from the gel (Figure 3.2), in the uninjected group without BspCNI, the 
band remained undigested at 300bp. In the uninjected group, with addition of BspCNI, 
almost all of the amplicon has been digested, with bands at 100bp and 200bp. 
However, in the gRNA1-injected group there is almost no digestion upon addition of 
BspCNI. This demonstrates that the DNA of this pooled group had a high proportion 
Figure 3.2: Restriction-based genotyping of CRISPR mutations. 
An example gel used for genotyping potential mutation efficiency by gRNA1. A 
100 bp ladder was used, with the 300 bp position marked. In the Uninjected group, 
the undigested band is ~300bp in length, and addition of BspCNI digests the band 
to two bands at ~100 and ~200 bp. In the Injected group, both the undigested and 
digested bands remain at 300 bp, suggesting a high efficiency of indels induced 




of mutation induced by the injections even at this acute phase, resulting in loss of the 
restriction site.  
 
3.2.2 - Establishing the stable chondrolectin -/- line 
 
Clutches of injected embryos were raised to adulthood, and adults injected with 
gRNA1 and gRNA2 were outcrossed to WIK wild-type zebrafish. Outcrossing the g0 
generation is vital to reduce the chance of off-target effects, if any are present in the 
clutch. The g0 clutches are mosaic, with some cells containing indels and some 
unaffected by the Cas9. The kind of indels, and whether it will generate a frame-shift 
mutation, is also stochastic. Thus, the next generation (F1) will contain a mixed 
population, with some wild-type eggs, and some which are heterozygous for a range 
of indels. The efficiency of the gRNA is again important to maximise the proportion of 
heterozygous chodl +/- eggs over the wild-type population. 
Because the gRNA1 was targeted at the most 5’ position of the chondrolectin 
sequence, and had the highest rating during the gRNA design, the F1 generation from 
this gRNA were fin-clipped first for genotyping using restriction digest analysis, 
followed by sequencing. From this, three heterozygotic fish containing frame-shift 
mutations were detected. By total chance, one male and one female had identical 4 
bp deletions, and one further female had a 5 bp deletion. The 4 bp deletion, ΔCTCA, 
leads to a predicted premature stop codon at amino acid position 10 from the start 
site, producing a protein just 9 aa in length, rather than the usual 296 aa of 
chondrolectin (Figure 3.3). As this stop codon occurs in the first protein domain, the 
signal peptide, it is highly likely that this truncated protein is non-functional, however 
we did not confirm nonsense-mediated decay and could not confirm loss of protein 
expression due to lack of antibodies to Chodl. However, we determined that our 
observed phenotype was specific to a loss-of-function of chondrolectin by rescuing 








As we had adults with identical mutations of each sex, this F1 pair was incrossed and 
the offspring screened at ~26 hpf for any phenotype. As the g0 background was 
HB9:GFP and then outcrossed to the WIK line, the majority of the F2 clutch were 
GFP-positive in their motor neurons, allowing easy screening of axonal phenotypes. 
The GFP-positive (~75% of the population) and GFP-negative embryos (~25% of 
population) were separated and all the GFP-negative embryos raised for later 
genotyping of the chodl ΔCTCA mutation. However, the GFP-positive could be further 
separated for their shortened axonal phenotype (predicted homozygote mutants) and 
those with the wild-type phenotype (assumed heterozygotes or wild-types) between 
26 and 30 hpf. The proportion of the GFP-positive embryos which also exhibited an 
axonal phenotype was around 25%, the expected Mendelian distribution for an 
incross of heterozygote mutants.  
In the F2 GFP-positive phenotypic population, several were confirmed for mutation 
homozygosity by sequencing, while the rest were raised to produce the stable chodl 
-/- line. In the GFP-positive population, the visible phenotype allowed validation of 
homozygotes at the embryonic stages, while the GFP-negative population was 
genotyped by fin-clipping and restriction analysis in the adults, in order to find 
homozygote mutants. The axonal phenotype was also confirmed in these GFP-
negative homozygous mutants using SV2 labelling, which allows the visualisation of 
motor axons. This led to the formation of a stable line, with a ΔCTCA mutation, on two 
transgenic backgrounds, either the HB9:GFP background (GFP-positive in the motor 
neurons), or a fully wild-type background without any transgenic reporter (GFP-
negative). 
Figure 3.3: The chodl -/- founder contains a 4 bp deletion which causes a frame-
shift mutation. 
The founder of the chodl -/- line has the deletion ΔCTCA, which leads to a 
predicted premature stop codon after 9 aa. This also destroys the restriction site 
for BspCNI which was used for genotyping. 
 
Figure 3-3: The CaP axons of chodl -/- embryos stall at the horizontal 
myoseptum.  
A: Representative images show that the CaP axons in wild-type control 28 hpf 
embryos have extended beyond the horizontal myoseptum choice point (blue 
dashed line) but are stalled at this point in chodl -/- embryos. SC = spinal cord, 
HM= horizontal myoseptum. B: Scoring the axon position as either at the HM 
(HM) or beyond it (HM+) demonstrates that there is a significant difference 
between control and mutant axon position. (Control vs chodl -/- HM, unpaired t-
test with Welch’s correction ****. Post-hoc power= 1.00. Control vs chodl -/- HM+, 
unpaired t-test with Welch’s correction ****. Post-hoc power= 1.00.) C: The CaP 
axon length is significantly shorter in chodl -/- embryos compared to wild-type 
controls. (Unpaired t-test with Welch’s correction ****. **** p<0.0001 Post-hoc 
power=1.00.) Scale bars= 50 µmFigure 3-4: The chodl -/- founder contains a 4 
bp deletion which causes a frame-shift mutation. 
The founder of the chodl -/- line has the deletion ΔCTCA, which leads to a 
premature stop codon after 9 aa. This also destroys the restriction site for BspCNI 





3.2.3 - Motor axon phenotypes in the chodl -/- embryo 
 
In the morpholino knockdown, there are two classes of stalled axons – approximately 
35% of the axons remain stopped at the HM and never grow beyond it, while 55% of 
the axons stalled temporarily and then continued to grow, passing beyond the HM but 
not reaching the wild-type length by 24 hpf (Zhong et al., 2012). 
In the chodl -/- embryos, we first measured the axonal phenotype by scoring the CaP 
axon position at ~28 hpf, adapted from the scoring system used in Zhong et al, 2012. 
Representative images of the axonal phenotype and the scoring at 28 hpf is shown in 
Figure 3.4. All of the CaP axons in wild-type embryos have passed the HM choice 
point. In the chodl -/- mutants, however, only 22.66% have passed the HM, and so 
77.34% of these axons are stalled at the horizontal myoseptum, which is statistically 
significant over the controls (Control HM= 0% ±0, n=16. chodl -/- HM= 77.34% ±6.062, 
n=16. Control HM+= 100% ±0, n=16. chodl -/- HM+= 22.66% ±6.062, n=16. Control 
vs chodl -/- HM, unpaired t-test with Welch’s correction **** p<0.0001. Control vs chodl 
-/- HM+, unpaired t-test with Welch’s correction **** p<0.0001.) The ratio of axons 
stalled at the HM is also more than twice the proportion stopped at the HM in the 
morphants observed in Zhong et al., 2012. This is most likely due to the full knockout 
of chondrolectin compared to morpholino knockdown, where there may be residual 
but low expression of the protein. 
As well as stalling at the HM, the axons are significantly shorter than controls at 28hpf. 
The chodl -/- axon length is 56.89% shorter than the mean control length. (Control 
mean= 95.73 µm ±3.212, n=13. chodl -/- mean= 41.27 µm ±1.763, n=10. Unpaired t-










Figure 3.4: The CaP axons of chodl -/- embryos stall at the horizontal 
myoseptum.  
A: Representative images show that the CaP axons in wild-type control 28 hpf 
embryos have extended beyond the horizontal myoseptum choice point (blue 
dashed line) but are stalled at this point in chodl -/- embryos. SC = spinal cord, 
HM= horizontal myoseptum. B: Scoring the axon position as either at the HM 
(HM) or beyond it (HM+) demonstrates that there is a significant difference 
between control and mutant axon position. (Control vs chodl -/- HM, unpaired t-
test with Welch’s correction ****. Post-hoc power= 1.00. Control vs chodl -/- HM+, 
unpaired t-test with Welch’s correction ****. Post-hoc power= 1.00.) C: The CaP 
axon length is significantly shorter in chodl -/- embryos compared to wild-type 
controls. (Unpaired t-test with Welch’s correction ****. **** p<0.0001 Post-hoc 




At 48 hpf, as well as the primary axons, the secondary axon network has also grown, 
using, although not requiring, the primary axons as pioneers during their pathfinding 
(Pike, Melancon and Eisen, 1992; Davis-Dusenbery et al., 2014). The pathway taken 
by the CaP axon pioneers a central axon bundle for the secondary motor neurons, 
with further axon branching into the myotome (Babin, Goizet and Raldúa, 2014). To 
determine if the secondary motor neurons are also affected by the loss of 
chondrolectin, we measured the central axon bundle at 48hpf (shown below, (Figure 
3.5 B). The axon length is significantly shorter in chodl-/- larva than wild-types. The 
axon bundle in the chodl -/- larva is 13.2% shorter than the controls (control mean 
length= 131.3 µm ±1.416, n= 20. chodl -/- mean length= 114 µm ± 2.023, n= 19. 
Unpaired t-test ****, p<0.0001). To quantify branching, I traced a line 10 µm anterior 
and posterior from each axon and counted the number of branches which crossed 
that line. There is a significant reduction in axonal branching in the chodl -/- mutant 
compared to the wild-type control group (Figure 3.5 C). The number of branches from 
the axon bundle is reduced by 46% (Control number of branches = 8.08 ±0.30, n=20. 
chodl -/- number of branches= 4.39 ±0.31, n=19. Unpaired t-test **** p<0.0001.) This 
suggests that as well as a growth deficit in the chodl -/- axons, as observed by the 
















Similar measurements were performed at 72 hpf (Figure 3.6). The main axon bundle 
length in the chodl-/- larva has caught up with wild-types, and there is no significant 
difference in the length of these axons. (Control nerve length= 159.8 µm ±4.707, n= 
10. chodl -/- nerve length= 160.1 µm ±3.905, n=7. Mann-Whitney test n.s., p= 0.8125).  
At 72 hpf, the number of branches from the main nerve bundle was analysed by 
tracing a line 15 µm from the ventral nerve both anterior and posterior and counting 
the number of branches to cross each line. It shows that there is a significant reduction 
in branching in the chodl -/- mutant compared to wild-type controls. The number of 
branches was reduced by 45% compared to the control value (control mean number 
of branches = 15.24 ±1.01, n= 10. chodl -/- number of branches= 8.45 ± 0.85, n= 7. 
Mann-Whitney test *** p= 0.0002.) This demonstrates that although the main nerve 
bundle catches up in length and reaches the ventral edge of the trunk, there are still 
deficits in the axons as they are less branched into the muscle. This is further shown 
in Chapter Four, where the lack of branching results in a reduction in the number of 
synapses in the trunk and may contribute to a behavioural deficit in the mutant larvae 
during turning behaviour.  
Figure 3.5: At 48pf, chodl-/- mutants exhibit significantly shorter axon bundles 
with aberrant branching compared to controls.  
A: Representative images of wild-type control or chodl -/- larva at 48 hpf. White 
arrowheads show branching of the axons in the control group which are not 
present in the chodl -/- mutant. Scale bar= 50 µm.  B: The axon bundle length is 
significantly shorter in the chodl -/- mutants compared to controls. (Unpaired t-
test, **** p<0.0001. Post-hoc power= 1.00). C: The number of axonal branches is 
significantly reduced in the chodl -/- mutant compared to controls (Unpaired t-test 













Figure 3.6: At 72 hpf, the ventral axon bundle is the same average length in chodl -
/- larva as in control larva. However, there are qualitatively fewer branches into the 
myotome in the mutants than controls. 
A: Representative images of the 72 hpf larvae. Axonal branching into the myotome 
are present in the control larvae but missing in the chodl -/- mutants (arrowheads).  
B: Measurements of the ventral axon bundle show no statistical differences 
between control and chodl -/- larvae. (Mann-Whitney test, n.s., p= 0.8125). Scale 
bars= 50 µm. C: There is a significant reduction in the number of branches in the 
chodl -/- larvae compared to the control larvae (Mann-Whitney test *** p= 0.0002, 





Overall, it is clear that the chodl -/- zebrafish exhibit motor axon deficits from 28 hpf 
which continue until at least 72 hpf. The CaP primary axon is stalled at the HM and is 
thus shorter than in wild-types at 28 hpf. At 48 hpf, when the secondary motor axons 
have also grown out of the spinal cord, the chodl -/- larvae have reduced branching 
and the axons remain shorter than age-matched wild-types. At 72 hpf, the axon 
bundle length has caught up to those in wild-type animals, and there is a significant 
reduction in branching. 
 
3.2.4 - Morphological phenotypes in the chodl -/- embryo 
 
To determine if knockout of chodl caused other effects in the embryo beyond the 
axonal phenotype, we measured several aspects of the embryo morphology in 
comparison to wild-type controls. Firstly, the gross body morphology was analysed by 
measuring the body length and the eye diameter. This is a simple method to 
determine abnormalities in the mutant, such as developmental delay or reduced 
growth.   
For both the body length and eye diameter measurements, there were no significant 
differences in either the wild-type or mutants at 30hpf. The measurements are shown 
below, (Figure 3.7). The body length is 0.45% shorter compared to wild-type controls. 
(Control average length= 2.253 mm ±0.0204, n= 14. chodl -/- average length= 2.243 
mm ±0.0209, n=17. Unpaired t-test n.s., p= 0.7301). The eye diameter is 0.57% 
shorter in chodl -/- embryos than controls (Control average diameter = 191.7µm ±3.40, 
n= 15, chodl -/- diameter= 190.6 µm ±3.84, n=17, unpaired t-test n.s., p= 0.8295). 
To determine if the muscle integrity is affected in the chodl -/- mutants, I performed 
phalloidin staining on wild-type and mutant embryos at 30hpf. Phalloidin labels the F-
actin in fast muscle fibres (Pagnon-Minot et al., 2008), and primary motor axons are 
known to innervate the fast muscle fibres (Babin, Goizet and Raldúa, 2014). 
Furthermore, chondrolectin has previously been found to be highly expressed in fast 
motor neurons in mice (equivalent to primary motor neurons in zebrafish) (Enjin et al., 
2010), so we expected systemic loss of chondrolectin to cause an axon phenotype 
without changing the muscle structure. However, mutations or knockdown in genes 




example the collagen 19a1 mutant, stumpy (Hilario et al, 2010). Collagen 15 
knockdown with morpholino leads to wide-spread muscle defects visible by phalloidin 
staining, as well as branching and outgrowth aberrations in the primary motor axons 
(Pagnon-Minot et al., 2008). Thus, to fully confirm that the axon phenotype is limited 
to axons, and not due to muscle defects, we performed phalloidin staining. Phalloidin 
is a toxin which binds actin, coupled with a fluorescent tag. I quantified any potential 
differences by counting the average number of myotubes, and the average thickness 
of each myotube. There were no differences between the wild-type controls and the 
chodl -/- embryos at 30 hpf (Fig 3.7, E). (Mean number of myotubes per somite in 
wild-type embryos = 20.94±0.81, n=6 embryos. Mean number of myotubes per somite 
in chodl -/- embryos = 21.56±0.54, n=6 embryos. Mann-Whitney test n.s., p= 0.331). 
There were also no differences in the average thickness of myotubes between the 
wild-type controls and chodl -/- embryos (Fig. 3.7, F). (Mean thickness of myotubes, 
control= 6.40 µm ±0.16, n=6 embryos. Mean thickness of myotubes, chodl -/- = 6.22 
µm ±0.18, n= 6. Mann-Whitney test n.s., p= 0.589). The gross morphology of the 
muscle therefore seems unchanged between the two groups. However, there may be 
potential defects that are not detectable with the phalloidin staining. Other staining 




Overall, chodl -/- mutant embryos are morphologically indistinguishable to wild-type 
at the same stage. This demonstrates that the axonal phenotype is due to 
chondrolectin loss and not a general developmental delay in the mutants. Also, the 
stalled axon phenotype is due to an axon-specific change rather than deficits in the 









Although not quantified with a survival curve, chodl -/- zebrafish survived to adulthood 
and were able to successfully breed, with fertility success similar to wild-types. No 
additional husbandry measures were necessary to maintain these fish, although 
homozygous stocks were sorted and raised separately from non-phenotypic siblings 
in case of out-competition during juvenile phases. Lifespan of the mutant was not 
measured, as adult homozygous stocks survived until at least 18 months old when 
they were culled by Schedule 1 methods due to their age. 
 
3.2.5 - Rescuing the chodl -/- mutant by re-expressing 
chondrolectin in motor neurons demonstrates that chodl is 
cell-autonomous 
 
3.2.5.1 – The stable transgenic line chodl -/-;HB9:Chodl-FLAG fish shows no 
differences in axon length to wild-types at 28 hpf 
 
A key control for specificity of a mutant phenotype is rescue by re-expression of the 
gene. In Zhong et al., 2012, mRNA injection of chondrolectin rescued the axonal 
phenotype in the morpholino-mediated knockdown. However, global expression of 
chodl from this injected mRNA also had an effect in the wild-type zebrafish due to 
excess chondrolectin, resulting in shorter axons. Using mRNA allows variable 
dosages to determine dose-response curves, but also allows global uptake of the 
Figure 3.7: The chodl -/- embryos are morphologically indistinguishable from 
age-matched controls. 
 A: Representative bright-field images of wild-type control and chodl -/- 
embryos at 30 hpf. B: Body length measurements show no differences 
between wild-types and chodl -/- embryos at 30 hpf. (n.s., 0.7301, unpaired t-
test.) C: The eye diameter is not significantly different between mutants and 
controls (Unpaired t-test n.s., 0.8295). D: Phalloidin staining shows no visible 
differences in muscle architecture between wild-type and chodl -/- embryos at 
30hpf.  E: The average number of myotubes per somite does not differ 
between wild-type controls and chodl -/- embryos at 30 hpf. (Mann-Whitney 
test, n.s.). F: The average thickness of the myotubes does not differ between 
the wild-type control and chodl -/- embryos at 30 hpf (Mann-Whitney test, n.s.) 




mRNA and thus translation of the protein in all cells. This may lead to ectopic 
expression of the protein in tissue where it is not usually present. For example, in 
zebrafish, in situ hybridisation data demonstrates that chodl is limited to motor 
neurons. In mice, chondrolectin is highly expressed in fast motor neurons (Enjin et al., 
2010), and Southern blotting also found expression in the muscle and spleen (Weng, 
Van Bockstaele, et al., 2003). Therefore, expression of chondrolectin only in motor 
neurons would be a useful tool to determine if its function is cell-autonomous and 
sufficient to rescue the mutant. 
As well as acute rescue of the phenotype, a stable line expressing tagged 
chondrolectin has several advantages for other applications. Due to the lack of 
antibodies for chondrolectin, it is not possible to perform pulldowns or binding assays 
of the native protein using immunoprecipitation. However, a zebrafish line expressing 
chondrolectin tagged with an artificial epitope such as FLAG would allow purification 
of the protein from zebrafish through antibodies against this tag.  
To produce a construct for generating this transgenic line, we utilised the Tol2 
transposon system (Balciunas et al., 2006). As has been described both in Chapter 
One and in the Introduction of this chapter (Section 3.13), this system allows insertion 
of a cassette randomly into the zebrafish genome, leading to mosaic integration in the 
injected embryos. This cloning methodology and primers are detailed in the Materials 
& Methods section. To limit expression of the cassette to motor neurons, Dr Ana-
Maria Oprişoreanu amplified a 3kb section of the HB9 promoter and subcloned it into 
the pMiniTol2 vector. This promoter sequence has been previously published as a 
MN-specific promoter for transgenesis in zebrafish (Flanagan-Steet et al., 2005).  
I amplified the coding sequence of chondrolectin from the previously designed RNA 
expression vector, pCMV-chodl-myc (Zhong et al., 2012). To enhance the likelihood 
of the construct successfully being expressed after integration, I added an artificial 
Kozak sequence optimised for zebrafish (Grzegorski et al., 2014). 
The pMiniTol2-HB9:chodl-FLAG plasmid was co-injected into chodl -/- embryos with 
transposase mRNA, and at 24 hpf, the embryos were selected for mosaic rescue of 
their CaP axons. Approximately 20% of the injected embryos displayed at least 3 
rescued axons and were raised separately as the g0 generation of the line. The exact 
proportion of axons rescued and the axon length at this acute stage was not recorded, 




Upon reaching sexual maturity, we attempted to incross the selected g0 zebrafish 
together to generate the chodl-/-;HB9:chodl-FLAG line. However, we never achieved 
breeding success with incrossing this group (around 5 attempts). Instead, we 
backcrossed the g0 zebrafish into the chodl -/- population, maintaining homozygosity 
of the chodl knockout but allowing germline transmission of the HB9:chodl-FLAG 
through one parent. From these clutches, we selected embryos at 24 hpf in which 
their entire CaP axon population was rescued to raise as our stable F1 population, 
selecting those with the longest axons. FLAG expression was confirmed in several 
rescued embryos, and was limited to HB9:GFP+ motor neurons. FLAG staining was 
visible in both the soma and axons of these cells. From this F1 generation, we 
incrossed and then measured axon lengths to compare with wild-type (Control), chodl 
-/-, and chodl-/-;HB9:chodl-FLAG embryos at 28hpf (Figure 3.8).  
The FLAG immunoreactivity is only present in the chodl-/-;HB9:chodl-FLAG line 
(Figure 3.8 A) and is limited to the motor neurons, both the cell bodies and axons. 
There is no signal in either the control or chodl -/- embryos, as expected, 
demonstrating the specificity of the staining and the success of the plasmid to have 
no leakiness in other cell types except MNs. After FLAG immunohistochemistry and 
measurement of the axon lengths, FLAG-negative embryos in the chodl-/-;HB9:chodl-
FLAG group were excluded and only those embryos expressing the HB9:chodl-FLAG 
signal were included in the statistical analysis. The axon length between the control 
and chodl -/- mutants is significantly different, with the chodl -/- axons shorter than the 
controls. This is a similar difference in length as was observed in Section 3.2.3. The 
axon length of the chodl -/- group is also significantly shorter than the chodl-/-
;HB9:chodl-FLAG group, less. This is because the axons in the chodl-/-;HB9:chodl-
FLAG group are fully rescued to control lengths, only shorter and not significantly 
different. (Control average length=78.88 µm ±2.71 , n=13. chodl -/- average length= 
32.69 µm ±0.50, n=13. chodl-/-;HB9:chodl-FLAG average length= 75.76 µm ±2.39, 
n= 15. Kruskal-Wallis ****, with Dunn’s mutliple comparison test. Control vs chodl -/- 
****, chodl -/- vs chodl-/-;HB9:chodl-FLAG ****, control vs chodl-/-;HB9:chodl-FLAG 
n.s., p=0.999. **** p<0.0001.) The complete rescue of the axon length in the stable 
chodl-/-;HB9:chodl-FLAG line shows that motor neuron-specific expression of 
chondrolectin is able to rescue the global knockout. This demonstrates the cell-




























3.2.5.2 – Over-expression of chondrolectin in wild-type motor neurons leads to 
shorter motor axons at 28 hpf 
 
As has been extensively discussed in this chapter, knockdown and knockout of 
chondrolectin leads to stalled CaP axons at the horizontal myoseptum at 28 hpf. 
Interestingly, over-expression of chondrolectin using mRNA also leads to shortened 
axons (Zhong et al., 2012). This suggests that the dosage of chondrolectin needs to 
be tightly controlled for healthy motor axons. However, mRNA injection is not tissue-
specific. This means that other tissues, such as muscle fibres or glia, may aberrantly 
express Chodl and influence the motor axon growth. For example, cell-surface 
molecules are known to have variable interactions either cis in the same cell 
membrane, or trans when associated in different cells (Held and Mariuzza, 2011). Our 
hypothesis is that chondrolectin acts as a cell-surface protein on the motor axon 
interacting with the ECM (discussed further in Section 3.3.3) so it may interact in both 
cis and trans orientation with itself and other proteins. Mis-localised expression in 
other tissue may lead to trans interactions that do not occur under normal conditions.  
Figure 3.8: Axon length and FLAG immunoreactivity shows that the chodl-/-
;HB9:chodl-FLAG line expresses the FLAG tag only in MNs and fully rescues the 
axonal length phenotype seen in chodl -/- mutants. 
A: Representative images of control, chodl -/-, and chodl-/-;HB9:chodl-
FLAGembryos are shown. The FLAG immunoreactivity is limited to the rescue line 
and is not expressed by the control or mutants. The HM is marked (yellow dashed 
line), showing that the control and rescue axons have grown beyond this point 
while the chodl -/- axons are stalled. 
B: Axon length measurements show that there is no statistical difference between 
the control and chodl-/-;HB9:chodl-FLAGaxons, but there are significant 
differences in axon length between chodl -/- and both control and chodl-/-
;HB9:chodl-FLAG embryos. (Kruskal-Wallis ****, Dunn’s multiple comparison test. 
Control vs chodl-/-;HB9:chodl-FLAG n.s, p= 0.999, Control vs chodl -/- ****, chodl -
/- vs chodl-/-;HB9:chodl-FLAG ****. **** = p<0.0001. Post-hoc power= 1.00) Scale 




However, we can utilise the Tol2:HB9:chodl-FLAG plasmid previously used to 
generate the stable chodl -/-;HB9:chodl-FLAG line, in order to investigate cell-specific 
effects of over-expression. The FLAG expression demonstrates which neurons are 
expressing the Chodl-FLAG cassette, and it is limited to motor neurons (Figure 3.8). 
This allows us to cause mosaic over-expression in acute injections and then compare 
the axonal lengths of the FLAG-positive axons, the internal control of FLAG-negative 
axons in the same embryo, and a further negative control of embryos injected with 
the Tol2:HB9 vector only. If over-expression leads to changes in the motor axons, the 
FLAG-positive axons of the injected group will be significantly shorter than the other 
axonal lengths. If the mRNA caused an artefact by exogenous expression of the 
chondrolectin in other cell types, we would expect no changes in the axon lengths 
between FLAG-positive or FLAG-negative axons, or with the control vector group.  
After injection, embryos were randomly selected at 28hpf and immunohistochemistry 
performed against GFP and FLAG. Due to the mosaicism and low efficiency of the 
construct integration, the number of FLAG-positive axons per injected embryo ranged 
from 0-3 out of 10 axons scored, with around 50% of embryos expressing FLAG in at 
least 1 axon. For the purposes of analysis, an axon was only accepted as FLAG-
positive if the cell body and initial axon had a morphology as has been described for 
the CaP neuron, (Myers, Eisen and Westerfield, 1986) and if FLAG staining was 
present along the full length of the axon. This is because, as previously discussed, 
the RoP and MiP axons also follow the same path as the CaP axon up to the HM, the 
point where the chodl -/- axons stall. Therefore, false positive axons could be counted 
if the FLAG positive axons had FLAG-positive RoP or MiP cell bodies and the CaP 










Comparing the axon length of the embryos injected with the Empty vector to the 
FLAG-negative axons injected with the Chodl-FLAG plasmid, there is very little 
difference and it is not statistically significant. The FLAG-negative axons are 0.49% 
longer on average than the Empty vector group. The FLAG-positive axons, which are 
expressing Chodl-FLAG, are significantly shorter than both their internal control, the 
FLAG-negative axons, and the axons in embryos injected with Empty vector. The 
Figure 3.9: Over-expression of chodl in wild-type zebrafish leads to truncated CaP 
axons. 
A: Representative images of 28 hpf zebrafish embryos injected with either the 
Tol2:HB9 (Empty vector) or Tol2:HB9:Chodl-FLAG (Full-length Chodl-FLAG) 
plasmid. Chodl-FLAG expression causes truncation of the axon with FLAG 
immunoreactivity (arrowhead). Scale bar= 50 µm B: The axon length is 
unchanged between axons injected with the Empty vector or FLAG-negative 
axons, but the FLAG-positive axons are significantly shorter than the other two 
groups (One-way ANOVA **** with Bonferroni’s multiple comparison test, Empty 
vector vs Full-length Chodl-FLAG FLAG-negative, n.s. Empty vector vs Full-length 
Chodl-FLAG FLAG-positive ****, Full-length Chodl-FLAG FLAG-negative vs 




FLAG-positive axons are 39.2% shorter than the FLAG-negative axons, and 38.9% 
shorter than the average axon length in the Empty vector group. (Empty vector 
average length= 73.67 µm ±3.27, n= 12. Full-length Chodl-FLAG FLAG-negative axon 
length= 74.03 µm ±2.23, n= 22. Full length Chodl-FLAG FLAG-positive length= 45.04 
µm ±5.18, n=9. One-way ANOVA **** with Bonferroni’s multiple comparisons test, 
Empty vector vs Full-length Chodl-FLAG FLAG-negative, n.s., p>0.999. Empty vector 
vs Full-length Chodl-FLAG FLAG-positive **** p<0.0001. Full-length Chodl-FLAG 
FLAG-negative vs FLAG-positive **** p<0.0001.) 
These findings confirm that the motor axon phenotype observed during mRNA over-
expression of chondrolectin previously reported are in fact specific to chondrolectin 
over-expression in the motor neurons. It is not an artefact from chondrolectin 
expression in non-endogenous cell types. This demonstrates that the dosage of 
chondrolectin in motor neurons must be tightly controlled to maintain the correct axon 
length. The mechanism by which over-expression of chondrolectin leads to reduced 
axon length is not immediately clear. It may be due to cis-acting interactions between 
chondrolectin monomers on the axon surface, which prevents its normal function. Or, 
surplus chondrolectin may bind its ligands excessively and be unable to induce axon 
growth beyond the HM. The mechanism of chondrolectin and its potential ligands are 




3.2.6 - Functional analysis of the chondrolectin protein by 
acute rescue using mutagenised over-expression 
constructs 
 
3.2.6.1 – Both the intracellular domain and C-type lectin domain of 
chondrolectin are required for its function in zebrafish 
 
We have now determined that the dosage of chondrolectin protein in the motor neuron 
must be tightly controlled for its correct function. At 28 hpf, knockdown or knockout 
stalls the CaP axon at the HM choice point, and over-expression also leads to 




motor neurons can cause the axonal phenotype, and motor neuron-specific 
expression of Chodl rescues the knockout. However, the mechanism by which the 
protein functions under normal circumstances is still elusive. There are few published 
papers on the biochemistry, ligands, or mechanism of chondrolectin in any model 
system. A lack of commercially available antibodies specific to chondrolectin across 
zebrafish, mouse, and human also limit the ability of researchers to investigate 
chondrolectin in immunohistochemistry or binding assays. However, the excellent 
transgenic manipulation methods available in zebrafish allow for functional analysis 
of chondrolectin through other means.  
As previously introduced, the chondrolectin protein is a transmembrane protein 
containing a C-type lectin domain at its N-terminus and a short (30aa) sequence at its 
C-terminus. To determine if any domains of chondrolectin are disposable for the 
correct function of the protein, I utilised the Tol2-HB9:chodl-FLAG plasmid used to 
generate the stable rescue line (Section 3.2.5). I further generated several related 
constructs which removed structural domains from chondrolectin. When injected into 
chodl -/- eggs, these constructs were used to investigate if they were also able to 
acutely rescue the axon phenotype. Figure 3.10 below illustrates the experimental 








I did not generate constructs removing the transmembrane domain or signal peptide, 
with the logical assumption that the transmembrane domain and signal peptide are 
required for the correct protein function. Removal of the signal peptide would result in 
an inability of the chondrolectin protein to be trafficked to the membrane, and it would 
potentially form toxic aggregates in the cytoplasm. Removal of the transmembrane 
domain would also have likely resulted in toxic aggregation of the protein in the 
cytoplasm of the motor neurons or even export of the protein out of the neuron if the 
signal peptide trafficked the protein into vesicles. This aggregation would be visible in 
the FLAG immunohistochemistry. If the FLAG labelling was limited to the cell body or 
entered the nucleus, it would suggest that the protein was aggregating or misfolding.  





Figure 3.11: Schematic of the chondrolectin constructs. 
Three constructs were generated, with the full-length chondrolectin, with the 
intracellular domain removed, or the C-type lectin domain removed. SP= signal 
peptide, CTLD= C-type lectin domain, TMD= transmembrane domain. 
 
Figure 3.10: Experimental setup for acute rescue experiments in the chodl -/- 
phenotype. 
A: An experimental timeline showing injection of chondrolectin constructs, 
followed by immunohistochemistry and imaging. The red box on the zebrafish 
trunk shows the region of image analysis. B: Examples of the phenotypic 
outcomes depending on the type of injected plasmid, whether there will be mosaic 






For an internal positive control, the plasmid containing the full-length chondrolectin 
was used, as this had demonstrated mosaic rescue of the chodl -/- phenotype during 
generation of the stable chodl -/-;HB9:chodl-FLAG line (Full-length Chodl-FLAG). The 
internal negative control was the plasmid backbone containing the HB9 promoter, as 
it should not exhibit toxic or rescue effects on the embryos (Empty vector). 
After generating constructs with the intracellular domain and C-type lectin domain 
removed, the constructs were injected in a similar set-up to that used to over-express 














In Figure 3.12, the axon length of embryos injected with the empty vector is consistent 
with the axon length of chodl -/- embryos at the same age seen in other experiments 
(32.92µm), indicating that the injections do not induce any axon length changes. For 
all injected constructs, the FLAG-negative axons are also the same length as the 
empty vector control group, showing that these constructs also do not induce axon 
length changes in axons, and that the FLAG immunohistochemistry is specific. The 
Full-length Chodl-FLAG FLAG-negative value is 10.4% longer than the Empty vector. 
The FLAG-negative axons from the chodl w/o ID are 0.34% shorter than the Empty 
vector average length, and the chodl w/o CTLD is 0.95% shorter than the Empty 
vector length. (Empty vector average length= 32.92 µm ±1.46, n=11. Full-length 
Chodl-FLAG FLAG-negative mean length= 36.36 µm ±1.57, n=31. chodl w/o ID 
FLAG-negative mean length= 32.81 µm ±0.774, n= 30. chodl w/o CTLD FLAG-
negative mean length= 32.61 µm ±0.687, n=24. One-way ANOVA with Bonferroni’s 
multiple comparison test, Empty vector vs Full-length Chodl-FLAG FLAG-negative 
n.s., Empty vector vs chodl w/o ID FLAG-negative n.s., Empty vector vs chodl w/o 
CTLD FLAG-negative n.s., n.s. p>0.999.) 
Figure 3.12: Both the C-type lectin and intracellular domains of chondrolectin are 
necessary for its function and to rescue the chodl -/- phenotype. 
 A: Representative lateral trunk view images of injected embryos at 28hpf, with 
separate GFP and FLAG staining, and the merged channel. The FLAG-positive 
axons are longer in the full-length Chodl-FLAG group but remain stalled at the HM 
in the groups missing the CTLD or intracellular domains. Solid arrowheads = 
rescued axons with FLAG immunoreactivity. Chevrons = FLAG positive axons that 
are still stalled at the HM. Scale bar= 50 µm. B: Graph of the average CaP axon 
length. For each construct, white points = FLAG-negative axons, black points = 
FLAG-positive axons. The Full-length Chodl-FLAG construct rescues the chodl -/- 
axons. The FLAG-positive axons are significantly longer than the FLAG-negative 
and the Empty vector axon lengths. However, both the chodl w/o ID or chodl w/o 
CTLD FLAG-positive axons are not significantly longer than their FLAG-negative 
counterparts or the Empty vector group. (One-way ANOVA ****, with Bonferroni’s 
multiple comparison test. Empty vector vs Full-length Chodl-FLAG FLAG-negative 
n.s., Empty vector vs Full-length Chodl-FLAG  FLAG-positive ****. Empty vector vs 
chodl w/o ID FLAG-negative n.s., Empty vector vs chodl w/o ID FLAG-positive n.s. 
Empty vector vs chodl w/o CTLD FLAG-negative n.s., Empty vector vs chodl wo/ 
CTLD FLAG FLAG-positive n.s. Full-length Chodl-FLAG FLAG-negative vs Full-
length Chodl-FLAG FLAG-positive ****. chodl w/o CTLD FLAG-negative vs chodl 
w/o CTLD FLAG-positive n.s. chodl w/o ID FLAG-negative vs chodl w/o ID FLAG-





As expected, the positive control (Full-length Chodl-FLAG) was able to rescue the 
axon length, with the FLAG-positive axons 30.7% longer than the FLAG-negative 
axons. This confirms that the construct is able to mosaically rescue the axonal 
phenotype in a way that is specific to the expression of the FLAG-tagged protein. 
(Full-length Chodl-FLAG FLAG-negative mean length= 36.36 µm ±1.57, n= 31. Full-
length Chodl-FLAG FLAG-positive average length= 47.53 µm ± 2.57, n= 21. One-way 
ANOVA with Bonferroni’s multiple comparison test, **** p<0.0001). 
Comparing the FLAG-positive axons to FLAG-negative axons for both the chodl w/o 
ID construct and the chodl w/o CTLD construct demonstrates that there is no rescue, 
as there is no significant difference between the values. For the chodl w/o ID 
construct, the FLAG-positive axons are only 5.55% longer than the FLAG-negative 
axons. For the chodl w/o CTLD construct, the FLAG-positive axons were 3.53% 
shorter than the FLAG-negative axons. (chodl w/o ID FLAG-negative mean length= 
32.81 µm ±0.774, n= 30. chodl w/o ID FLAG-positive mean length= 34.63 µm ±2.12, 
n= 19. chodl w/o CTLD FLAG-negative mean length= 32.61 µm ±0.687, n=24. chodl 
w/o CTLD FLAG-positive mean length= 31.46 µm ±1.08, n= 8. One-way ANOVA with 
Bonferroni’s multiple comparison test. chodl w/o ID FLAG-negative v FLAG-positive 
n.s., chodl w/o CTLD FLAG-negative vs FLAG-positive n.s. n.s. p>0.999) 
The constructs are correctly translated, and the protein trafficked into the axons, as 
the FLAG immunoreactivity spans the length of the motor axons and was excluded 
from the nucleus of the cell (visible in Figure 3.12 A). Therefore, the protein is present, 
but without each domain it is non-functional. Overall, this data indicates that 
chondrolectin is likely acting as a signalling molecule, with the C-type lectin interacting 
with a binding partner in the ECM and the intracellular domain transducing a signal 
within the axon during its outgrowth. A colleague in the group also used modified 
versions of the constructs from this section in HEK cells, performing binding assays 
to determine potential ligands of chondrolectin for the C-type lectin domain. The data 
gained from that work is detailed in the Discussion & Conclusion section of this 
chapter. Given the lack of structural motif in the intracellular domain, and its relatively 
short length, I further investigated the biochemical properties of this domain, detailed 





3.2.6.2 – Phosphorylation of the intracellular domain is necessary for its 
function in zebrafish 
 
The intracellular domain is a short 30aa chain and does not contain any structural 
motifs indicated by the amino acid sequence. However, it does contain 12 serine and 
threonine residues, and thus a high proportion of its sequence are charged residues 
that are classical phosphorylation targets. Due to the wealth of published material 
where signalling molecules transduce their signal via intracellular phosphorylation 
(Plattner and Bibb, 2012; Day, Sosale and Lazzara, 2016), I decided to further explore 
the potential phosphorylation of chondrolectin. Using a similar experimental set-up as 
used when removing domains, I instead mutagenised the intracellular domain to 
convert the serine and threonine residues to alanine. This has been previously used 
to remove phosphorylation targets, as alanine is a simple uncharged amino acid which 
cannot be phosphorylated (Dephoure et al., 2013).  
The full methodology to mutagenise this domain is detailed in the Materials & Methods 
section, but briefly, multiple overhang PCR primers were designed which bound 
sequentially to the intracellular domain but whose sequence replaced any Ser (AGT, 
AGC, TCX) or Thr (ACX) codons with Ala (GCT or GCG). Please note that one Thr 
was left intact due to a typing error during primer design. The same constructs for the 
positive and negative controls were used as previously described. Representative 






Figure 3.13: Removal of the intracellular domain’s phosphorylation sites abolishes its 
ability to rescue axon length in chodl -/- embryos. 
A: Schematic of chondrolectin, with the intracellular domain amino acids shown. The 
serine and threonine residues altered to alanine are marked with red boxes. The Thr 
residue left intact is marked with an asterisk. B: Representative images of embryos 
injected with the constructs empty vector, full-length Chodl-FLAG, and the construct 
chodl w/ ID (S/T->A). Solid arrowheads = FLAG-positive axons with length rescued. 
Chevrons = FLAG-positive axons without length rescue. Scale bars= 50 µm. C: Graph 
of axonal length measurements. There is a significant increase in length by Full-length 
Chodl-FLAG FLAG-positive axons over the Empty vector group and Full-length Chodl-
FLAG FLAG-negative axon lengths. There is no significant difference between the 
chodl w/ID (S/T->A) FLAG-positive axons and the FLAG-negative axons in that group 
or the Empty vector group. (Kruskal-Wallis **** with Dunn’s multiple comparison test. 
Empty vector vs Chodl-FLAG FLAG-positive axons ****, Full-length Chodl-FLAG 
FLAG-negative vs Full-length Chodl-FLAG FLAG-positive **. Empty vector vs chodl 
w/ID (S/T->A) FLAG-positive n.s., p= 0.0853 chodl w/ID (S/T->A) FLAG-negative vs 
chodl w/ID (S/T->A) FLAG-positive n.s., p= 0.1989. ** p= 0.001, **** p<0.0001. Post-





As was also observed in the previous dataset, the Empty vector axons remain at a 
similar length to previously measured chodl -/- axons. The positive control, the Full-
length Chodl-FLAG construct, again shows rescue of the axon length in the FLAG-
positive axon population. These FLAG-positive axons are 87.8% longer than the 
Empty vector average length and 55.0% longer than the FLAG-negative population, 
and in both comparisons, this is statistically significant. However, the construct that 
cannot be phosphorylated, chodl w/ID (S/T->A), does not have a significantly 
increased axon length in its FLAG-positive axons. (Empty vector mean length= 32.55 
µm ±1.11, n=7. Full-length Chodl-FLAG FLAG-negative average axon length= 39.43 
µm ±1.60, n=28, Full-length Chodl-FLAG FLAG-positive average length= 61.13 µm ± 
3.99, n=16. chodl w/ID (ST->A) FLAG-negative average length= 36.84 µm ±, n= 39, 
chodl w/ID (S/T->A) FLAG-positive average length= 44.64 µm ±2.78, n= 21. Kruskal-
Wallis with Dunn’s multiple comparison test.) 
Therefore, the removal of residues that are phosphorylation targets results in a non-
functional protein which cannot rescue the mutant phenotype. This suggests that 
phosphorylation is necessary for the function of chondrolectin in vivo. Overall, these 
acute rescue experiments support the notion that chondrolectin acts as a signalling 
molecule, where the C-type lectin domain interacts with ligands in the ECM, and the 
intracellular domain undergoes phosphorylation to induce a signal inside the axon, 
allowing the axon to extend past the horizontal myoseptum. Further discussion of 
potential mechanisms, and other methods to confirm this hypothesis are discussed in 
the next section, 3.3.3. 
 
3.3 - Discussion & Conclusions 
 
3.3.1 – Successful generation of a chondrolectin knockout 
which phenocopies the published morphant 
 
We have generated a chondrolectin knockout zebrafish using the CRISPR/Cas9 
system. To ensure that the knockout is specific to chodl, several control checks must 
be employed. One of the disadvantages of CRISPR/Cas9 is the chance it will produce 
off-target effects. Because the Cas9 is targeted to the gene of interest via the gRNA 




between the off-target sequence and the gRNA are considered acceptable to abolish 
binding (Ran et al., 2013; Anderson et al., 2015), and matches in intronic regions are 
considered to be less risky than matches in the exonic part of a gene, as indels in 
intronic regions will not form frame-shift mutations. While designing the gRNA, 
sequences that have only 0 or 1 base change to another gene, or where the sequence 
similarity sits inside exonic regions, should be avoided where possible. This forms 
part of the CRISPR design tool published in Hsu et al., 2013, where potential off-
targets are displayed (Shown in Table 3.1 for each gRNA).  
There are two control experiments that can be performed to ensure there are no off-
target mutations. The first, and most simple, is to outcross the line sufficiently, 
selecting for the germline transmission of the desired indel. Given the stochastic 
generation of mutations in mosaic, the likelihood of transmission of both the desired 
mutation and a deleterious off-target is low. This is the approach I took to establish 
the line, as zebrafish can generate large clutches that be rapidly screened (Prykhozhij 
et al., 2017). The second method is to design genotyping primers for the region known 
to be a potential off-target site (Ran et al., 2013). Then, in combination with genotyping 
for the desired gene target, the off-target sites can be checked as well. This is 
frequently performed when using CRISPR/Cas9 in mice. The genome editing is 
carried out either in embryonic stem cells, which can be cultured and thus genotyped 
fully before injection into blastocysts, or directly at the zygote stage in vitro before 
implantation into foster mothers. Due to the labour-intensive process of implantation, 
pre-screening is preferable to implanting more blastocysts or extra breeding (Wang 
et al., 2013; Sakurai et al., 2014; Yang, Wang and Jaenisch, 2014). 
Although I did not directly sequence the chodl -/- zebrafish to look for off-targets, I 
consider the phenotype to be true and specific to loss of chondrolectin rather than an 
off-target. This is due to two factors: Phenocopy of the published morphant, and the 
complete rescue of the phenotype by re-expression of chondrolectin in the mutant 
zebrafish. Firstly, all 3 gRNAs designed against multiple exons were able to induce a 
mosaic phenotype in the motor axons (Section 3.2.2). This demonstrates that all 
gRNAs were of high cutting efficiency to cause the acute phenotype, and that frame-
shift mutations in different domains of the protein can cause the same loss-of-function 
phenotype. In the stable chodl -/- mutant line, 75% of the CaP axons were stalled at 
the horizontal myoseptum at 28 hpf (Section 3.2.3). The rescue of the axonal 




of evidence that the knockout phenotype is specific (Section 3.2.5). This 
demonstrates that the axonal phenotype is solely due to the loss of chondrolectin. 
The rescue is quantifiable both as a stable transgenic line, and in the acute injections. 
Use of the HB9 promoter, limiting expression to MNs only, is also a key part of the 
next section, discussing the cell-autonomous function of chondrolectin. 
When CRISPR/Cas9 generates a frame-shift indel, the loss of function occurs as the 
mRNA containing a premature stop is rapidly degraded by nonsense-mediated decay 
(NMD). Usually, the presence of a premature stop codon during translation signals to 
the NMD complex to cause rapid degradation of the mRNA. This is developmentally 
vital to prevent truncated proteins accumulating in the cell and causing toxicity 
(Wittkopp et al., 2009). Methods to determine if the knockout leads to nonsense-
mediated decay include in situ hybridisation, comparing the signal intensity between 
wild-type and mutant samples, although this may not be sensitive enough to detect 
the reduction in mRNA caused by NMD. Another method to measure changes to the 
transcript level include qPCR of cDNA. However, one unintended consequence of 
indel generation is the increase in exon skipping (Anderson et al., 2017; Sharpe and 
Cooper, 2017), caused by sequence changes which generate exon splice enhancers. 
In some cases, the exon skipping leads to cryptic start sites or constitutively active 
protein (Mou et al., 2017). For chondrolectin, further data demonstrates that removal 
of either the CTLD or ID causes the protein to be non-functional (Section 3.2.6). This 
would suggest that even if exon skipping were to occur in the chodl mutant, and 
generate a truncated protein, it would still be either a loss-of-function mutant or 
dominant negative mutant. A dominant negative mutant, however, would not be fully 
rescued by re-expression of Chodl, as I observed in Section 3.2.5. For example, the 
collagen19a1 mutant stumpy is a dominant negative mutant, and so over-expression 
of Col19a1 by mRNA injection does not rescue the phenotype. Instead, morpholino 
to knockdown the collagen 19a1 must be co-injected with the mRNA, which does 
cause rescue of the phenotype (Hilario, Wang and Beattie, 2010). 
The lack of translated protein can be easily observed if an antibody to the protein of 
interest is available, as Western blotting of the embryos should demonstrate a 
reduction in band intensity in the heterozygotes, and loss of the band in the 
homozygous mutants. An example of this is the generation of smn mutant zebrafish 
to model SMA (Boon et al., 2009; Hao et al., 2013). As there are no zebrafish-




the tools that I have access to, it seems likely that mutant zebrafish generated in this 
chapter is a successful knockout mutant of chondrolectin. 
 
3.3.2 – Chondrolectin acts cell-autonomously in motor 
neurons in zebrafish to affect motor axon growth 
 
The chodl -/- zebrafish generated in this thesis are robustly healthy, with no observed 
survival deficits, and are morphologically indistinguishable from controls. As 
described in Section 3.2.4, the body length at 30 hpf is not different form that of 
controls, showing there is no associated growth problems with the loss of 
chondrolectin. The eye diameter is also identical, showing that morphogenesis also 
occurs correctly (Section 3.2.4). As well as the normal morphology, this is observed 
by the lack of change to phalloidin staining, which stains the F-actin present in muscle 
fibres. Phalloidin has been used widely to reveal changes to muscle architecture in 
zebrafish, including in collagen mutants and disease models such as muscular 
dystrophy (Pagnon-Minot et al., 2008; Johnson, Farr III and Maves, 2013). After 
quantifying the number of myotubes and the thickness of the myotubes per somite 
between the wild-type and mutant, there are no significant differences between the 
two groups. There is no detectable change between wild-type and chodl -/- embryos, 
suggesting that the muscle is healthy and its architecture is unchanged, but further 
antibodies for different muscle markers could be used to fully confirm this. For 
example, there are antibodies validated in zebrafish for the myosin heavy chain, F59 
(Wehner et al., 2017), and myosin light chain, F310 (Thomas-Jinu et al., 2017).  
The previous in situ data published in zebrafish demonstrates that a chondrolectin 
mRNA is highly enriched in motor neurons, the trigeminal ganglion, and the hindbrain 
(Chapter One, Section 1.4.2, Zhong et al., 2012, Thisse et al., 2004). However, initial 
characterisation of chondrolectin in mice found it widely expressed in muscle and 
spleen (Weng et al., 2002; Weng, Hübner, et al., 2003). Later studies demonstrated 
chondrolectin is enriched in the fast-twitch motor neurons (Enjin et al., 2010). The cell-
autonomous action of chondrolectin, specific to motor neurons, is demonstrated in 
this thesis in Section 3.2.5. Use of the HB9 promoter limits the expression of the 
chondrolectin only in motor neurons. This is confirmed via the fused FLAG-tag and its 
specific immunoreactivity in motor neurons (Section 3.2.5). The cell-specific 




3.2.6) and as a stable transgenic line (Section 3.2.5). The cell-autonomous action of 
chondrolectin is therefore demonstrated by the full rescue of a global knockout by this 
MN expression. As well as mosaic expression through plasmid injection, 
transplantation studies could be used to demonstrate the cell-autonomous role of 
chondrolectin, for example as demonstrated with the splicing factor SFPQ (Thomas-
Jinu et al., 2017). The sfpq -/- mutant fails to extend axons from the spinal cord, but 
wild-type motor neurons explanted into sfpq -/- mutants extended axons normally. 
Conversely, sfpq -/- motor neurons transplanted into wild-type embryos were unable 
to extend axons. 
In the mRNA injections performed in Zhong et al., 2012, wild-type eggs injected with 
the mRNA to induce over-expression of chondrolectin exhibited axonal defects 
themselves (see in Section 1.4.2). However, in that case it was not possible to 
determine if this was due to the high level of protein in the motor axons causing growth 
deficits, or if aberrant expression in the muscle caused unexpected interactions with 
the axons. Utilising the HB9:Chodl-FLAG construct again, we over-expressed chodl 
in the wild-type motor neurons (Section 3.2.5.2). We measured a significant reduction 
in the length of FLAG-positive axons compared to their FLAG-negative axons and 
those injected with the vector alone. This confirms that the dosage of chondrolectin in 
the MN is key to the growth of the axon. The phenotype when chondrolectin is over-
expressed is specific to the motor neuron expression and is not an artefact from 
ectopic expression of the protein from a different cell type.  
The mechanism behind the dosage effects of chondrolectin in motor neurons is not 
immediately clear. As will be discussed in depth in Section 3.3.3, we hypothesise that 
chondrolectin acts as a cell-surface recognition molecule. We assert that 
chondrolectin is trafficked to the cell membrane and its C-type lectin domain interacts 
with ligand targets in the ECM to induce correct axon growth, particularly at the HM. 
Because of this, knockdown or knockout of the protein likely leads to a reduction in 
the chondrolectin-ligand binding. Without a sufficient level of this interaction, the axon 
is prevented from extending past the HM. When the normal level is restored, by mRNA 
or transgenesis, the axon is rescued. The over-expression of chondrolectin in wild-
type embryos may have retarded growth if the high level of protein interacts with itself 





Although the HB9 promoter was used to express chondrolectin specifically in motor 
neurons, it is not the endogenous promoter of chondrolectin. Attempts by a colleague 
in the group were made to generate the chodl promoter region, using the UCSC 
Genome Browser to identify 5’ UTR regions (https://genome.ucsc.edu/index.html) and 
BACPAC to generate large clones of the putative sequence 
(https://bacpacresources.org/). However, cloning success of this potential promoter 
was never achieved. HB9 was chosen as it is a well-characterised promoter for motor 
neuron expression (Arber et al., 1999; Flanagan-Steet et al., 2005). However, the 
exact level of expression compared to the chondrolectin promoter could not be 
determined. The HB9 promoter is known to be active from approximately 9 hpf 
onwards in the zebrafish (Wendik, Maier and Meyer, 2004), compared to a detectable 
expression of chondrolectin from 12 hpf onwards (Zhong et al., 2012). 
The number of copies of the HB9:Chodl-FLAG cassette integrated into the embryos 
for experiments in Section 3.2.5 and 3.2.6 were also not determined, and so the true 
level of Chodl-FLAG expressed in each embryo is unknown. Although the chodl -/- 
axons at 28 hpf were fully rescued in the stable transgenic line in Section 3.2.5, data 
will be presented in Chapter Four which demonstrates that the rescue is not complete 
when quantified at 3 dpf. Also, the FLAG-positive axons of acutely injected embryos 
with the Chodl-FLAG cassette are significantly longer compared to the axon length in 
the chodl -/- embryos, but they do not reach the length of wild-types. For example, in 
Section 3.2.6, the FLAG-positive axons expressing the Chodl-FLAG had average 
lengths of 47.53 µm and 61.13 µm. In comparison, the wild-type axon length in 
Section 3.2.5 was 82.54 µm. This can be explained by the stochastic nature of the 
Tol2 transposon, where some axons will have received the optimal number of copies 
of Chodl-FLAG to rescue the length, and others will have received too few or too 
many. In each case, both an excess or deficit of chondrolectin would have affected 
axon length. 
The axonal growth phenotype of the chodl -/- mutant seems to be temporally limited, 
which is also observed in the morphant data (Zhong et al., 2012). Although at 28 hpf, 
only 25% of axons have extended beyond the HM, a sub-population of axons which 
have stalled are not permanently stopped. By 31 hpf approximately 40% of axons 
have extended beyond the HM (discussed in more detail in Chapter 4, section 4.2.2). 
The published morphant data also showed a mixed population of CaP axons which 




before continuing to extend. Several mechanisms for this could be possible. In 
response to an arrested axon, there could be upregulation of compensatory genes 
from either the surrounding muscle cells or the chodl deficient axon itself. This may 
allow some axons to extend beyond the HM. The requirement for chondrolectin in 
primary axon growth may also only persist for several hours. As I did not differentially 
stain for primary vs secondary axons (using an antibody such as Zn-5 which only 
labels secondary axons) and look at the primary axons after 31 hpf, it could be 
possible that the primary axons also do catch up eventually, albeit after the time period 
that I observed.  
The contribution of chondrolectin to the axonal growth also seems to differ between 
primary motor axons and secondary motor axons. Although the primary axons stall at 
the HM, the secondary axons seem able to extend, as at 48 hpf and 72 hpf the bundle 
of secondary axons (and potentially the primary CaP axons) have extended beyond 
the HM. At these time points it is not possible to distinguish individual axons, and 
multiple secondary axons extend at the same time before branching. Although the 
axon length is significantly shorter at 48 hpf compared to wild-type controls (Section 
3.2.3), this difference has disappeared at 72 hpf and there are no significant 
differences between the lengths of axon bundles. As well as extending along the 
ventral pathway, using the CaP axon as a pioneer, the secondary axons begin to 
branch into the muscle and innervate it. At both 48 and 72 hpf, the number of branches 
in the chodl -/- group are significantly reduced compared to the wild-type larvae 
(section 3.2.3). This supports data later in this thesis, where the lack of branching also 
mirrors a reduction in the number of synaptic puncta in the muscle at 3 dpf (Chapter 
Four). Further investigation of the axonal phenotype at even later stages (5 dpf or 
older) would be useful to determine if this branching deficit is delayed or permanently 
arrested, especially as the chodl -/- mutants can feed and swim normally and have no 
visible phenotype as juveniles or adults.  
The difference in phenotype between primary and secondary axons could be 
expected, as the growth pattern and branching of the two groups differ significantly. 
Primary and secondary axons also express different genes, such as islet-1 which is 
enriched in secondary motor neurons but not primary motor neurons (Babin et al., 
2014). Thus the requirement of chondrolectin and its mechanism between the two 
groups of neurons may also differ. Although the mechanism for the chondrolectin 




questions about the exact pathway and other interaction partners chondrolectin may 
have to induce these axonal phenotypes in both the primary and secondary motor 
neurons.  
 
3.3.3 – Chondrolectin acts as a cell-surface molecule 
 
From the acute rescue data presented in Section 3.2.6, the C-type lectin domain 
(CTLD) and intracellular domain (ID) are both indispensable for the function of Chodl 
in zebrafish. Removal of either of these structural domains abolishes the rescue of 
the chodl -/- phenotype, while the full-length construct is able to rescue the axons. 
Furthermore, we show that the ID functions via phosphorylation of its Ser/Thr 
residues, as mutagenesis of these residues to alanine also abolishes the axonal 
rescue. Given the other domains of chondrolectin include a signal peptide and a 
transmembrane domain, it seems feasible that chondrolectin is a cell-surface protein 
that binds other proteins, either in the ECM or the intracellular region of the MNs, or 
both. 
The involvement of the C-type lectin domain of chondrolectin in motor axon guidance 
and growth is rare for the domain, as CTLDs are normally expressed in immune cells, 
recognising microbial proteins during infection (Yan, Ohno and Tsuji, 2013; Hoving, 
Wilson and Brown, 2014; Dambuza and Brown, 2015). However, a transmembrane 
C-type lectin protein, CLEC-38, has been shown to regulate axon outgrowth in C. 
elegans (Kulkarni, Li and Wadsworth, 2008). The protein suppresses axon growth, 
preventing over-growth past the axon target. Interestingly, this protein was also 
demonstrated to remodel pre-synaptic terminals on the axon, as CLEC-38 mutants 
have fewer pre-synaptic puncta along the axon length. This supports our findings in 
the zebrafish, and Chapter Four covers the relationship between chondrolectin and 
synaptogenesis. 
The only published binding study of the chondrolectin protein identified Rab 
geranylgeranyl transferase β (Rabggtb) (Claessens, Weyn and Merregaert, 2008), 
and that the binding occurs via the intracellular domain. However, no further functional 
analysis was performed. Rabggtb is the catalytic component which isoprenylates Rab 
GTPase during its association with the plasma membrane. Rab GTPases are involved 




that chondrolectin acts as a stabilising protein for the Rabggtb. They determine that 
Chodl is unlikely to be a target for isoprenylation itself, due to a lack of target motif for 
the modification.  
Another potential ligand for chondrolectin is collagen19a1 (Col19a1). The mutant 
stumpy, a dominant negative mutant of Col19a1, phenocopies the stalled CaP axons 
of the chodl -/- embryos, (Hilario, Wang and Beattie, 2010). Morpholino knockdown of 
Col19a1 also induces axon stalling. Expression analysis of colXIXa1 using in situ 
hybridisation showed a dynamic expression pattern from 19 hpf until 36 hpf, the same 
stages as primary axonal outgrowth from the spinal cord. Particularly of interest to my 
thesis work is that the expression pattern at 19 hpf is in the region of the horizontal 
myoseptum. This would imply that Col19a1 is present in the ECM at the HM at the 
same time the motor axons are reaching the HM choice point. The HM is of clear 
importance to both the chondrolectin and collagen19a1 function, given that the axonal 
phenotype is focused around the HM. At later stages, the in situ pattern is both more 
dorsal and ventral, corresponding to the path of the MiP (dorsal) and CaP (ventral). 
This suggests that Col19a1 is influencing the axonal growth cones of these primary 
motor neurons (Hilario, Wang and Beattie, 2010).  
A range of unpublished data from colleagues in my group demonstrates that the C-
type lectin domain of Chodl binds Col19a1. The findings are summarised in Table 3.2. 
Firstly, genetic interaction of chodl and colXIXaI was observed, as injection of either 
the chodl or col19a1 morpholino alone at a sub-threshold dosage does not induce the 
axonal phenotype. However, combining these sub-threshold doses does lead to an 
axonal phenotype, demonstrating their synergistic interaction.  
Using HEK cells, Dr Ana-Maria Oprişoreanu performed biochemical assays on these 
proteins. There are no commercially available antibodies for Col19a1 and Chodl, as 
the mouse CHODL antibody used in Weng, Hübner, et al., 2003; Enjin et al., 2010 
are no longer available for sale. However, HEK cell-adapted plasmids of Col19a1-HA 
and Chodl-FLAG were generated to use in binding assays and Western blotting, as 
the HA and FLAG peptide are widely used, and their antibodies are well-
characterised. Initial binding assays demonstrate that the Col19a1 and Chodl can 
bind in vitro. This was performed by isolation of both proteins from transfected HEK 





I speculate that chondrolectin functions as a cell-surface protein, and thus refute the 
previous findings that chondrolectin is mostly expressed in the perinuclear region and 
cytoplasm (Weng, Hübner, et al., 2003; Enjin et al., 2010). Instead, I hypothesise that 
chondrolectin is trafficked and inserted into the cell membrane, in order to interact 
with Col19a1 in the ECM. Unfortunately, my data in zebrafish using the HB9:Chodl-
FLAG plasmid alone cannot prove this. Although the FLAG staining is excluded from 
the nucleus (visible in Section 3.2.5), the staining is widespread in the cytoplasm and 
membrane. This is due to our use of the HB9 promoter and not the endogenous chodl 
promoter. As a future experiment, co-staining of a membrane marker such as HNK-1 
(Nourizadeh-Lillabadi et al., 2010) and the FLAG, in high-resolution, should 
demonstrate that the Chodl-FLAG is present in the membrane as well as the 
cytoplasm in the zebrafish.  
Using HEK cells Dr Oprişoreanu demonstrated that Chodl is trafficked to the plasma 
membrane and requires the C-type lectin domain to bind Col19a1. Col19a1 
supernatant was added to Chodl-FLAG transfected HEK cells. After washing, fixation, 
and immunolabelling, we observe that the Chodl-FLAG constructs are membranous 
and can retain the Col19a1 (in other words, binding the collagen) only when the CTLD 
is present. This supports our hypothesis that the CTLD is interacting with ECM 
proteins including Col19a1, and that it does this while Chodl is bound to the 
membrane. 
The HEK cell data supports the acute rescue experiments I performed in Section 
3.2.6, and further develops it. Both the CTLD and ID are required for the chondrolectin 
function in zebrafish, and this may be because the CTLD binds with Col19a1 during 
axon outgrowth. Other proteins may also bind the CTLD, but the phenocopy of stumpy 









Zebrafish  Sub-threshold dosage of both 
chodl and col19a1 morpholino 












Western blotting after binding 
assays, using tagged proteins 
produced by HEK cells. 
 
Col19a1 supernatant added to 
Chodl-FLAG transfected HEK 
cells is retained due to binding 




Col19a1 via its C-
type lectin domain 
HEK 
cells 
In binding assays followed by 
WB, binding between Chodl and 
Col19a1 is abolished if the C-type 
lectin domain is removed. 
 
Col19a1 supernatant is not 
retained on HEK cells transfected 





domain of Chodl 




Binding assays followed by WB 
are unaffected if the ID is 
removed from the construct 
transfected into HEK cells. 
 
Col19a1 supernatant added to 
Chodl-FLAG (w/o ID) transfected 
HEK cells is retained due to 








Confocal imaging of HEK cells 
transfected with Chodl-FLAG 
shows FLAG immunoreactivity in 
the plasma membrane 
Dr Ana-Maria 
Oprişoreanu 
Table 3.2: Summary of unpublished findings demonstrating the interaction of 





At this time, we do not know which proteins bind the ID to transduce the outgrowth 
signal, and the exact mechanism with regard to how the ID is involved, although it is 
almost certain that it includes Ser/Thr kinases, as phosphorylation of the ID is also 
required for the function in zebrafish. In this thesis, we substituted 11/12 of the serine 
and threonine residues for alanine, but a further development of this would be to 
systematically substitute each residue, and repeat the rescue experiments, to identify 
the minimum phosphorylation sites that are required for the protein to function. As 
well as generating a construct that cannot be phosphorylated (i.e., it is constitutively 
non-phosphorylated), a future study could investigate the effect of a constitutively 
phosphorylated domain. This would offer insight into the effect of activating 
chondrolectin outside of its normal stages of function. Rather than substituting Ser/Thr 
to Ala, these ‘phosphomimetic’ residues are instead aspartic or glutamic acid 
(Dephoure et al., 2013). 
In mice, several splice variants have been identified with differences in the ID (Sleigh 
et al., 2014). The 3 isoforms of chondrolectin have varying length of intracellular 
domain, with the C-type lectin and transmembrane domains remaining identical 
across the variants. The zebrafish Chodl is 293aa in length, which mostly closely 
corresponds to the Chodl-001 isoform at 273aa. The Chodl-002 isoform is 292aa in 
length, and Chodl-003 is 246 aa, with only 6 aa of the intracellular domain conserved. 
However, Chodl-003 isoform is not detectable in the spinal cord (Sleigh et al., 2014), 
so its potential role is unknown. The comparison between orthologues of 
chondrolectin isoforms between species are shown in Section 1.4.1.1. Ensembl 
(https://www.ensembl.org/index.html) does not predict different splice variants in the 
zebrafish orthologue of chondrolectin, and deleting the whole intracellular domain 
abolishes the rescue of the axonal phenotype in chodl -/- zebrafish (data presented 
in Section 3.2.6). It would be interesting to use these splice variants to attempt to 
rescue the chodl -/- zebrafish, to determine the minimum sequence required to rescue 
the axonal phenotype. 
Use of kinase inhibiting compounds, to look for phenocopy of chodl -/- axons, might 
identify the specific kinases involved in chondrolectin. However, kinase inhibitors 
often target multiple kinases, making determination of the exact mechanism 
challenging (Klaeger et al., 2017). One method to identify intracellular binding 
partners would be to perform mass spectrometry on Chodl-FLAG protein isolated from 




spectrometry is large, representing several hundred embryos. The likelihood of 
capturing a kinase bound to the ID would also be low, as the binding to phosphorylate 
the residues would be transient compared to the Col19a1 binding the CTLD. However, 
this is a potentially useful avenue to develop in the future, to determine other proteins 
which may interact with chondrolectin apart from Col19a1. 
In this chapter, I have generated and characterised a chondrolectin knockout 
zebrafish, which exhibits motor axon growth defects but has grossly normal 
morphology. I have also generated a transgenic line re-expressing motor-neuron 
specific chondrolectin in the chodl -/- background, demonstrating the cell-autonomous 
function of chondrolectin. I have presented novel functional data offering a potential 
mechanism for chondrolectin, namely that it binds collagen19a1 in the ECM via its C-







Chapter Four – Investigating the 
novel role of chondrolectin in 
synapse stabilisation 
 
4.1 – Introduction 
 
In this chapter, I will present data showing that chondrolectin expression affects the 
formation and stabilisation of motor synapses. As will be discussed, as well as 
evidence that chondrolectin is a downstream gene of Smn dysfunction in SMA 
models, synapse defects are widely observed in SMA. I thus hypothesise a 
relationship between chondrolectin and synaptogenesis, which may contribute to the 
pathology in SMA.  
 
4.1.1 – Neuromuscular junction defects have been 
observed in models of Spinal Muscular Atrophy 
 
Spinal Muscular Atrophy is an inherited form of motor neuron disease which affects 
children. The most severe form, Type I, has an average disease onset of six months 
and a life expectancy of two years (Lunn and Wang, 2008). SMA affects lower motor 
neurons in humans, and neuromuscular junction (NMJ) defects are detected in human 
patients as well as many animal models (Murray, Talbot and Gillingwater, 2010; Boyd 
and Gillingwater, 2016). Neuromuscular junctions are the synaptic connection 
between the motor axon and the muscle, with chemical signalling occurring between 
the pre-synapse (axon) and post-synapse (muscle) to induce motor movement 
(Darabid, Perez-Gonzalez and Robitaille, 2014). 
During SMA disease progression, the motor neuron degeneration begins at the NMJ, 
and thus it is important to investigate how the NMJ develops and stabilises (Goulet, 
Kothary and Parks, 2013). The reasons for NMJ vulnerability in SMA are hypothesised 
to be due to failure of mRNA transport along axonal processes, reducing the local 




of embryonic and post-natal mice, suggesting that the protein itself may function in 
the NMJ which is impaired in SMA (Dombert et al., 2014). For these reasons, the NMJ 
is considered a key target to investigate in SMA pathology (Murray, Talbot and 
Gillingwater, 2010; Boido and Vercelli, 2016). 
There is also increasing evidence that the motor neurons and neuromuscular 
junctions are affected during developmental stages, so rather than purely 
degenerative, SMA also has a developmental component. In foetal tissue of Type I 
SMA patients, there is neurofilament accumulation in the neuromuscular junctions, 
and a failure of the pre-synapse to fully occupy the post-synaptic compartment 
(Martínez-Hernández et al., 2013). This demonstrates that aberrant changes to the 
NMJ occur even before birth of the SMA patient and onset of symptoms. In Kariya et 
al., 2008, diaphragm muscle samples donated from human SMA Type I patients also 
show aggregation of NF and poor arborisation of the motor terminals. This 
demonstrates widespread structural defects in the NMJ of human SMA patients, even 
in muscle considered to be less vulnerable to SMN loss, as the diaphragm is usually 
spared in Type I SMA (Kariya et al., 2008). However, it is not known in humans if this 
is a fully developmental failure or extremely early degeneration. 
In mouse models of SMA, several key findings demonstrate that there are 
neuromuscular junction defects, supporting the idea that NMJs are a key target for 
investigation. Firstly, motor axon growth to the muscle is unaffected even in severe 
SMA mice (Mcgovern et al., 2008), but there are widespread changes to the NMJs 
even at early stages (Goulet, Kothary and Parks, 2013). As mentioned previously, in 
both embryonic and post-natal mice, the SMN protein localises to the pre-synaptic 
terminal of the motor axons, and complexes with ribonucleotide proteins (RNPs), 
suggesting a role for SMN in the NMJ (Dombert et al., 2014). In cultured mouse motor 
neurons, taken from embryonic SMA model mice, there is reduced Ca2+ channel 
clustering in the axon terminals, which also leads to reduced spontaneous excitability 
(Jablonka et al., 2007). Reduction of SMN in mice appear to prevent the maturation 
of the NMJs, as the post-synaptic densities are not correctly remodelled into the 
‘pretzel’ shape, remaining a solid patch but becoming progressively weaker in AChR 
staining intensity, which phenocopies defects observed in diaphragm muscle samples 
from human patients (Kariya et al., 2008). This paper also indicates pre-synaptic 
defects, with the axon terminal remaining bulb-shaped and failing to branch into and 




of neurofilament, which supports the human data described in Martínez-Hernandez 
et al., 2013. The concept of SMN reduction preventing maturation of NMJs was also 
supported by impaired synaptic vesicle release observed in mouse electrophysiology 
data (Kong et al., 2009). A later study also demonstrated a requirement of SMN for 
organisation of the active zone of the motor synapse, including microtubule and 
synaptic vesicle maturation, as well as synaptic vesicle recycling (Torres-Benito et al., 
2011). Reduction in SMN protein levels in the mouse model results in fewer 
mitochondria. This is also observed in zebrafish Smn knockdown, where increasing 
mitochondrial biogenesis rescues the axonal defects, and vulnerable motor neuron 
populations in mouse models have an altered bioenergetic profile than those 
populations less vulnerable to degeneration (Boyd et al., 2017). 
In the zebrafish, a severe SMA model exhibits pre-synaptic deficits (Boon et al., 2009). 
There is a reduction of SV2 staining in 11 dpf larvae, but the post-synaptic labelling 
remains intact, leading to a decrease in co-localisation of these two labels. However, 
this reduction appears to be SV2-specific, as labelling with synaptotagmin shows no 
change between the controls and mutants. Introduction of the human SMN2 gene in 
these mutant zebrafish extended their lifespan by several days, and rescued the 
synaptic defects for these days, although the loss of SV2 staining re-emerged by the 
time these mutants died (Hao, Burghes and Beattie, 2011). This demonstrates that 
zebrafish models of the disease recapitulate certain synaptic defects associated with 
SMA. 
 
4.1.2 – Synaptogenesis in zebrafish and other organisms 
 
During motor axon growth in zebrafish, clusters of pre- and post-synaptic proteins 
form between the extending axon and muscle and remodel over time. In mammals, 
the motor axon innervates each muscle fibre with only a single NMJ. The relationship 
between signalling proteins derived from axons and muscles have been explored both 
in axonal pathfinding and synaptogenesis. 
Before motor axons exit the spinal cord in zebrafish, clusters of acetylcholine 
receptors (AChRs) form in pre-patterns in the muscle, from approximately 16 hpf 
onwards (Flanagan-Steet et al., 2005). These pre-patterns form along the vertical 




illustrating the pre-patterning of AChRs before axon growth is shown in Chapter One, 
in Section 1.2.4, with diagrams of the key developmental stages.. 
The pre-patterning of AChRs in zebrafish is dependent on the muscle-specific kinase 
(MuSK). MuSK zebrafish mutant unplugged exhibits axonal pathfinding defects, 
including stalling of the CaP axon and aberrant pathfinding of the RoP axon (Zhang 
et al., 2004). MuSK signalling induces expression of ECM molecules in axonal 
pathfinding choice points including the horizontal myoseptum. Unplugged mutants do 
not express Tenascin-C, an ECM molecule important for the correct axonal 
pathfinding (Schweitzer et al., 2005). In unplugged  zebrafish, the pre-patterns remain 
scattered on the muscle fibres, and do not form into a clustered pre-pattern along the 
middle of the myotome as is seen in wild-types (Jing et al., 2009).  
During motor axon growth in zebrafish, the growth cone filopodia are preferentially 
stabilised upon contact with AChRs on the muscle, and so axonal pathfinding tends 
to follow these pre-patterns (Panzer, Song and Balice-Gordon, 2006). AChRs not 
contacted by axons are eventually dispersed, but the clusters contacted by axons are 
also stabilised ((Flanagan-Steet et al., 2005). These are known as en passant 
synapses, as they cluster along the length of the axons rather than form single 
terminal NMJs, as in mammals (Burden, 2002; Wu, Xiong and Mei, 2010). Although 
initially elongated in shape, the AChRs become more punctate and condensed over 
time. In mice, aneural pre-pattern clusters of AChRs also form, but are dispersed if 
not innervated by the motor axon (Darabid, Perez-Gonzalez and Robitaille, 2014). 
These findings demonstrate that the clustering of AChRs on the muscle does not 
initially require signals from the motor neuron, but at later stages require axonal 
contact to stabilise the post-synapse and remodel the pre-patterns into an active 
synapse.  
The further stabilisation of the post-synapse after axonal contact requires both 
muscle-derived and neuron-derived signal proteins (Wu, Xiong and Mei, 2010). One 
neuron-derived protein necessary for further NMJ remodelling is agrin. Agrin-null mice 
do not develop NMJs and die at birth (Gautam et al., 1996). Similar to the MuSK 
mutant, morpholino-induced knockdown of agrin in zebrafish causes axonal 
pathfinding errors. Furthermore, the AChR pre-patterns can be induced but not 
stabilised, and thus the AChR clusters disperse after axonal growth (Kim et al., 2007). 
MuSK is necessary for post-synaptic differentiation in mammals, where it recruits 




(Burden, 2002). However, zebrafish unplugged mutants still develop synapses, 
although the larvae have reduced numbers of, and smaller sized, post-synaptic 
puncta, showing that it is dispensable in zebrafish (Zhang et al., 2004). Ectopic 
expression of MuSK in mice promotes synapse formation, and can rescue the lack of 
synapses normally observed in agrin-null mice (Kim and Burden, 2008).  
Further zebrafish mutants have elucidated the synaptic proteins required for correct 
synapse stabilisation. The rapsyn mutant twitch once is unable to correctly initiate an 
escape swim when startled, and the mutant larvae have diffuse AChR clusters which 
leads to reduced motility (Ono et al., 2002). Rapsyn is a scaffolding protein which 
forms part of the post-synaptic density on the muscle fibres, and defects in rapsyn 
have been linked to myasthenic syndrome in humans (Ohno et al., 2002). Rapsyn 
requires acetylcholine receptors for the protein to be transported from the Golgi 
apparatus to the synapse (Ono et al., 2001; Park et al., 2012).   
In larval zebrafish, when the secondary axons have differentiated and extended motor 
axons, the axons begin to branch and innervate the myotome outside of the ventral 
axon bundle. This pathfinding does not require pre-patterning of AChR clusters, which 
have dispersed if not contacted by axons before 30 hpf. Several zebrafish mutants 
exhibit reduced numbers of synaptic puncta in larval stages, as well as reduced 
branching of the axons (Panzer et al., 2005). This includes the Collagen19a1 mutant 
stumpy, a putative binding partner of chondrolectin. 
The relationship between axonal branching and synaptogenesis is unknown in 
zebrafish, but evidence in Xenopus motor axons and the retinal ganglion cells (RGCs) 
in both zebrafish and Xenopus suggest that synaptic sites are required to maintain 
nascent axonal branches. In RGC axons, in vivo imaging of pre-synaptic proteins 
demonstrates that nascent dendritic arbours are unstable and retract unless pre-
synaptic proteins cluster on the branch point. Branches preferentially emerge from 
synaptic sites on the trunk of the axon (Meyer and Smith, 2006; Ruthazer, Li and 
Cline, 2006). This also occurs in the motor axons of Xenopus tadpoles (Javaherian 
and Cline, 2005). Overall, this suggests that axonal branching is closely related to 
synaptogenesis and proposes that synaptogenesis facilitates the number and location 






4.1.3 – Zebrafish behavioural assays 
 
The rapid development of zebrafish leads to behavioural responses within 24 hpf. 
Behavioural assays are thus an excellent method to functionally probe defects in the 
synapses. At 24 hpf the embryos are still inside the chorion, and although some 
spontaneous twitching is observable, the embryos are unable to swim at this age 
(Menelaou et al., 2008). After hatching, at around 3 dpf, the larvae are capable of 
flight responses to escape from a stimulus, but they do not perform free swimming at 
this stage. Free swimming and feeding behaviour begins at 5 dpf, when the swim 
bladder inflates, and the larvae have exhausted their supply of yolk (Granato et al., 
1996; Goolish and Okutake, 1999). At this stage, the larvae must be capable of 
hunting and escape behaviours, and with the swim bladder can control their depth as 
well as their horizontal movement. The larvae also undergo avoidance behaviours 
from predatory stimuli such as dark areas, moving images, or open spaces (Colwill 
and Creton, 2011). 
After a touch stimulus to the tail, the zebrafish initiates a flight escape by rapidly 
swimming forwards for a short period, away from the stimulus. The larvae can cover 
around 25 mm within the first 15 seconds (Wehner et al., 2017). The swimming 
reaction is mediated by sensory Mauthner cells and the fast-twitch muscles, which 
are innervated by the primary and some secondary neurons (Kohashi and Oda, 2008). 
Assaying this response has been widely used in a variety of contexts, including injury 
and repair, disease models, and developmental studies. Mechanical lesioning of the 
spinal cord leaves the larvae paralysed caudal to the injury site and unable to respond 
to the tail tap (Ohnmacht et al., 2016; Wehner et al., 2017). Regeneration of the spinal 
cord also correlates with a functional recovery to this behaviour. Mutations in synaptic 
proteins, such as rapsyn, often have paralysis or show reduced movement 
phenotypes (Panzer et al., 2005; Park et al., 2014).  
When startled by either touch or auditory vibration near the head of the larval 
zebrafish, the larvae undergo a rapid coiling of the body and swim away from the 
stimulus (Granato et al., 1996; Bhandiwad et al., 2013). This movement is mediated 
by the Mauthner cells, which are a pair of large reticulospinal cells in the hindbrain, 
which cause contraction of all motor neurons on the contralateral side of the 




characteristic C-bend shape in the body of the larva. A schematic of this escape is 







Changes to either the escape flight or turning response during escape have been 
observed in zebrafish with muscle, motor neuron, and synapse mutations. A wide-
ranging behavioural screen was performed in the Tübingen ENU mutant screen, with 
a range of observed behaviours (Granato et al., 1996). This included complete 
paralysis, inability to sense touch stimuli, and reduced swimming ability. A rapsyn 
mutant, which fails to correctly localise acetylcholine receptors (AChRs) to the muscle 
surface, are able to initiate an escape but have easily-fatigued muscles so cannot 
swim after this initial response (Ono et al., 2002). In the chondrolectin mutant, with 
reduced axonal branching at 3 dpf (Chapter Three), we would therefore hypothesise 
that its behaviour either in swimming or turning at this stage would be impaired. 
Zebrafish mutants with deficits in axonal pathfinding or axon growth often also exhibit 
synapse defects. This includes unplugged, stumpy, and SMA model larvae (Panzer 
et al., 2005; Boon et al., 2009; Jing et al., 2009). Chondrolectin is also linked to SMA, 
of which NMJ dysfunction is a key pathological feature, therefore I hypothesised that 
synaptogenesis or synapse development would be impaired in the chodl -/- zebrafish 
compared to wild-types. In this chapter, I present data at embryonic and larval stages, 
showing defects in synapse labelling in the mutants which are partially rescued in the 
Figure 4.1: Schematic illustrating the C-bend response.  
When startled by a touch stimulus or vibration, the larva performs a tight bend, 
with its head contacting its tail in a C-shape (third frame). The larva then swims 




stable rescue line. I also performed behavioural assays which demonstrated a turning 
defect in the chodl -/- larvae during an escape response. 
 
 
4.2 – Results 
 
4.2.1 - Synaptic labelling of the horizontal myoseptum at 
28 hpf shows pre-synaptic defects in chodl -/- embryos 
 
To determine changes to synaptic organisation in the chodl -/- mutants, we first 
compared the pre- and post-synapse at the horizontal myoseptum at 28 hpf. The 
horizontal myoseptum was selected as it is the location of the axonal stalling in the 
mutant, and morphant data demonstrated no changes in axon behaviour between the 
spinal cord exit and reaching the HM (e.g. the pre-HM axon) (Zhong et al., 2012). Pre-
synaptic defects have been observed in the SMA zebrafish models, of which 
chondrolectin is a downstream gene (Boon et al., 2009). We therefore wanted to 
examine the synaptic puncta at the HM region, to determine if there are differences 
between the synaptic compartments in wild-type and chodl -/- embryos.  
To label the pre-synapse, we used anti-SV2, an antibody widely used in zebrafish 
synaptic preparations (Flanagan-Steet et al., 2005; Boon et al., 2009). Synaptic 
vesicle protein 2 is found in all synapses and is a transmembrane transporter on the 
vesicle surface (Feany et al., 1992). Antibodies against synaptotagmin (znp-1) were 
also used by colleagues to label the pre-synapse and validate the pre-synaptic 
phenotypes, and the data is also discussed later in this chapter. The post-synapse 
was labelled with an anti-AChR antibody validated in zebrafish, mAb 35 (Park et al., 
2014). α-bungarotoxin is frequently used to label the post-synapse, but we were 
unable to replicate the labelling in our hands, using protocols published in Flanagan-
Steet et al., 2005; Panzer, Song and Balice-Gordon, 2006; Park et al., 2012.  
To measure synaptic differences at the HM at 28 hpf, a 20 µm x 20 µm square region 
around the HM was cropped after staining and imaging. The puncta were analysed 
after thresholding each channel to generate binary images. Briefly, after LUT 




each channel with a rolling ball radius at 1/3 of the image width. A 20% threshold was 
then applied, based on the maximum grey value measured for each image. The 
Analyse Particle function was then performed, with a minimum particle size of 0.5 
µm2.  A detailed method on thresholding the images is described in the Materials & 











In the data shown in Figure 4.2, the chodl -/- embryos exhibit a reduction in the pre-
synaptic compartment clusters at the HM, but the total area of the SV2 pre-synaptic 
compartment is not significantly changed. 
The total area covered by SV2 labelling does not differ between chodl -/- embryos 
and controls (Control total area= 43.00 µm2 ±, n= 28. chodl -/- total area= 45.36 µm2 
±, n= 35. Unpaired t-test n.s., p= 0.340). However, the average number of pre-
synaptic clusters are significantly reduced in the chodl -/- embryos compared to 
controls, with a reduction by 34% (Control cluster number= 3.652 ±0.210, n= 28. chodl 
-/- cluster number= 2.41 ±0.122, n= 35. Unpaired t-test **** p<0.0001) (B, E). 
This suggests that the organisation of the SV2 protein is disrupted in the chodl -/- 
embryos, and the SV2 fails to coalesce into discernible clusters as in the wild-type. 
However, the overall size of the HM area is not different between groups, shown by 
the unchanged total area, suggesting the overall amount of SV2 is unchanged. 
The post-synaptic compartment, labelled with AChR antibody, is not different between 
genotypes. The total post-synaptic area is unchanged between control and chodl -/- 
embryos (Control total area= 58.29 µm2 ±2.26, n= 28. chodl -/- total area= 56.36 µm2 
±1.81, n= 35. Unpaired t-test n.s., p= 0.502) The number of post-synaptic clusters are 
not significantly different between control and chodl -/- embryos (Control puncta 
number= 6.13 ±0.314, n= 28. chodl -/- cluster number= 5.869 ±0.391, n= 35. Unpaired 
t-test n.s. p= 0.612) (C, F). This suggests that there is an axon-mediated deficit in pre-
Figure 4.2: The pre-synaptic clusters are reduced in number but their total area is 
unchanged in chodl -/- 28 hpf embryos compared to controls. 
A: Representative images of the lateral view of the CaP axon at 28 hpf. The HM 
region is shown (yellow box). The raw image, thresholded image, and cluster outline 
are shown. Scale bars= 20 µm and 10 µm. B: The total pre-synaptic compartment 
area is unchanged between control and chodl -/- embryos (Unpaired t-test n.s, p= 
0.340) C: The total post-synaptic compartment area is unchanged between control 
and chodl -/- embryos (Unpaired t-test n.s, p= 0.502).  D: The total double-labelled 
compartment area is unchanged between control and chodl -/- embryos (Unpaired t-
test n.s., p=0.611) E: The average number of pre-synaptic clusters are significantly 
reduced in chodl -/- embryos compared to controls (Unpaired t-test **** p<0.0001. 
Post-hoc power= 0.996).  F: The average number of post-synaptic puncta is 
unchanged between control and chodl -/- embryos (Unpaired t-test n.s. p=0.612) G: 
The average number of double-labelled clusters are unchanged between control 




synaptic organisation at the HM at this developmental stage, but that this axonal loss 
of chondrolectin does not mediate any effect in the AChR expressed on the muscle. 
With changes to the SV2 pre-synaptic label but no differences in the post-synapse, 
the double-labelled cluster area and number (from the overlap of SV2/AChR) is not 
changed between the two groups. The total double-labelled area is not significantly 
different between control and chodl -/- embryos (Control total area= 23.93 µm2 ±1.34, 
n= 28. chodl -/- total area= 24.84 µm2 ±1.18, n=35. Unpaired t-test n.s., p=0.611). The 
number of double-labelled clusters is unchanged between control and chodl -/- 
embryos (Control cluster number= 4.49 ±0.197, n= 28. chodl -/- cluster number= 4.15 
±0.215, n= 35. Unpaired t-test n.s. p= 0.257) (D, G). 
This comparison between the wild-type controls and chodl -/- embryos demonstrates 
that loss of chondrolectin expression leads to changes in the SV2 organisation in the 
axon at the horizontal myoseptum. The AChR clusters, expressed on the muscle, do 
not change. This suggests that changes to the pre-synapse, mediated by the loss of 
chondrolectin, does not perturb clustering of AChR immunoreactivity on the muscle.   
To determine if this pre-synaptic phenotype is rescued in the chodl -/-;HB9:Chodl-
FLAG line, a colleague in the group utilised the same protocol and image analysis 
method. However, due to the transgenic background of HB9:GFP in the chodl -/-
;HB9:chodl-FLAG line, the same secondary antibodies could not be used as were 
used in Figure 4.2. The α-AChR was originally visualised using AF488 α-rat, but this 
was changed to AF647 α-rat. The use of α-SV2 and AF594 α-mouse remained the 
same. To maintain true comparison between the groups, the HB9:GFP transgenic 
controls and mutants were also used, rather than the purely wild-type background 
used previously. A new batch of antibodies were also used. Although the SV2 
antibody batches had comparable concentrations of proteins, the AChR new batch 
had a higher concentration of protein, which may also explain differences in labelling 
of the post-synapse observed by the other researcher.  
The pre-synaptic data is replicated in this experiment, demonstrating its reliability 
across different researchers, and in the rescued chodl -/-;HB9:Chodl-FLAG line there 
is a full rescue of the cluster number to wild-type values, showing that the synapse 
defect is rescued as well as the axonal defect at 28 hpf. However, there are some 
differences in the post-synaptic values in that the cluster number is also reduced in 





4.2.2 – Changes in the pre-synaptic compartment in chodl 
-/- embryos persist when the axons grow beyond the 
horizontal myoseptum 
 
The chodl -/- phenotype at 28hpf discussed in Chapter Three shows that ~75% of the 
CaP axons are stalled at the horizontal myoseptum, and around ~25% have grown 
beyond this choice point, although the axons are still shorter than the wild-type axons 
at the same time point. Because of this stalling, it is possible that the enlarged pre-
synapse seen in the chodl -/- axons are a result of the axon just being delayed, and 
thus a consequence of the stalled axon, rather than directly linked to the loss of 
chondrolectin. To further investigate this, we imaged both wild-type and chodl -/- 
embryos at 31hpf, to determine if the pre-synaptic differences persist into later time 
points. 31 hpf was chosen as it is before the outgrowth of the secondary axons at 33 
hpf, but the proportion of mutant axons which have managed to grow beyond the HM 
is higher than at 28 hpf, rising to 42% (27/64 axons in 16 embryos, data not shown). 
The same imaging protocol was used as in Section 4.2.1 above, and the analysis was 
























The measurements of the axons shown in Figure 4.3 demonstrate that the pre-
synaptic puncta are significantly larger than controls at the 31 hpf timepoint. At this 
timepoint, the total area labelled with SV2 is also significantly larger in the chodl -/- 
embryos, 20.4% larger compared to the control area. (Control pre-synaptic average 
total area= 43.9 µm2 ±2.25, n= 20. chodl -/- average pre-synaptic total area= 52.86 
µm2 ±3.73, n= 17. Unpaired t-test * p=0.040). The number of pre-synaptic puncta are 
significantly reduced, with 25.0% fewer puncta in the chodl -/- embryos compared to 
controls. (Control pre-synaptic puncta number= 5.25 ±0.369, n= 20. chodl -/- pre-
synaptic puncta number= 3.94 ±0.422, n= 17. Unpaired t-test * p= 0.0247) (B, D). This 
reduction in cluster number persists from the data at 28 hpf, where the number of pre-
synaptic clusters was reduced by 34% compared to the control group.  
At 31 hpf, there is no difference between the post-synaptic compartments in control 
or chodl -/- embryos. The total post-synaptic area is unchanged between chodl -/- and 
control embryos at 31 hpf (Control average area= 66.06 µm2 ±3.53, n= 20. chodl -/- 
average pre-synaptic puncta area= 72.01 µm2 ±3.36, n= 17. Unpaired t-test n.s p= 
0.236). The number of puncta in the post-synaptic compartment is unchanged 
between the control and chodl -/- embryos at 31 hpf. (Control average puncta 
number= 7.21 ±0.495, n= 20. chodl -/- average pre-synaptic puncta number= 7.13 
±0.696, n= 17. Unpaired t-test n.s. p= 0.924) (C, F). 
Figure 4.3: Pre-synaptic defects are present at 31 hpf in axons which have passed 
the horizontal myoseptum.  
A: Example images of wild-type control and chodl -/- axons which have passed the 
HM at 31 hpf, taken from lateral trunk views. The ROI is shown (yellow square). For 
both the SV2 and AChR channels, the raw, thresholded, and puncta outline are 
shown. Scale bars= 20 µm and 10 µm. B: The total pre-synaptic area labelled with 
SV2 is significantly larger in chodl -/- embryos than controls. (Unpaired t-test * 
p=0.040).  C: The total post-synaptic area labelled with AChR is unchanged 
between chodl -/- and control embryos (unpaired t-test n.s., p= 0.236). D: The total 
area double-labelled with both SV2 and AChR is unchanged between control and 
chodl -/- embryos (Unpaired t-test n.s. p= 0.208). E: The number of pre-synaptic 
clusters are reduced in the chodl -/- embryos compared to controls (Unpaired t-test * 
p=0.0247).  F: The number of post-synaptic clusters are unchanged between control 
and chodl -/- embryos. (Unpaired t-test n.s. p= 0.924).  G: The number of double-
labelled clusters are unchanged between control and chodl -/- embryos (Unpaired t-




The double-labelled area, from the overlap of the SV2 and AChR label, is unchanged 
between control and chodl -/- embryos at 31 hpf. The total area of overlap between 
the SV2 and AChR label is not significantly different between the control and chodl -
/- embryos at 31 hpf (Control average area= 26.42 µm2 ±2.21, n= 20. chodl -/- average 
pre-synaptic puncta area= 30.63 µm2 ±2.43, n= 17. Unpaired t-test n.s. p= 0.208). 
The number of double-labelled puncta is not significantly different between control 
and chodl -/- embryos at 31 hpf (Control average number= 5.79 ±0.348, n= 20. chodl 
-/- average pre-synaptic puncta number= 5.12 ±0.347, n= 17. Unpaired t-test n.s. p= 
0.184) (D, G). 
The 31 hpf data, limited to axons which had extended beyond the HM, demonstrates 
that the pre-synaptic deficits observed in the 28 hpf embryos persist even after the 
axons have escaped the HM. The number of pre-synaptic puncta are significantly 
reduced in the chodl -/- embryos at both 28 hpf and 31 hpf. Interestingly, the total area 
labelled by SV2 is not significantly different between controls and mutants at 28 hpf 
but is significantly larger in the chodl -/- 31 hpf embryos. This suggests that as the 
axons extend, there are continued deficits in the pre-synaptic organising into distinct 
clusters, which includes an increase in pre-synaptic total area at 31 hpf. 
 
 
4.2.3 - At 3 dpf, chodl -/- larvae show reduced numbers of 
pre- and post-synaptic puncta, which is partially rescued in 
the chodl -/-;HB9:Chodl-FLAG larvae 
 
After the primary motor axons have grown along the mid-segmental pathway, a 
secondary set of motor neurons differentiate, and the secondary motor axons exit the 
spinal cord at ~33 hpf. These secondary motor neurons are more numerous per 
somite compared to the primary neurons. The axons follow the path of the primary 
axons as pioneers. After growing along this midsegmental pathway, both the primary 
and secondary axons branch into the myotome, to fully innervate the muscle blocks 
(Lewis and Eisen, 2003; Menelaou and Svoboda, 2009). A schematic illustrating this 









To analyse the synapses in the larvae at 3 dpf, we therefore measured the number of 
synaptic puncta in the myotome as well as the size of the clusters. Due to the larger 
larval trunk compared to the embryo, a 40 µm x 40 µm square in the ventral region 
was selected as a region of interest. The ventral trunk was selected to avoid noise 
from the spinal cord in the dorsal region and limit the labelling to axonal puncta. The 
number of clusters and the average puncta size are shown below, comparing the wild-
type controls, chodl -/- mutants, and the chodl -/-;HB9:chodl-FLAG rescue line (Figure 
4.5). 
 
Figure 4.4: Schematic of the motor axon and synaptic puncta at 28 hpf and 3 
dpf.  
A single myotome in each case is shown, with the axons (green), synaptic 
puncta (orange) and region of interest for analysis (blue). At 28 hpf, there is a 
single CaP axon per somite. At 3 dpf, secondary motor neurons have 
differentiated, extended axons, and branched into the myotome. The number of 












The chodl -/- pre-synaptic puncta number was reduced by 70% compared to the 
control numbers. The chodl -/-;HB9:chodl-FLAG group has 27.52% fewer pre-
synaptic puncta than the controls, and 133% more synaptic puncta than the chodl -/- 
larvae. Although the rescue is not recovered to control levels, this still demonstrates 
Figure 4.5: The synaptic puncta number are greatly reduced in the chodl -/- at 3dpf 
compared to controls, and this is partially rescued in the chodl -/-;HB9:chodl-FLAG 
line. 
A-I: Representative images of the lateral trunk of 3 dpf larvae, labelled with SV2, 
AChR, and the merged channels. Red boxes show the ROIs selected for analysis. 
Scale bars = 50 µm. A’-I’: The higher magnification of the red ROIs. Scale bar = 10 
µm. J: The number of pre-synaptic puncta is significantly reduced in chodl -/- larvae 
and partially rescued in the chodl -/-;HB9:chodl-FLAG group. (One-way ANOVA **** 
with Bonferroni’s multiple comparison test, control vs chodl -/- **** p<0.0001, control 
vs chodl -/-;HB9:chodl-FLAG *p= 0.024, chodl -/- vs chodl -/-;HB9:chodl-FLAG *** p= 
0.0001. Post-hoc power= 1.00). K: The number of post-synaptic puncta is 
significantly reduced in the chodl -/- larvae compared to controls, and partially 
rescued in the chodl -/-;HB9:chodl-FLAG group. (One-way ANOVA **** with 
Bonferroni’s multiple comparison test. Control vs chodl -/- **** p<0.0001, chodl -/- vs 
chodl -/-;HB9:chodl-FLAG **p=0.0022, control vs chodl -/-;HB9:chodl-FLAG ***p= 
0.0004. Post-hoc power= 1.00) L: The number of double-labelled puncta is 
significantly reduced in chodl -/- larvae compared to controls and partially rescued in 
the chodl -/-;HB9:chodl-FLAG group (One-way ANOVA **** with Bonferroni’s 
multiple comparison test. Control vs chodl -/- ****p<0.0001, chodl -/- vs chodl -/-
;HB9:chodl-FLAG ****p<0.0001, control vs chodl -/-;HB9:chodl-FLAG *p= 0.0483. 
Post-hoc power= 1.00). M: The average pre-synaptic puncta size is not significantly 
changed between control and chodl -/- larvae but is significantly larger in chodl -/-
;HB9:chodl-FLAG larvae compared to controls. (Kruskal-Wallis **p=0.019 with 
Dunn’s multiple comparison test. Control vs chodl -/- n.s. p= 0.371, chodl -/- vs chodl 
-/-;HB9:chodl-FLAG n.s. p= 0.111, control vs chodl -/-;HB9:chodl-FLAG **p=0.0014. 
Post-hoc power= 0.664). N: The average post-synaptic puncta size is not 
significantly different between control and chodl -/- larvae. The puncta size of the 
chodl -/-;HB9:chodl-FLAG group is significantly larger than both the control and 
chodl -/- larvae. (Kruskal-Wallis with Dunn’s multiple comparison test. Control vs 
chodl -/- n.s. p>0.999, chodl -/- vs chodl -/-;HB9:chodl-FLAG *p= 0.113, control vs 
chodl -/-;HB9:chodl-FLAG **p= 0.0017. Post-hoc power= 0.701.) O: The average 
double-labelled puncta size for the overlap of SV2 and AChR is significantly larger in 
the chodl -/-;HB9:chodl-FLAG larvae compared to controls. (One-way ANOVA with 
Bonferroni’s multiple comparison test. Control vs chodl -/- n.s. p= 0.270, chodl -/- vs 
chodl -/-;HB9:chodl-FLAG n.s. p= 0.184, control vs chodl -/-;HB9:chodl-FLAG **p= 




that re-expression of chondrolectin in motor neurons is sufficient to increase the 
numbers of synaptic puncta compared to the knockout mutant. (SV2 puncta number 
control = 23.26 ±1.99, n= 14. chodl -/- SV2 puncta number= 7.21 ±1.07, n= 19. chodl 
-/-;HB9:chodl-FLAG SV2 puncta number = 16.86 ±1.72 n=19. One-way ANOVA **** 
with Bonferroni’s multiple comparison test. Control vs chodl -/- ****, control vs chodl -
/-;HB9:chodl-FLAG *, chodl -/- vs chodl -/-;HB9:chodl-FLAG***. *p= 0.024, ***p= 
0.0001, **** p<0.0001) (J). 
Similarly to the pre-synaptic puncta, the number of post-synaptic puncta is 
significantly reduced in the chodl -/- larvae, and partially rescued in the chodl -/-
;HB9:chodl-FLAG line compared to the control values. There was a 60% reduction in 
post-synaptic puncta number in chodl -/- larvae compared to controls. The chodl -/-
;HB9:chodl-FLAG values were 33.3% fewer puncta than controls, and 65.4% larger 
than the chodl -/- puncta number. (Control average post-synaptic puncta number= 
26.12 ±1.90, n= 14. chodl -/- average post-synaptic puncta number= 10.53 ±1.15, n= 
18. chodl -/-;HB9:chodl-FLAG average post-synaptic puncta number= 17.42 ±1.32, 
n= 19. One-way ANOVA with Bonferroni’s multiple comparison test, control vs chodl 
-/- **** p<0.0001, chodl -/- vs chodl -/-;HB9:chodl-FLAG **p=0.0022, control vs chodl 
-/-;HB9:chodl-FLAG ***p= 0.0004) (K). 
The number of double-labelled puncta is significantly reduced in the chodl -/- larvae 
compared to controls, with a reduction of 73.4% in the mutants compared to controls. 
The number of double-labelled puncta in the chodl -/-;HB9:chodl-FLAG group is 177% 
larger than the chodl -/- values, and 26.1% lower than the controls. (Control average 
double-labelled puncta number= 14.95 ± 1.437, n= 14. chodl -/- average double-
labelled puncta number= 3.982 ± 0.5307, n= 19. chodl -/-;HB9:chodl-FLAG average 
double-labelled puncta number= 11.05 ± 1.20, n= 19. One-way ANOVA **** with 
Bonferroni’s multiple comparison test. Control vs chodl -/- ****, chodl -/- vs chodl -/-
;HB9:chodl-FLAG ****, control vs chodl -/-;HB9:chodl-FLAG *. ****p<0.0001, *p= 
0.0483) (L). 
Comparisons of the puncta size between controls, chodl -/-, and chodl -/-;HB9:chodl-
FLAG larvae demonstrates that there is no significant difference between control and 
chodl -/- larvae, for any labelling, but the chodl -/-;HB9:chodl-FLAG group has 
significantly larger puncta. 
For the pre-synaptic SV2 labelling, the chodl -/- puncta size is 23.5% larger than 




average area, which is significantly increased, and 30% larger than the chodl -/- area, 
which is not significantly different. (Control average pre-synaptic puncta size= 2.342 
µm2 ± 0.103, n= 14. chodl -/- average pre-synaptic puncta area= 2.893 µm2 ±0.272, 
n= 18. chodl -/-;HB9:chodl-FLAG average pre-synaptic puncta size= 3.761 µm2 
±0.344, n= 19. Kruskal-Wallis **p=0.019 with Dunn’s multiple comparison test. Control 
vs chodl -/- n.s. p= 0.371, chodl -/- vs chodl -/-;HB9:chodl-FLAG n.s. p= 0.112, control 
vs chodl -/-;HB9:chodl-FLAG **p=0.0014) (M). 
In the post-synaptic AChR labelling, the chodl -/- puncta area is 7.8% larger than the 
control area, which is not statistically significant. The chodl -/-;HB9:chodl-FLAG 
puncta area is significantly larger than the chodl -/- area, with an increase of 26.3%. 
The average chodl -/-;HB9:chodl-FLAG puncta area is statistically larger than the 
control area, increased by 36.1%.  (Control average post-synaptic puncta area= 3.848 
µm2 ± 0.167, n= 14. chodl -/- average post-synaptic puncta= 4.145 µm2 ± 0.330, n= 
18. chodl -/-;HB9:chodl-FLAG average post-synaptic puncta area= 5.237 µm2 ± 0.333, 
n= 19. Kruskal-Wallis ***p= 0.0009, with Dunn’s multiple comparison test. Control vs 
chodl -/- n.s. p>0.999, chodl -/- vs chodl -/-;HB9:chodl-FLAG *p= 0.0113, control vs 
chodl -/-;HB9:chodl-FLAG **p= 0.0017) (N). 
In the double-labelled puncta of the overlap between SV2 and AChR, there is no 
statistical difference in puncta area between control and chodl -/- larvae. The average 
puncta area in the chodl -/-;HB9:chodl-FLAG line is not significantly larger than the 
chodl -/- value, but 44.8% larger than the control average area, which is statistically 
significant. (Control average double-labelled puncta area= 2.351 µm2 ±0.110, n= 14. 
chodl -/- average double-labelled puncta area= 3.048 µm2 ±0.374, n= 18. chodl -/-
;HB9:chodl-FLAG average double-labelled puncta area= 3.405 µm2 ±0.225, n= 19. 
Kruskal-Wallis **p= 0.0023 with Dunn’s multiple comparison test. Control vs chodl -/- 
n.s. p= 0.2697, chodl -/- vs chodl -/-;HB9:chodl-FLAG n.s. p= 0.1835, control vs chodl 
-/-;HB9:chodl-FLAG ** p= 0.0016) (O). 
Overall, this data shows that there are deficits in motor synapses in the chondrolectin 
mutant at 3 dpf. Both the pre- and post-synapse are affected, with reductions to the 
puncta number in the chodl -/- larvae compared to the wild-type controls. This is 
partially rescued by MN-specific re-expression of chondrolectin, although the values 
do not return to wild-type numbers. Interestingly, there is also an enlargement of the 
average puncta size in the chodl -/-;HB9:chodl-FLAG group, compared to the control 




-/- average puncta area. This suggests that although the number of puncta are not 
fully rescued, this size increase may be compensatory, as behavioural differences are 
fully rescued (Section 4.2.5). The potential mechanisms for these changes, and the 
comparisons between the data at 28 hpf, 31 hpf, and 3 dpf are discussed further in 
Section 4.3.  
 
4.2.4 – Branching analysis suggests that axonal branching 
requires stabilisation by synapse formation 
 
At 3 dpf in the chodl -/- mutants, there is an obvious lack of both axonal branches into 
the myotome and synaptic puncta, seen first in the HB9:GFP transgene (Chapter 
Three). The data shown in this chapter in Section 4.2.3 demonstrates defects in 
synapse formation in the chodl -/- larvae, with a reduction in the number of pre- and 
post-synaptic puncta. As these are static preparations, it is difficult to determine if the 
lack of axonal growth prevents synapse formation, or if the mutant has a deficit in 
forming stable synapses, which then leads to instability and collapse of axon 
branching as observed in the retinal ganglion. To determine if synapses are important 
for motor axonal branching in larvae, I stained and imaged wild-type HB9:GFP larvae 
for SV2, AChR, and GFP. I then analysed the axon branch points to determine if the 
branch point was also associated with the pre- and post-synaptic puncta. The data is 
shown below (Figure 4.6). 
This analysis demonstrates that almost all branch points of motor axons are also 
associated with both pre- and post-synaptic puncta. Although not conclusive 
evidence, it does support the hypothesis that the axon branches can only emerge in 
the presence of synapses, as 96.8% of branch points contained the synaptic labels. 
This suggests that in the case of the chondrolectin mutant, the lack of axonal 
branching is caused by defective synaptogenesis. This further indicates a novel role 
for chondrolectin in stabilising synapse puncta, as well as its previously published role 








Figure 4.6: Axonal branch points at 3 dpf are heavily enriched with synaptic 
puncta.  
A: Representative images of wild-type 3 dpf trunk labelled with the axon, SV2, 
and AChR. Single optical sections are shown. Scale bar= 25 µm. B: Analysis 
was performed on 10 larvae, 3 myotomes per larvae, and between 12-15 branch 
points quantified per myotome. Of 443 branch points, 429 were also associated 
with synaptic puncta and 14 without synapse labelling. This means 96.8% of 





4.2.5 - Behavioural phenotypes in chodl -/- larvae at 3 dpf 
 
4.2.5.1 – The distance travelled to escape a tail stimulus is unchanged 
between wild-type and chodl -/- larvae 
 
Due to the widespread reduction in synaptic puncta in the chodl -/- larvae at 3 dpf, we 
sought to investigate possible differences in swim behaviour of the mutants compared 
to wild-type. The first behavioural assay we performed was a flight response from tail 
tap stimulus. As described in Wehner et al., 2017, we recorded the total escape 
distance for 15s after touching the medial fin with a fire-pulled glass pipette. The 
distance travelled by the larvae was then compared between the wild-type and chodl 
-/- larvae, shown below (Figure 4.7). 
 
 
There was no significant difference in the total distance travelled between wild-type 
and chodl -/- larvae. The chodl -/- larvae travelled 19.2% shorter distances than 
controls, but this does not lead to a statistically significant difference. (Control average 
distance= 57.45 mm ±8.07, n= 21, chodl -/- distance= 46.42mm ±6.00, n=28. Mann-
Whitney test n.s., p=0.256). For both groups, the variation in values is large, leading 
Figure 4.7: There is no difference between control and chodl -/- larvae in the 
distance travelled after a tail stimulus. 
A: Example swim tracks (red) for 15s after an escape response from a tail tap, for 
control and chodl -/- 3 dpf larvae. Scale bar= 10mm. B: There is no significant 
difference between the distance travelled after a tail-tap stimulated escape. (Mann-




to an SEM that is approximately 15% of the mean values. Therefore, the effect size 
from this data is also very small (d= 0.345). Using this effect size in an a priori power 
calculation leads to a necessary sample size of 231 for each group to gain 
significance. This sample size is unrealistically high and thus the non-significance 
between this data set means that despite the lack of synaptic puncta in the mutant 
larvae, there are enough functional synapses to elicit a swimming response that 
replicates the wild-type reaction. Reasons for this will be discussed further in the 
Section 4.3, the discussion and conclusions section of this chapter. 
 
4.2.5.2 – The C-bend response is impaired in chodl -/- larvae, leading to a reduced 
escape angle from a head tap stimulus 
 
Although the swimming distance between control and mutant larvae was unchanged, 
other assays can be used to investigate behavioural differences in larval zebrafish. 
The C-bend is a highly stereotyped escape behaviour seen during a startle response. 
The startle can originate from an auditory or vibratory stimulus, or a contact stimulus 
to the head of the larva (Bhandiwad et al., 2013). During the C-bend, the larva makes 
a tight contraction of its body, bending its head to contact its tail, followed by swimming 
away from the dangerous stimulus. This is thus likely more sensitive to changes in 
the synapses and more challenging to the larvae to correctly perform. 
To investigate if this contraction is impaired in the chodl -/- larvae, we used high-speed 
video recording to assay the C-bend startle response. By recording at 1000 
frames/second, the initial startle turn can be analysed, which takes around 1 second 
(Fetcho, Higashijima and McLean, 2008). However, the high-speed recording does 
not produce images of sufficient resolution to measure the C-bend angle directly. 
Instead, we measured the angle of escape after this C-bend, when the swim is 
initiated. We predicted that the escape from a head touch would be to perform the C-
bend, orienting the larva’s head away from the danger, and then it initiates an escape 
swim. We hypothesised that the lack of synapse puncta in the chodl -/- larvae would 
potentially affect the ability to perform this C-bend, leading to a measurable change 
in this escape angle. We also included the transgenic line chodl -/-;HB9:chodl-FLAG, 
to determine if any behavioural phenotype is rescued. The data from this behavioural 







The wild-type average escape angle is 144.2°, supporting previous data that 
demonstrates the larvae will turn quickly to swim away from the stimulus. The chodl -
/- larvae make a turn with a smaller angle of escape than the control larvae, a 
reduction of 27.5% compared to controls. The chodl -/-;HB9:chodl-FLAGlarvae have 
a fully restored behaviour to control values. The chodl -/-;HB9:chodl-FLAG group 
angle is 47.0% larger than the chodl -/- angle, and only 6.7% larger than the control 
escape angle. (Control angle= 144.2° ±4.60, n= 32, chodl -/- angle= 104.6° ±3.56, n= 
35, chodl -/-;HB9:chodl-FLAG angle= 153.8° ±6.16, n= 12. One-way ANOVA with 
Bonferroni’s multiple comparison test, control vs chodl -/- ****, chodl -/- vs rescue ****, 
control vs rescue n.s. **** p<0.0001, n.s. p= 0.689.)  This suggest that the loss of 
innervation in the chodl -/- results in a weaker C-bend contraction, and thus the 
reduction in escape angle. The full restoration of escape angle in the chodl -/-
Figure 4.8: chodl -/- larvae exhibit a reduced turning angle after a head stimulus, 
which is rescued in the chodl -/-;HB9:chodl-FLAG line. 
A: Montages of example turning responses. The full turn occurs within 1.2s of the 
touch stimulus. Red arrows show the direction and angle of the larval head. B: The 
escape angle is significantly reduced in the chodl -/- larvae compared to the control 
group. The escape angle is completely rescued in the chodl -/-;HB9:chodl-FLAG 
line, back to the control value. (One-way ANOVA **** with Bonferroni’s multiple 
comparison test, control vs chodl -/- ****, chodl -/- vs chodl -/-;HB9:chodl-FLAG 
****, control vs chodl -/-;HB9:chodl-FLAG n.s. **** p<0.0001, n.s. p= 0.689. Post-





;HB9:chodl-FLAG rescue larvae suggests that although the number of synapses are 
not fully rescued, and they are larger than in the control, they are functional and able 
to compensate to rescue the behaviour. The specific motor defect in this behaviour 
may also be caused by changes to the hindbrain organisation, which is discussed in 
more detail in Section 4.3.2. 
 
 
4.3 – Discussion & Conclusions 
 
4.3.1 – Chondrolectin has a novel role in synapse 
stabilisation 
 
4.3.1.1 – The chodl -/- embryos have  fewer pre-synaptic puncta around the 
horizontal myoseptum during embryonic stages 
 
For measuring synaptic differences in the embryonic stages, we chose to focus on 
the horizontal myoseptum for several reasons. Firstly, it has been demonstrated that 
the axon growth rate from spinal cord exit until the HM is identical between control 
and chodl morphant embryos (Zhong et al., 2012). It would therefore be unlikely that 
there would be any differences in examining that portion of the axon. At 28 hpf, when 
the chodl -/- axon phenotype is most visible, the axons are mostly stalled at the HM 
in the mutant but fully extended in the wild-type. It is not possible to quantify synapses 
in axons beyond the HM, as they are not present in the mutants. The HM is also 
enriched with ECM molecules including collagens, which were discussed as potential 
ligands to chondrolectin in Chapter Three. The horizontal myoseptum was thus a key 
location for further investigation. 
The data collected at 28 hpf demonstrate that loss of chondrolectin leads to a pre-
synaptic deficit, with a reduced number of defined puncta in the HM region (Section 
4.2.2). Given the co-expression of chondrolectin and pre-synaptic proteins in the 
motor axon, it suggests a novel role for chondrolectin in synaptogenesis or synapse 
organisation in the motor axon. This is also supported by other staining performed by 
Dr Oprişoreanu (unpublished data, not shown), where synaptotagmin-positive puncta 




chodl -/- embryos compared to controls. Synaptotagmin is much more abundant in 
the pre-synapse than SV2, which may explain why its total area is increased (Wilhelm 
et al., 2014). During synaptogenesis, it is clear that both the pre- and post-synapse 
clusters remodel as the axon grows, becoming more co-localised and tightly clustered 
(Panzer, Song and Balice-Gordon, 2006). Thus the phenotype in the chodl -/- 
embryos seem to be a failure to remodel the pre-synapse into these tighter junctions. 
Explanation for this data difference may be that the new batch of AChR used by Dr 
Oprişoreanu was more concentrated than the batch I used, and so in using the same 
protocol with equal dilutions of the antibody, the staining would be stronger for her 
than in my data. There were also changes in the secondary antibody, where the SV2 
secondary antibody remained the same, but the secondary antibody for the AChR 
labelling was changed due to the presence of the HB9:GFP transgene in the rescue 
line. This could have led to slight differences in the labelling, which cannot be 
discounted, and thus changes in the measurements. Dr Oprişoreanu performed 
similar experiments using synaptotagmin (znp-1, syt2b) as the pre-synaptic marker 
(unpublished, data not shown). This replicated the defects in both the pre-synapse 
and the post-synapse. It therefore seems that the pre-synaptic deficits in the chodl -/- 
embryos are robust, representing a failure in pre-synaptic maturation that includes 
multiple pre-synaptic proteins. 
It is unlikely that chondrolectin directly binds pre-synaptic proteins such as SV2 or 
synaptotagmin, given the small intracellular domain of the chondrolectin protein, 
discussed in Chapter Three. SV2 and synaptotagmin are also membrane-associated 
proteins involved in synaptic vesicle structure and exocytosis (Feany et al., 1992; 
O’Connor and Lee, 2002). Further binding studies or mass spectrometry to identify 
‘bridging’ proteins which interact with both chondrolectin and the pre-synaptic proteins 
would need to be performed to elucidate the mechanism by which chondrolectin 








4.3.1.2 – At 3 dpf, there is a reduction in synaptic puncta in the chodl -/- larvae 
which is partially rescued in the chodl -/-;HB9:Chodl-FLAG larvae 
 
Unlike the data shown at 28 hpf, at 3 dpf both the pre-synaptic and post-synaptic 
puncta are affected in the chodl -/- larvae (Section 4.2.3). This is likely due to changes 
in the motor neuron network between these developmental stages. Although at 28 hpf 
only the primary motor axons have extended from the spinal cord, at 3 dpf the 
secondary motor axons have also grown across the myotome. The increased number 
of motor axons and their changed behaviour (branching into the trunk muscle) leads 
to a punctate synapse staining and widespread synaptic puncta in the musculature, 
compared to the focused analysis of the puncta around the HM performed in the 28 
hpf data. 
During synapse remodelling, the pre- and post-synaptic puncta co-localise closely 
together, and AChRs which are not contacted by axons are dispersed by 26 hpf 
(Flanagan-Steet et al., 2005). However, axon growth and motor synapses are still 
able to form in mutants completely lacking these aneural prepatterns (Jing et al., 
2009). This is observed in the chodl -/- embryos, whose axons are temporarily stalled. 
At 31 hpf, approximately 42% of axons are able to grow beyond the HM despite the 
dispersal of these pre-patterns (Section 4.2.2).  
The branching analysis presented in Section 4.2.4 demonstrates that axonal branch 
points are usually associated with synapses. The lack of axonal branching in chodl -
/- larvae at 3 dpf is therefore likely due to the synaptic deficit, which prevents 
maintenance and stability of nascent axonal branching into the myotome. As well as 
a lack of axonal branches, there is a severe reduction in the number of pre-synaptic 
puncta at 3 dpf, and a reduction in the post-synapse as well, as the AChR puncta are 
not maintained without the axon present. This also causes a reduction in the double-
labelled puncta, and so a reduction in active synapses. This leads to the turning deficit 
in the chodl -/- larvae observed in Section 4.2.5, discussed in more detail in Section 
4.3.2.  
With a reduction by 72% in the number of synapses in the chodl -/- mutant compared 
to wild-types, there is a partial rescue in the chodl -/-;HB9:Chodl-FLAG line (i.e. 
Rescue line). The chodl -/-;HB9:chodl-FLAG line has 26% fewer synapses than the 
wild-type larvae. The lack of full rescue in puncta values is likely to be due to 




endogenous chodl promoter. The number of integrated HB9:chodl-FLAG cassettes in 
the transgenic line are also not known, so this may also be a consequence of the 
gene dosage in this line. This also may explain the increased puncta size in the chodl 
-/-;HB9:chodl-FLAG line compared to both the control and chodl -/- larvae (Section 
4.2.3). I speculate that the size may also be compensatory in nature, which is why the 
behavioural turning phenotype is fully rescued. Electrophysiology of the larvae to 
determine the activity of the motor neurons (discussed later in this Section) would 
clarify whether the puncta size affects the activity of the synapses.  
 
4.3.1.3 – Links between synaptic defects and Spinal Muscular Atrophy 
 
As previously introduced, multiple SMA models demonstrate defects in the 
neuromuscular junction (NMJ), visible before the onset of motor symptoms. Human 
foetal tissue shows accumulation of neurofilament and a failure of the axon to fully 
occupy the post-synaptic density in Type I SMA (Martínez-Hernández et al., 2013). In 
mouse models of SMA, the reduction in Smn protein prevents the maturation of the 
neuromuscular junction, with accumulation of NF and poor occupancy of the motor 
endplate before any motor symptoms were recorded (Kariya et al., 2008; Kong et al., 
2009). This demonstrates that as well as being a degenerative disease of the motor 
neuron, synapse pathology is also a key aspect of SMA (Boyd and Gillingwater, 
2016). 
Importantly, a zebrafish model of SMA also exhibits deficiency in pre-synaptic SV2 
staining in the larvae. The phenotype differs from the chodl -/- data in that there is 
only reduction in SV2 immunoreactivity. Synaptotagmin labelling was performed in 
these larvae and there was no change between the SMA model and controls. The 
AChR puncta labelled with α-bungarotoxin are also unaffected. Therefore, the SMA 
model zebrafish presented in that paper do not show a global loss of synapses as is 
observed in the chodl -/- larvae (Boon et al., 2009). Synaptotagmin staining in the 28 
hpf chodl -/- embryos was performed in our group (data not shown) and shows a 
reduction in cluster number, similar to the SV2 data shown in Section 4.2.1. The 
synaptotagmin area is also enlarged in the chodl -/- embryo, suggesting a general 
pre-synaptic defect which is not limited to SV2. In complete loss of chondrolectin 
expression, it therefore seems that synaptogenesis and synapse stabilisation is 




double-labelled synaptic clusters in the trunk muscle. However, in the SMA model, 
the Smn protein level is reduced and other downstream genes (including 
chondrolectin) are mispliced and dysregulated. The reduction in normal chondrolectin 
expression may therefore also have implications for synapse stability, and this 
dysregulation of chondrolectin could be contributing to the synapse pathology in SMA 
model fish. 
 
4.3.1.4 – Future directions for investigating the role of chondrolectin in 
synaptogenesis and synapse maintenance 
 
With this novel potential role for chondrolectin in synapse stabilisation, a key future 
investigation would be to perform electrophysiology in the motor neurons, to see if the 
synaptic vesicle release is altered in chodl -/- larvae. In motor axons that are spared 
and able to form synapses, the functional abilities of these axons are unknown. 
Impaired synaptic vesicle release is observed in the motor neurons of SMA model 
mice, (Torres-Benito et al., 2011), further linking the synaptic phenotype between 
chondrolectin loss and SMA.  
Live in vivo imaging of synaptogenesis would also be an excellent future study. For 
example, acute expression of a synaptophysin-GFP plasmid in the RGCs (Meyer and 
Smith, 2006; Ruthazer, Li and Cline, 2006) could be applied to the motor neurons in 
control and chodl -/- embryos and larvae. This would allow confirmation of the 
relationship between axonal branching and synapse stabilisation, rather than relying 
on the static preparations in Section 4.2.4. In a similar avenue, the F-actin rich 
filopodia, which extend during axon growth and dendrite formation, have a reduced 
lifespan and lower number in SMA model zebrafish, labelled with LifeAct-GFP (Hao 
et al., 2013). This was interpreted as a loss in the axonal stability in and thus increased 
likelihood to degenerate but could also be related to the loss of synaptic stability. Use 
of the LifeAct-GFP construct to label F-actin in the chondrolectin mutants could be 
used to determine if the same filopodial defects are present. 
Imaging other markers of synapse proteins could also be informative. For example, 
SV2 is localised to synaptic vesicles, and Synaptotagmin forms the calcium-sensing 
portion vesicle exocytosis complex (Feany et al., 1992; O’Connor and Lee, 2002). 
Bassoon and Piccolo are cytoskeletal proteins in the active zone of the NMJ 




embryos would show if the active zones of the synapses are affected as well as the 
general pre-synaptic density. Post-synaptic labels such as Rapsyn could also be 
labelled, which complex with AChRs in the muscle and tether it to the muscle surface 
(Lin et al., 2001; Park et al., 2012). However, whether the same range of synaptic 
antibodies would function in zebrafish immunohistochemistry as in mouse is 
unknown. SV2 and synaptotagmin antibodies have been well characterised in 
zebrafish (α-SV2 and α-znp-1), hence their use in this thesis. Rapsyn antibodies have 
been validated in zebrafish, and show a similar labelling pattern as the α-AChR 
antibody used in this chapter (Park et al., 2012). Bassoon and Piccolo antibodies have 
not been published in zebrafish so it is unclear if these labels could be used to 
investigate the active zone of the motor synapses in the chodl -/- embryo.  
 
4.3.2 – chodl -/- larvae at 3 dpf exhibit a reduction in turning 
angle to escape a head touch, compared to wild-type and 
chodl -/-;HB9:chodl-FLAG larvae 
 
As discussed in Chapter Three, the chondrolectin mutants exhibit normal survival. 
From qualitative assessment of the juvenile fish and adults during development of the 
line, there did not seem to be any mobility issues in the mutants. They also breed 
normally. The ability to breed relies on close shoaling of the fish together, and failure 
to breed is seen in fish after ablation of their dopaminergic neurons, modelling a 
Parkinson’s disease-like phenotype (Caldwell et al., 2018). Analysis of adult 
swimming behaviour could be a future outlook, as there are several behavioural 
assays available in the adult zebrafish. For example, as well as free swimming 
distance, application of a water current can be used to assay the stamina of adult 
zebrafish to swim against resistance (Dias et al., 2012). Given the synapse defects 
seen in the chodl -/- larvae, this might not affect the free swimming distance, but the 
reduced number of synapses could reduce the endurance of the fish to swim against 
a water current. The rapsyn mutant twitch once shows muscle fatigue in larval stages 
(Ono et al., 2002), demonstrating that mutations to NMJ genes leads to a range of 
behavioural responses.  
The initial behavioural test, measuring the distance travelled after a flight reaction, did 
not show any difference between wild-type controls and chodl -/- larvae. This 




lesions in the larvae (Ohnmacht et al., 2016; Wehner et al., 2017), and whether 
manipulations of gene expression improve the recovery timeline. However, this 
technique does not seem sensitive enough to measure small differences in behaviour 
caused by the motor synapse defects. Using the HB9:GFP transgenic line, and 
comparing wild-type to mutant larvae, the ventral nerve bundle is intact at 3 dpf, and 
the somite boundaries contain synapses which are active. It is therefore possible that 
the motor circuit is able to compensate for this swimming distance. As also mentioned 
in Section 4.2.5.1, the SEM in the distances travelled are around 15% of the mean 
value, and the range of values covers 120 mm. This means that the distance swum 
during this escape is heterogeneous, even for the wild-type larvae, meaning that 
subtle differences between groups could be lost in the noise of the data points. 
The collagen19a1 mutant, stumpy, also shows stalling of the primary CaP axon at 28 
hpf and a reduction in synaptic clusters at 5 dpf. However, there was no detectable 
change to the behaviour of these mutant larvae compared to controls (Panzer, Song 
and Balice-Gordon, 2006; Hilario, Wang and Beattie, 2010). I speculate that the 
mutant, given the axonal and synaptic phenocopy of the chodl -/- larvae, would likely 
also show turning deficits if the assay I used were performed with the mutants. I 
hypothesise that the behavioural assays used in the published studies were not 
sensitive enough to detect changes to the turning, as I observed in the chodl -/- larvae. 
Analysing the behaviour at high speed, specifically the initial turn after the head 
stimulus, demonstrates a reduction in turning in the chodl -/- larvae (section 4.2.5.2). 
This is fully rescued in the  chodl -/-;HB9:chodl-FLAG line. This suggests that the loss 
of synaptic puncta in the chondrolectin mutant induces a behavioural deficit, and the 
behaviour can be rescued even though the synaptic puncta are only partially rescued 
in the chodl -/-;HB9:chodl-FLAG larvae. A good assay to measure muscle contraction 
would be to perform close analysis of the tail bending angles performed by the larvae, 
during both the C-bend and burst swimming (Budick and O’Malley, 2000; Colwill and 
Creton, 2011). However, the resolution of imaging equipment available to us was not 
sufficient to record the tail bending angle.   
From the two behavioural tests, the chodl mutant exhibits a turning defect but swims 
normally in terms of distance travelled when escaping a stimulus. This suggests there 
is a specific response that is deficient in the chodl mutants. As well as the reduced 
numbers of motor synapses, measured at 3 dpf (Section 4.2.3), this dysfunction could 




fast escape response is mediated by motor neurons after the response is started by 
the Mauthner or analogous non-Mauthner cells, all of which reside in the hindbrain. 
mRNA expression of chodl visualised using in situ hybridisation shows expression in 
the hindbrain (Thisse et al., 2004, images shown in Chapter 1, Fig 1.6). I did not 
compare the structure of the hindbrain axons between the wild-type and mutant 
larvae, so cannot discount the possibility that the chodl -/- has a phenotype in the 
hindbrain. It would be possible to visualise the hindbrain neurons and their axons to 
confirm any changes in the mutant compared to wild-type, using an antibody such as 
3A10 which labels hindbrain neurons including Mauthner cells (Brand et al., 1996). 
Although the chodl -/- mutants are able to grow normally to adulthood, this reduction 
in turning ability would give an evolutionary disadvantage to the mutants in the wild. 
The zebrafish larvae are prey animals, which is why they perform escape behaviours 
after the stimulus of touch, noise, and moving dark shapes (Colwill and Creton, 2011). 
An inability to fully move away from the stimulus would likely result in its predation in 
the wild. 
This chapter presents a novel role for chondrolectin in synapse stabilisation. Changes 
to the pre-synapse, labelled with multiple pre-synaptic proteins, show changes to the 
pre-synaptic clustering at 28 hpf and 31 hpf. This means that the synaptic changes 
are independent of the axon growth, as the chodl -/- axons which pass the HM still 
show defects. This is a clear link between SMA and chodl, as NMJ defects are 
observed in the disease model. The loss of synapses in the chodl -/- larvae is partially 
rescued in the stable chodl -/-;HB9:chodl-FLAG line, and leads to a turning 








Chapter Five - Using the chodl-/- 
mutant zebrafish as a screening tool 
for molecules that enhance axon 
growth 
 
5.1 – Introduction 
 
5.1.1 – Rationale for using the chodl -/- phenotype for a 
small molecule screen 
 
The chondrolectin mutant zebrafish are an excellent target for screening small 
molecules due to its link to Spinal Muscular Atrophy and its role in axonal growth. For 
a medium-throughput screen, there are several factors which give the chodl -/- 
embryos an advantage over using the smn morpholino. Breeding homozygote 
mutants is much faster and less labour-intensive than injecting morpholino. A total 
knockout also has advantage over a dose-dependent knockdown which must be 
measured and calibrated for the best phenotype.  
For phenotypic scoring and determining drug-dependent rescue, axons in zebrafish 
after Smn knockdown have been quantified in various ways. The axonal phenotype 
is multidimensional, with missing, branched, or truncated axons. For example, in 
McWhorter et al., 2003, Smn knockdown is quantified by measuring the ratio of 
branching and ratio of truncations and presenting them separately. However, in 
Wishart et al., 2014, the phenotype is presented as a combined ratio under the 
umbrella of ‘aberrant morphology’, combining excessive branching with truncation. 
Sleigh et al., 2014 assigns a numerical value to each axon between 0-3 depending 
on the severity of the phenotype, then compares the average score to the wild-type. 
In comparison, the chodl -/- phenotype is much more easily quantified, as almost all 
axons are stalled at the horizontal myoseptum, and at 26-30 hpf there is no other 
confounding morphological difference between axons except this stalling (discussed 
in Chapter Three). This increases the speed of scoring such axons for improved 




As was introduced and discussed in Chapter One, chondrolectin is downstream of 
Smn dysfunction. It is mis-spliced at early timepoints in mouse SMA models, and 
chondrolectin over-expression rescues Smn knockdown in zebrafish (Bäumer et al., 
2009; Sleigh et al., 2014). Therefore, although the chodl -/- mutants are not directly 
modelling SMA, the chodl -/- mutants can be used to find axon-stabilising compounds. 
The link between SMA and chondrolectin means that potential hit compounds from 
the chodl -/- screening could then be screened in Smn knockdown embryos or other 




5.1.2 – Current strategies in drug development for SMA 
 
For the drug screening described in this thesis, we are using a phenotypic-based 
approach, which is a common use for zebrafish in drug discovery (discussed in the 
next section). Although SMA is monogenic and thus Smn would be an excellent target, 
the mechanism for the disease is still unclear. Several mechanisms have been 
proposed, including splicing defects or improper RNA transport (Dombert et al., 2014; 
Boyd and Gillingwater, 2016; Fallini et al., 2016).  
The only approved treatment for SMA is the antisense oligonucleotide (ASO) 
treatment nusinersen. By binding to the SMN2 transcript, the ASO corrects the 
splicing error and prevents the skipping of exon 7 (Rigo et al., 2012). Thus, the 
proportion of normal SMN protein increases due to the reduction in the defective 
SMNΔ7 protein. After undergoing clinical trials, (Finkel et al., 2016, 2017; Swoboda 
et al., 2016), nusinersen is now approved as the first treatment specifically for SMA. 
Despite the approval of nusinersen, further treatments for SMA are being developed 
and there is still a need for new therapies. Although nusinersen improves the 
symptoms in patients, it is not a complete cure and they are not completely healthy. 
although long-term studies are ongoing, there is no data currently for potential long-
term effects of nusinersen treatment. Due to the high price of ASO production, and 
the likelihood that nusinersen treatment would be required every 4 months lifelong, 





Several drugs have been repurposed for use in SMA. (Calder, Androphy and 
Hodgetts, 2016). As discussed in Chapter One, Section 1.3.4, SMA is caused by loss 
of function of SMN1, and lack of compensation by SMN2 due to its transcript 
degeneration, caused by exon skipping during translation. Repurposed drugs 
therefore were focused on increasing the expression of SMN2, to increase the 
abundance of SMN protein in cells . HDAC inhibitors such as trichostatin A or valproic 
acid showed increased SMN2 transcription in patient-derived cells and mouse models 
(Tsai et al., 2008; H. Liu et al., 2014). However, these compounds are non-specific, 
with HDAC inhibition affecting the expression of other genes apart from SMN2. The 
neuroprotective compound riluzole, which is an approved treatment for ALS, has also 
been used in SMA. Riluzole has been found to prolong survival in ALS patients by 
approximately two to three months (Miller, Mitchell and Moore, 2012), and its exact 
MMOA is unknown, although it is thought to inhibit glutamate release. In a phase I 
trial, mean survival of the treated group was higher than in placebo, but the sample 
size was too small to perform statistical testing (Russman, Iannaccone and Samaha, 
2003). 
Several other potential treatments are undergoing clinical trials at different phases, 
(Shorrock, Gillingwater and Groen, 2018). These include viral vectors to deliver an 
enhanced SMN1 through the blood-brain barrier to neurons, AVXS-101. It is currently 
entering a Phase 2 trial after success in Phase 1 (Shell et al., 2018). A high-throughput 
screen was performed to find compounds which specifically increased the SMN2 
transcript, unlike the broad HDAC inhibitors. Roche identified a compound called 
RG7800 which showed pre-clinical results but failed in human trials. Structure 
refinement led to risdiplam (RG7916), which has been designed with improved 
pharmacokinetics. This compound is now entering part 2 of its first clinical trials (Ratni 
et al., 2018).  
  
5.1.3 – Use of zebrafish in drug screening and drug 
development 
 
Zebrafish are an increasingly popular model system for modelling motor neuron 
diseases (MNDs). With approximately 70% gene orthology between human and 
zebrafish (Howe et al., 2013), multiple disease models have been generated in 




utilisation of the zebrafish for translational approaches is also increasing. MND 
models include C9ORF72 knockdown (Ciura et al., 2013), SOD1 over-expression 
(Ramesh et al., 2010), and SMA models (Hao, Burghes and Beattie, 2011). 
Zebrafish have been traditionally used in phenotypic screens to identify biologically 
active compounds (MacRae and Peterson, 2015). This is because of their biological 
accessibility during embryonic and larval stages, and their optical transparency for 
imaging studies. Due to the large clutch sizes, ease of drug incubation in the aqueous 
medium, and physiological relevance of analysing the whole organism, zebrafish are 
an excellent model for medium- to high-throughput drug screening (Langheinrich, 
2003; Tamplin et al., 2012; Phillips and Westerfield, 2014). 
Many examples of screening using zebrafish have been performed to discover new 
pathways or find potential therapeutics. For example, drugs which altered the gross 
morphology were identified as phenocopying hedgehog-null mutants. Further study 
into the compound target showed that it bound to other proteins than the canonical 
Hedgehog / Patched / Smoothened pathway (Williams et al., 2015). In another screen, 
assays measuring increased motor response to light was used to find compounds 
which activate sensory neurons in the embryo (Kokel et al., 2013). Cessation of a 
seizure response in mutant zebrafish were used to screen compounds that could treat 
Dravet syndrome (Baraban, Dinday and Hortopan, 2013). Ephrin4A was identified as 
a disease-modifying protein in ALS using a morpholino-based screen. A SOD1 
overexpression model was screened for axonal rescue after injection by a library of 
morpholino. Knockdown of Ephrin4A rescued the axons, demonstrating that inhibition 
of its expression could be a therapeutic target (Van Hoecke et al., 2012). A screen to 
identify regenerative pathways used a fin amputation model and looked for 
compounds which abolished regeneration. From this, glucocorticoids were identified 
as necessary for the regeneration, offering insight into the regenerative mechanisms 
(Mathew et al., 2007). 
In our screen, we sought to identify compounds that rescued the phenotype of the 
chodl -/- mutants, and thus compounds which improve motor axon growth. Thus, we 
begin with the aberrant phenotype of the mutant – stalled CaP motor axons – and 






5.1.4 – The VAST BioImager is an automated platform to 
handle, array, and image zebrafish larvae 
 
Zebrafish are particularly amenable to drug screens due to their large clutch sizes and 
easy incubation directly in drug solutions in multi-well plates, all of which increase 
their throughput to a rate higher than that of rodent models. However, in our screen, 
we must be able to image and thus analyse the axonal phenotype of the chodl -/- 
embryo. The HB9:GFP transgenic line can be used to directly image the motor 
neurons without the need for extra staining, but the bottleneck is the imaging process. 
Arraying, mounting, and imaging the embryos represents the rate-limiting step in this 
protocol.   
To increase the throughput of zebrafish screens, an automated loading and imaging 
platform has been designed by Union Biometrica. It is an adjusted large object flow 
cytometry platform, optimised for zebrafish. Known as the VAST (Vertebrate 
Automated Screening Tool) BioImager, it uses an automatic plate loader (the LP 
Sampler) and microfluidic pumps to draw anaesthetised larvae from a multi-well plate 
through the platform. The platform contains an imaging chamber to which a 
microscope can be mounted. In our centre, the imaging is performed by a custom 
Spinning Disk Confocal Microscope (SDCM) (Early et al., 2018). This allows image 
acquisition much more quickly than with a standard confocal microscope (Jonkman 
and Brown, 2015). Inside the imaging chamber, a glass capillary holds the larvae in 
place and is fully rotatable, allowing complete control over imaging orientation. 
(Pardo-Martin et al., 2010; Letamendia et al., 2012). The zebrafish larva is detected 
as it passes through the capillary, as the imaging chamber contains a light gate which 
scatters light when solid objects pass through it. This triggers stoppage of the pumps 
and recall of the object to be rotated and imaged. Bubbles and debris can be 
discriminated from larva due to the differences in light scatter through the 
photodetection system. Recognition of the correct orientation is automated by 
software comparisons between the in-built CCD camera in the imaging chamber and 
a user-generated template of the dorsal and lateral views of the head (Chang et al., 
2012). Schematic representation of the VAST BioImager is shown below (Figure 5.1) 












5.1.5 – The Epigenetic Probes Collection from the 
Structural Genomic Consortium is an open-access library 
of epigenetic compounds 
 
When choosing a library to screen using the chodl -/- embryos, several factors were 
considered. There are many commercially available libraries, themed for their range 
of targets (e.g. kinase or phosphatase inhibitors, or epigenetic modifiers). The 
Structural Genomics Consortium is a mixed public-private, non-profit organisation 
which collaborates on protein structural chemistry and drug discovery. The SGC has 
produced and sells a 38-compound library called the Epigenetic Probes Collection. 
We selected this library for our initial screen due to its small number of compounds, 
useful for a pilot study, as well as its availability from a colleague in the University 
(received from Professor Neil Carragher, with thanks). Data on the targets and 
molecular structure for each compound are also freely available online for further 
investigation into hit compounds (https://www.thesgc.org/chemical-
probes/epigenetics). The compounds in the library were selected by the Structural 
Genomics Consortium due to their known activity in cell-relevant concentrations (<1 
Figure 5.1: Schematic representation of the VAST BioImager. 
A: The VAST and spinning disk confocal setup. (1): The holding platform for multi-
well plates and robotic sampler arm, which selects and loads larvae from each 
well. (2): The imaging chamber. The larvae are fed from the LP Sampler into the 
imaging chamber and each larva is held in the capillary during imaging. (3) The 
custom Spinning Disk Confocal Microscope from Zeiss allows rapid image 
acquisition. (4) The VAST controller and pump control the rate of movement by the 
larvae through the platform. (5) A computer connected to the microscope and 
VAST BioImager allows user control of the platforms. B: The custom SDCM used 
in our screening platform. In this image, (1) from A is out of frame. (2) The VAST 
imaging chamber is fixed under the imaging objective, a 10x water-dipping lens. (3) 
The spinning disk microscope was chosen due to its higher speed over a line-
scanning confocal. The Z-stack speed is increased through use of a high-speed 
piezo drive. C: A close-up schematic of the capillary and microscope objective. (2) 
refers to its location in the A and B images. The capillary can be rotated, and the 
larvae positioned along the x-axis to be imaged. 6 tiles are shown, to image the 
length of the larva. D: A schematic of a 4 dpf larvae, marked by the number of tiles 





µM), and target several methods of epigenetic modification: acetylation/deacetylation, 
methylation/demethylation, or histone-binding proteins (Brown and Müller, 2015; 
Müller et al., 2018). 
 
5.2 – Results 
 
5.2.1 - Design of a drug screening paradigm utilising chodl 
-/- embryos 
 
5.2.1.1 – Adaptation of the VAST BioImager protocols 
 
According to specifications written by Union Biometrica, the company which designed 
and built the VAST BioImager platform (henceforth referred to as VAST), the minimum 
developmental stage that the platform can support is 48 hpf. This is mostly due to the 
physical durability of the larvae, which may be damaged by the pressure when they 
are passed through the apparatus. Damage or yolk tearing was not observed in any 
48 hpf larvae (n=450) in the VAST’s initial methods paper (Pardo-Martin et al., 2010), 
but the yolk sac is much larger in younger embryos than 48 hpf larvae. However, it 
was necessary to image chodl -/- embryos at around 27-30 hpf as this is the stage 
when the axon phenotype is most striking. The method of axon analysis is discussed 
in the next section, but as this earlier developmental stage was necessary, we needed 
to adapt the VAST protocols for this screen. 
Once loaded into the VAST system, the detection, alignment, and imaging of the 
larvae is automated using a photodetection system. As pigmented objects such as 
larvae, debris, or bubbles pass through and break the light beam, it signals to stop 
the microfluidics pump and backup the object into the viewing window. The automated 
program then rotates the object, attempting to match it to the template images it has 
for the experiment settings. It discards any object which do not match the template at 
a high enough threshold, and thus does not image bubbles or debris. This is more 
efficient in larvae older than 48 hpf, where the melanocytes have proliferated and thus 
the zebrafish eye and head are darkly pigmented (Kimmel et al., 1995). In younger 
embryos, which do not have this dark pigmentation, there will be a lower chance of 




and is thus flushed through to waste without stopping. Secondly, the automated 
program may also have difficulty matching the image template to the live image, as 
there is not a strong difference in intensity patterns that can be recognised by the 
computer. Shown below are example template images of wild-type zebrafish at 30 hpf 
and 72 dpf, used by the VAST experiment settings (72 hpf experiment settings 
designed by Dr Jason Early, unpublished, used with permission). In Figure 5.2, the 
difference in pigmentation intensities between the two developmental stages are 
clear. The differing head direction between stages in Figure 5.2 (i.e., the mouth of the 
30 hpf embryo is oriented upwards while it is downwards in the 72 hpf larvae) is also 
due to the y-axis size limits of the microscope objective. To image the full trunk of the 
embryo, it must be oriented like this as the large yolk sac holds the trunk closer to the 





Figure 5.2: Example template images used by the VAST BioImager to orient 
zebrafish larvae for imaging. 
Both lateral and dorsal views are used when determining the orientation. 
Differences in image size are due to the differing size of embryo. In each 
case, the program requires a coarsely sized region of interest from the head 





To refine the standard protocol to allow imaging of 27-30 hpf embryos, we made 
several adjustments to the VAST loading and detection settings. This was done by 
trial-and-error with wild-type embryos, and thus the exact timeline of changes has not 
been recorded. These changes are tabulated below, Table 5.1. Firstly, to reduce the 
damage caused by the hydraulic system which feeds embryos from the plate to the 
imaging chamber, we reduced the loading speed and thus the pump pressure (Table 
5.1, Pump settings). Next, due to the larger yolk sac, the embryos loaded together 
from a single well could not overtake each other in the loading tube. This meant that 
the embryos tended to clump together and two could be loaded into the imaging 
capillary together. We reduced both the flushing and unloading volumes to 
compensate for this, so that if two were arranged closely in the loading tube the 
second would re-trigger the detection gate as the first was flushed post-imaging. If 
these changes had not been successful, we would have had to load only a single 
embryo per well instead of the standard 3 fish per well. This would have greatly 
increased the time required to screen the embryos. These changes to the pump 
settings did reduce the rate at which embryos could be imaged, but this was balanced 
by the increased rate of embryo detection (Table 5.1, Load/unload settings). 
The embryo detection was extremely poor when the standard settings were applied. 
At first, embryos would often not be detected as objects due to the weaker 
pigmentation to break the light gates. We decreased the light intensity drop for object 
detection, to force a larger proportion of objects to be detected by the VAST (Table 
5.1, Object detection settings). This meant that bubbles and debris such as damaged 
embryos were more likely to be detected as well, further slowing the screening rate. 
For the imaging, the lack of intensity differences in the template also meant that the 
embryo was often not rotated correctly, or it would be discarded as it was not similar 
enough to the template. At first, we manually corrected the embryo rotation to the 
lateral position before imaging. However, this completely abolished the automated 
aspect of the screen, and greatly increased the time it took to image each embryo. To 
mitigate this, we then decreased the minimum similarity to the template to be accepted 
for imaging. Again, this sometimes meant that embryos were imaged at an offset 
angle from lateral alignment, or that bubbles were accepted as embryos. However, 
this did allow us to automate the imaging, without need for manual correction. The 




below, (Table 5.1).  
 
 
 Table 5.1: Differences in VAST experiment settings to allow automated loading    and 
imaging of 30 hpf embryos compared to a standard protocol for 72 hpf larvae. 
 
Despite these adjustments, there was still an attrition rate of embryos lost during this 
process. The loss of embryos at each stage is tabled below (Table 5.2), based on the 
first full screen performed using the SGC library discussed later in Section 5.2.2. 
Survival after drug treatment is ~95%, but during loading and imaging by VAST some 
embryos are still not be detected, and thus lost. Furthermore, although the reduction 
in template similarity increased the number of images generated, some images were 
crooked and not laterally aligned properly. Depending on the severity of misalignment, 
the axonal scoring cannot be performed. However, the throughput of the screening 
was still faster than manual mounting and imaging. As is clear in Table 5.2, the attrition 
rate is mostly caused by the VAST not detecting the embryos correctly. Despite 
refining settings to overcome this, the limits of our troubleshooting will be further 
discussed in the Discussion & Conclusions section of this chapter (5.3.1). However, 
this marks the first time that embryos of 26-30 hpf have been successfully imaged by 
the VAST system. In future screens, this attrition rate has been reduced due to minor 
adjustments to the loading algorithm, both from our own adjustments and updates to 
the software from Union Biometrica.  
 




Pump settings   
Loading Speed 110 arbitrary units 90 arbitrary units 
Load / unload settings   
Maximum volume between flushes 400 µl 300 µl 
Unloading volume 2 180 µl 160 µl 
Object detection settings   
Minimum intensity drop 20% 10% 




Stage of screening Number of embryos that 




Start of treatment 264 (starting value) N/A (100%) 
Treatment survival 251 95.1% 
Loading and imaging by the 
VAST BioImager 
166 62.9% 
Scoring-quality images (i.e. 
without misalignment) 
143 54.2% 
Table 5.2: Tabulated results of screening attrition rate. 
At each stage, there is loss of embryos from the treatment, the loading of the VAST 
BioImager, and any issues with the imaging quality. 
 
5.2.1.2 – Design of a scoring system utilising the chodl -/- phenotype 
 
The main benefit of a drug screen using the chodl -/- embryo is that the phenotype is 
highly stereotyped and predictable. The aim of using the mutant over smn morpholino 
is speed in both generating embryos to treat with the compounds (injection of MO 
compared to breeding homozygote mutants) and speed in scoring potential hits. As 
discussed in Chapter Three, the chodl -/- mutants are homozygous viable and breed 
normally as adults. This allowed maintenance of two homozygous tanks that were 
incrossed to generate chodl -/- clutches for drug treatment, which were alternated to 
allow twice-weekly breeding and thus two screening days a week. These adults 
contained the HB9:GFP transgenic background, and the tanks were selected and 
confirmed to give 100% GFP+ offspring. As will be described later, the compounds 
were applied before MN generation, so the presence of GFP could not be used to pre-




Similarly to previous analyses, we scored 8 axons per embryo from somite 7 caudally, 
the part of the trunk that contains the yolk extension. As the VAST BioImager and its 
associated macros processes maximal intensity projections (MIP) that are easily 
loaded and analysed, we analysed only the visible axons on one side of the spinal 
cord rather than both. An example of an image generated by the VAST BioImager is 
shown below (Figure 5.3) with the axons to be scored marked by a red box.  
 
 
As was noted in Chapter Three, between 27 hpf and 30 hpf, the CaP axon is stalled 
at the horizontal myoseptum, and approximately 25% of the axons have crossed this 
Figure 5.3: An example image generated by the VAST Bioimager.  
A 30 hpf HB9:GFP chodl -/- embryo is shown, with both the brightfield (BF) and 
GFP channels. The axons scored during the drug screen are indicated in the 
red box, with a higher magnification shown below. 
 8 axons are shown, located at somites 7-15 which grow along the yolk 
extension. Asterisked axons are considered to have passed the HM, at the 
expected 25% rate, while the rest are stalled at the HM. Scale bars = 400 µm 





threshold, although the axons are still shorter than their wild-type counterparts. This 
is shown above in Figure 5.3, as the asterisked axons demonstrate the expected 25% 
of axons that pass the horizontal myoseptum. At the same age in wild-type embryos, 
100% of the axons have crossed the HM (Chapter Three). Therefore, we chose to 
use the proportion of axons crossing the HM as our readout for compounds which 
improved axon growth. To threshold what could be considered a hit, we chose 60% 
of axons crossing the HM as a successful treatment. This correlated to an 
improvement by a factor of 2.5 and correlated to an average number of axons crossing 
the HM as an average 5 out of 8 per embryo scored. Because the number of axons 
escaping the HM increases to around 3 or 4 out of 8 by 31hpf, and the secondary 
axons begin to extend at 33 hpf, we limited our imaging window from 27 hpf to 31 hpf. 
This reduced the number of samples that could be screened each day, as our imaging 
was limited to this 4-hour period. However, we found that the speed of loading and 
imaging the embryos allowed us to screen a maximum of 48 wells containing 3 
embryos, a theoretical maximum of 144 embryos per screening afternoon.  
The chosen starting concentration was 10 µM. Since the stock solution of 10mM was 
dissolved in 100% DMSO, the final concentration of compounds contained 0.1% 
DMSO. The library we used showed biological activity in cell culture at 1 µM (Brown 
and Müller, 2015). Previous zebrafish screens have used concentrations between 2 
µM and 1 mM (Baraban, Dinday and Hortopan, 2013; Early et al., 2018), so we chose 
a starting concentration of 10 µM. To prevent developmental delays or potentially 
adverse effects from the compounds, the embryos were added to the drug medium 
after gastrulation, between 6-8 hpf. The embryos were incubated in the drug medium 
until 24 hpf. The treatments were performed in 24-well plates containing 1ml of 
medium and 6 embryos per well. This gave the embryos enough space to develop 
correctly without wasting drug solution. Although most small molecules can penetrate 
the chorion, we dechorionated all embryos before treatment to ensure direct contact 
between the embryo and drug-containing medium. The chorion would also risk 
slowing down the imaging, as any debris present in the loading wells would potentially 
be detected by the VAST’s light gates before being classified as debris and flushed 
from the system. 
Each screening day, the embryos were moved from the 24 well plate to 96 well plates 
containing fresh E3 medium at ~24hpf. To maintain developmental consistency 




treated controls at both the beginning, middle, and end of the plate. This allowed 
internal comparison of the controls to ensure the 25% axon escape was maintained 
throughout the imaging. We treated 6 embryos per condition, but a maximum of 3 
embryos can be loaded in each well of the 96 well plate, so each treatment well was 
repeated too and distributed across the plate in a similar way to the controls. 
After imaging, automated imaging processing was performed (Early et al., 2018). 
These macros generated Maximal Intensity Projections from the Z-stacks and re-tiled 
the images into a single file. The VAST also produces an Excel file containing the 
image numbers and the well location, allowing unblinding after scoring. After 
processing the images in this way, I scored the axons as described above. An 
experimental timeline of the screening protocol is shown below (Figure 5.4). The first 
screen completed using this protocol used a 38-compound open access library, the 
Epigenetic Probes Collection, from SGC. Results from this screen are shown in the 







5.2.2 – Results of a screen using the SGC Epigenetic 
Probes Collection 
 
As previously mentioned, the library chosen for an initial screen using the chodl -/- 
embryos was the 38-compound SGC Epigenetic Probes Collection (Brown and 
Müller, 2015). The initial screen, using 6 embryos per condition, were imaged and 
scored. The data is presented below (Figure 5.5). Although 6 embryos were treated 
with each compound, there were two DMSO wells, and the library itself contained two 
wells of KDOAM25 and IOX2, to acts as internal controls. Thus there were 7 embryos 
for each of those treatments. Of the compounds that passed the 60% threshold, only 
IOX1 reached significance in comparison to the DMSO-treated controls. The IOX1 
group increased by 247% compared to control values and was statistically significant 
(DMSO-treated average HM+ axons= 22.5% ±7.29, n=5. IOX1-treated average HM+ 
axons= 78.13% ±3.13, n= 4. One-way ANOVA **p= 0.0085 with Bonferroni’s multiple 
comparison test, DMSO vs IOX1 **p= 0.0081).  
No other compounds reached statistical significance with the number of axons 
crossing the HM compared to DMSO treatment. This is partially due to attrition of the 
embryos during the experiment. As presented previously (Table 5.2), there are losses 
of embryos during the treatment and imaging due to non-recognition of the embryos 
by the VAST. Compounds which caused the average axon score to cross the 60% 
threshold were re-screened to determine if the results were replicable. This re-
screening was performed even if statistical significance compared to vehicle-treated 
controls was not reached. 
Figure 5.4: Timeline of the experimental protocol used in the drug screen. 
After breeding homozygous chodl -/- mutants, the eggs were dechorionated at 6 
hpf and incubated in compound solution. On the imaging day, embryos are 
moved to a 96-well plate and the location of vehicle-treated controls randomised. 








Figure 5.5: Screening of the SGC Epigenetic Probes in the chodl -/- embryos. 
Numbers on each bar refer to the number of embryos analysed for each treatment.  
The graphs show 2 screening days, with the % of axons that cross the HM. DMSO-
treated controls (white bar) show the expected 25% of axons crossing the HM. The 
60% threshold is marked with a black dashed line. From the initial screen, 
GSK2801, SGC CBP30, and IOX1 passed this screening threshold. IOX1 is 
significantly increased compared to DMSO controls (One-way ANOVA **p= 0.0085 




Several compounds reduced axon outgrowth compared to controls. One compound, 
JQ1 (a bromodomain inhibitor, Filippakopoulos et al., 2010) caused widespread 
developmental delays, and an example of the embryos are shown (Figure 5.6). The 
embryos, although chronologically 30 hpf, grossly resemble 14 hpf embryos, 
demonstrating a large developmental delay. Furthermore, there is evidence of 
necrotic tissue in the head and tail (arrowheads, Figure 5.6). We chose not to rescreen 
JQ1 at a lower concentration to determine if it still resulted in toxicity, as a colleague 
in an adjacent group had previously screened this compound at 1 µM and still 






Figure 5.6: Treatment with JQ1 10 µM causes widespread developmental delays 
and toxicity.  
Lateral views of 30 hpf embryos are shown in the VAST borosilicate tube, rostral 
to the left, dorsal pointed up. The vehicle-treated embryo has not been delayed 
by the addition of DMSO and is at the correct stage of development for a 30 hpf 
embryo. However, treatment of JQ1 causes widespread toxicity and severe 
developmental delay, visible in the shortened body and small head compared to 




5.2.3 – Re-screen of potential hits from the Epigenetic 
Probes Collection 
 
From the initial screening, several compounds were re-screened to determine 
reproducibility of the rescue. We chose those that passed the 60% threshold and 
IOX2, which is structurally related to IOX1. The first compound which passed the 60% 
threshold was GSK2801, an inhibitor of BAZ2A and BAZ2B bromodomains (Chen et 
al., 2016). The second compound was SGC-CBP30, an inhibitor of CBP/p300 
bromodomains (Hay et al., 2014). One compound which missed the 60% threshold, 
UNC0642, had one embryo with 75% of axons passing the HM and one embryo with 
the expected 25% of axons passing the HM, leading to a very large variance, so we 
chose to rescreen this compound as well. Because IOX1 had statistically significant 
rescue and low variance, we screened this compound in a concentration series 
directly, as is described in section 5.2.4. Maintaining the same concentrations and 
conditions, the rescreened compounds did not reach the 60% threshold, except for 
UNC0642 which had a significantly higher proportion of rescued axons. The 






As can be seen from the DMSO-treated embryos, in this experiment, the proportion 
of vehicle control axons which crossed the HM was higher than expected. The mean 
is higher than the expected 25% at 36%, and there are several embryos with scores 
higher than 50%. This was due to an error with the incubator, which had increased 
from 28°c to approximately 29°c. This increase in temperature was enough to 
accelerate the development of the embryos, leading to an increased proportion of 
axons passing the HM. The GSK2801 treatment group was not significantly 
increased, although the value increased by 57% compared to the DMSO value. 
GSK2801 treatment failed to reach the 60% threshold with a mean value of 57.5%. 
After re-screening, the SGC-CBP30 and IOX2 treatment groups were also not 
significantly different compared to the DMSO-treated controls. (DMSO mean HM+ 
Figure 5.7: Rescreening potential hits from the SGC Epigenetic Probes Collection. 
This repeated the treatment of compounds from Figure 5.5 which reached or just 
fell short of the 60% threshold. (Kruskal-Wallis *p= 0.0246 with Dunn’s multiple 
comparison test. DMSO vs SGC-CBP30 n.s., DMSO vs GSK2801 n.s., DMSO vs 




axons= 36.54% ±7.55, n= 13, GSK2801 mean HM+ axons= 57.5% ±6.37, n= 5, SGC-
CBP30 mean HM+ axons= 41.67% ±11.93, n= 6, IOX2 mean HM+ axons= 43.75% 
±6.25, n= 8, UNC0642 mean HM+ axons= 77.08% ±6.783, n= 6. Kruskal-Wallis *p= 
0.0246 with Dunn’s multiple comparison test. DMSO vs SGC-CBP30 n.s., DMSO vs 
GSK2801 n.s., DMSO vs IOX2 n.s., DMSO vs UNC0642 *p= 0.0180. n.s. p>0.999).  
Considering the higher baseline of the control group and the failure of these 
compounds to cross the 60% threshold after re-screening, I chose not to pursue these 
compounds further. Treatment with UNC0642 significantly increases the proportion of 
axons crossing the HM, although with the DMSO-treated group higher than expected, 
the value is 2.1 times larger than the control group rather than the 2.5x ratio that the 
60% threshold was designed for. However, this result led us to further investigate 
UNC0642 as a hit and is further discussed in section 5.2.5.  
 
5.2.4 – Further analysis of IOX1 as an axon growth 
enhancing compound 
 
As it reached significance in the first screening and surpassed the 60% threshold, with 
a mean value of 78.13%, we took IOX1 forward as our first hit in rescuing the chodl -
/- phenotype. Some example images from this first screening round (from Figure 5.5), 








To determine the best concentration of IOX1 treatment to gain the best axon rescue, 
I performed a concentration series. As well as scoring the number of axons which 
passed the HM, I measured the lengths of the CaP axon. The scoring of axon position 
was fast and simple, suitable for assessing a large number of compounds in a library 
but gives binary data of either crossing or stalled axons. Measuring the axon length 
gives more information about the extent of rescue. In DMSO-treated conditions, such 
as in Figure 5.8 above, the axon has crossed the HM, but is still shorter than would 
be observed in wild-type axons. The results of the IOX1 treatment concentration 












Figure 5.8: Representative example images of DMSO and IOX1 treatment from 
the screening presented in Section 5.2.3. Lateral views of the trunk with 28 hpf 
HB9:GFP;chodl -/- embryos are shown, after treatment with either 0.1% DMSO 
or 10 µM IOX1. Asterisked axons pass the horizontal myoseptum, compared to 


















The axon scoring in Figure 5.9 B shows a concentration-dependent increase in the 
proportion of axons crossing the HM with treatment by IOX1. Treatment by 0.1 µM or 
1 µM did not significantly increase the proportion of axons crossing the HM compared 
to DMSO-treated chodl -/- controls. 10 µM IOX1 treatment increased the proportion 
of axons crossing the HM by 133% compared to controls, and 50 µM IOX1 treatment 
increased the percentage of axons crossing the HM by 182% compared to controls. 
(DMSO mean HM+ axons = 29.69% ±5.25, n=8. 0.1µM IOX1 mean HM+ axons = 
23.21% ±6.36, n=7. 1µM IOX1 mean HM+ axons = 36.61% ±4.98, n= 14. 10µM IOX1 
mean HM+ axons = 69.32% ±5.43, n= 11. 50µM IOX1 mean HM+ axons = 83.75% 
±5.29, n= 10. Kruskal-Wallis ****, p<0.0001 with Dunn’s multiple comparison test. 
DMSO vs 0.1 µM IOX1 n.s., p>0.999. DMSO vs 1 µM IOX1 n.s., p p>0.999. DMSO 
vs 10µM IOX1 **, p=0.0074. DMSO vs 50µM IOX1 ***, p=0.0003) 
The increasing drug concentration also correlates to an increasing axon length, with 
a statistically significant difference in axon length at both 10 µM and 50 µM of IOX1 
treatment. The 10 µM IOX1 treatment increases the mean axon length by 35% 
compared to DMSO-treated embryos. For the 50 µm IOX1 group, the CaP axon length 
was increased by 55% over the control values. For all other treatments, the axon 
length is not significantly different from the DMSO-treated group. (1% DMSO mean= 
37.74 µm ±2.35, n= 8. 0.1 µM IOX1 mean= 35.37 µm ±1.56, n= 7. 1 µM IOX1 mean= 
40.63 µm ±2.10, n= 14. 10 µM IOX1 mean= 52.68 µm ±2.05, n= 11. 50 µM IOX1 
Figure 5.9: Treatment by different IOX1 concentrations leads to a dose-
dependent rescue of the chodl -/- axonal phenotype.  
A: Representative images of the lateral view of chodl -/- embryos at ~28 hpf are 
shown. Aberrant axonal branching is shown with white arrowheads. B: The 
proportion of axons passing the HM with treatment by DMSO or IOX1. 10 µM and 
50 µM IOX1 doses lead to a significant increase in the proportion of axons 
crossing the HM. (Kruskal-Wallis ****, p<0.0001 with Dunn’s multiple comparison 
test. DMSO vs 0.1 µM IOX1 n.s., p>0.999. DMSO vs 1 µM IOX1 n.s., p p>0.999, 
DMSO vs 10µM IOX1 **, p=0.0074. DMSO vs 50µM IOX1 ***, p=0.0003) Post-
hoc power= 1.00 C: Axon length for each treatment group. The 10 µM and 50 µM 
IOX1 treatment significantly increases the axon length compared to DMSO-
treated controls (Kruskal-Wallis **** p<0.0001, with Dunn’s multiple comparison 
test. DMSO vs 0.1 µm n.s. p>0.999, DMSO vs 1 µm n.s. p>0.999, DMSO vs 10 
µm IOX1 * p= 0.0444, DMSO vs 50 µm IOX1 *** p= 0.0002). Post-hoc power= 




mean= 59.63 µm ±2.03, n= 10. Kruskal-Wallis **** p<0.0001, with Dunn’s multiple 
comparison test. DMSO vs 0.1 µm n.s. p>0.999, DMSO vs 1 µm n.s. p>0.999, DMSO 
vs 10 µm IOX1 * p= 0.0444, DMSO vs 50 µm IOX1 *** p= 0.0002). 
Although the length improves at the higher treatment doses, qualitative assessment 
of the axons treated with 50 µM IOX1 shows excessive branching compared to the 
10 µM IOX1 group or wild-type axons (asterisked axons). This suggests that although 
the length continues to improve with increased IOX1 dose, this does not necessarily 
mean that the axons are comparative with wild-type axons. Treatment until 100 µM 
was performed, however all embryos died after treatment at 100 µM and so could not 
be imaged. The toxicity came from the IOX1 itself and not the DMSO solvent, as the 
DMSO-treated group survived exposure to the same amount of DMSO (1%).  
 
5.2.5 – Further analysis of the hit compound UNC0642 
 
After re-screening and seeing repeatable rescue of the chodl -/- phenotype by 
UNC0642 treatment (example images shown below, Figure 5.10), we also performed 




Figure 5.10: Representative images of lateral views of trunks of DMSO and 
UNC0642 treatment in chodl -/- embryos at the level of somite 7-11, from the re-






We performed a concentration series, and this time included a 5 µM UNC0642 
treatment group (Figure 5.11). Our rationale was that upon re-screening the 
compounds using the compound library, the compound had been freeze-thawed 
several times, which might have reduced its effective concentration. The 
concentration series was performed using a fresh batch of UNC0642, so we also 












The data in Figure 5.11 suggests that the optimal treatment concentration is 5 µM, in 
terms of scoring the axon position, as it is the only group significantly different to the 
DMSO control group. The percentage of axons crossing the HM increases by 61%. 
(DMSO mean= 48.75% ±5.34, n=20. 0.1 µM UNC0642 mean= 55.56% ±5.56, n= 9. 
1 µM UNC0642 mean= 36.11% ±6.40, n=9. 5 µM UNC0642 mean= 78.57% ±3.57, 
n=7. 10 µM UNC0642 mean= 29.17% ±4.67, n=15. 50 µM UNC0642 mean= 37.5% 
±5.10, n= 4. Kruskal-Wallis **** p<0.0001, with Dunn’s multiple comparison test. 
DMSO vs 5 µM UNC0642 *, p=0.0297). 
However, from analysis of the axon length measurements, there is no significant 
increase in the axon length from any treatment. The 10 µM treatment is significantly 
shorter than the DMSO controls, with a reduction in length by 19.6%. (DMSO mean= 
45.31µm ±1.48, n=20. 0.1 µM UNC0642 mean= 44.93µm ±2.46, n= 9. 1 µM UNC0642 
mean= 39.27 µm ±1.56, n=9. 5 µM UNC0642 mean= 49.73 µm ±2.53, n=7. 10 µM 
UNC0642 mean= 36.43 µm ±1.17, n=15. 50 µM UNC0642 mean= 37.92 µm ±2.05, 
n= 4. Kruskal-Wallis **** p<0.0001, with Dunn’s multiple comparison test. DMSO vs 
10µM UNC0642 ** p=0.0011). 
The interpretation of this data is that although the ratio of axons passing the HM may 
increase, the axon length is not statistically increased. The interpretation of this data 
is that the axon only grows a short distance beyond the HM, so is counted as HM+ 
for scoring but the axon is not significantly longer. This contrasts with the IOX1 
treatment, where there is correlation between the axon crossing score and the axon 
Figure 5.11: The concentration series of UNC0642 in chodl -/- embryos shows 
an increase in axons passing the HM at 5 µM UNC0642 compared to DMSO-
treated chodl -/-, but the average axon length is unchanged. A: Representative 
images of chodl -/- embryos at ~28 hpf treated with either DMSO or different 
concentrations of UNC0642. B: Scoring the proportion of axons crossing the HM 
shows that there is a significant increase with 5 µM UNC0642 treatment 
compared to DMSO-treated controls. (Kruskal-Wallis **** p<0.0001, with Dunn’s 
multiple comparison test. DMSO vs 5 µM UNC0642 *, p=0.0297.) Post-hoc 
power= 0.994. C: The average axon length is unchanged between DMSO and 
UNC0642 treatment, except for 10 µM UNC0642 which is significantly shorter 
than the DMSO group. (Kruskal-Wallis **** p<0.0001, with Dunn’s multiple 
comparison test. DMSO vs 10µM UNC0642 ** p=0.0011.) Post-hoc power= 




length measurements. This suggests a potential pitfall in our screening method to find 
growth-enhancing compounds, and this will be further discussed in the Discussion & 
Conclusions section of this chapter.  
The variability of results seen with UNC0642 might have several explanations. Firstly, 
the lack of statistical improvement with UNC0642 in Figure 5.11 may be due to an 
incubator issue, where the temperature was increased from 28° to 29. This may have 
accelerated the development of the embryos by a few hours, enough to affect the 
axonal growth. This is likely as the DMSO vehicle control has a mean score of 48.75% 
of axons passing the HM, compared to the 25% normally observed in other parts of 
this thesis and the original screening in Figure 5.5. As well as heightening the control 
baseline for comparison to the UNC0642 treatment groups, there is no way to know 
if this developmental acceleration may also have affected the mechanism of the drug 
itself, reducing its efficiency. 
Re-examining the data from the re-screen of compounds (Figure 5.7), its statistical 
post-hoc power was only 0.58, below the recommended 0.8. This suggests that this 
re-screen was under-powered, and so the statistically significant finding of the 
UNC0642 rescuing the phenotype may not be true. This original statistical 
significance from the re-screen may be an artefact from an underpowered experiment 
that needed more samples. This might also be why repeated treatments in the 
concentration series (Figure 5.11) were not statistically significant. The concentration 
series is sufficiently powered for both the axon scoring and the axon lengths, at 0.994 





5.2.6 – Delaying treatment by both IOX1 and UNC0642 
until after motoneuron differentiation abolishes axonal 
rescue in chodl -/- embryos 
 
The drug treatment window in the previous section was from 6 hpf until approximately 




in the 96-well plate. The treatment starting at 6 hpf has previously been used in drug 
treatments, including compounds to ameliorate effects of Smn knockdown (Wishart 
et al., 2014). This precedes the differentiation of motor neurons, which begins at 
approximately 9 hpf, and axonal growth, which begins at approximately 16 hpf (Myers, 
Eisen and Westerfield, 1986). To determine if the drug hits can rescue the axonal 
phenotype after motor neuron differentiation, I treated chodl -/- embryos at 16 hpf with 








By delaying the drug treatment to a timepoint after motor neuron differentiation to 
the beginning of axon growth, the phenotype rescue is lost for both IOX1 and 
UNC0642 (Figure 5.13). The IOX1 group mean increases by 29% from the DMSO 
value to 44.44%, and the UNC0642 group mean increases by 23% to 41.96%. In 
comparison, the initial screening in Section 5.2.2 caused the proportion of IOX1-
treated axons crossing the HM to increase by 247%. This suggests that the 
mechanism of both compounds to rescue the chodl -/- phenotype occurs before or 
during motor neuron differentiation, and not during the axon growth stage of 16 – 24 
hpf. In other words, the effect of the compounds in rescuing the axonal growth is not 
targeting the active growth or extension stages but affects gene expression in the 
motor neuron previous to that, which offers insight into potential therapeutic timing.  
In human SMA patients, the motor axon outgrowth is generally normal, as the axons 
reach the NMJ. However, as discussed in Chapter Four, there are some deficits in 
the NMJ occupancy even in fetal stages of SMA patients (Martinez-Hernandez et al., 
2013.). There is also evidence of neurofilament accumulation and blebbing of the 
motor axon (Kariya et al., 2008). This suggests that although the growth is normal, 
the axons are unable to form a stable connection with the post-synaptic part of the 
NMJ, and this is the starting point for the axonal degeneration observed in SMA. 
Because the onset of potentially pathological changes are so early, this necessitates 
an early intervention window, potentially with pre-natal testing for SMA to identify 
affected foetuses in utero. The zebrafish data suggests that a very early therapeutic 
Figure 5.12: Drug treatment from 16 hpf by IOX1 and UNC0642 abolished the 
rescue of the chodl -/- phenotype seen when treatment began at 6 hpf. 
A: Example images of DMSO, IOX1, and UNC0642 treated chodl -/- embryos at 
~29hpf are shown. B: There is no significant difference in scores between any 
treatment groups for the proportion of axons passing the HM. (0.1% DMSO mean= 
33.84% ±4.39, n= 17. 10 µM IOX1 mean= 44.44% ±5.15, n= 9. 5 µM UNC0642 
mean= 41.96% ±5.65, n= 14. One-way ANOVA n.s. p=0.306, Bonferroni’s multiple 
comparison test DMSO vs IOX1 n.s, p= 0.523. DMSO vs UNC0642 n.s. p= 0.707) 
C: There is no significant difference in axon length between any treatment groups. 
(0.1% DMSO mean= 43.09 µm ±1.75, n= 17. 10 µM IOX1 mean= 44.96 µm ±3.93, 
n= 9. 5 µM UNC0642 mean= 46.66 µm ±2.27, n= 14. One-way ANOVA n.s. p= 
0.536, Bonferroni’s multiple comparison test DMSO vs IOX1 n.s., p= 1. DMSO vs 





intervention with IOX1 would be required for any beneficial effect, which may not be 
easily performed in humans. However, if the compounds can enhance growth of a 
zebrafish axon which is normally unable to extend, it may be able to stabilise a human 
motor axon which grows but is unstable and prone to degeneration. This is highly 
dependent on the mechanism by which these compounds target, which would need 
further investigation. The potential timeline for therapeutic treatment with compound 




5.3 - Discussion & Conclusions 
 
5.3.1 – Successes and failures of the VAST BioImager 
platform utilising chodl -/- embryos 
 
5.3.1.1 - The VAST BioImager increases throughput rate, but there is also a 
high attrition of embryos during the screen 
 
Using the VAST BioImager to automatically load and imaged compound-treated 
embryos increases the rate of throughput, although it does have a high learning curve 
both in operating the platform and troubleshooting protocols that are outside of its 
expected use. The largest change made for this project was the developmental stage 
of the zebrafish, as Union Biometrica recommends its system for use in larvae from 
48 hpf onwards. As discussed in the Introduction, this is partially due to the pressure 
acting on the larva as it is loaded through the machine, which can tear the larger yolk 
sac in embryos. The detection and repositioning of the larva for imaging also depends 
on pigmentation to match a template image to the live image. Melanocytes proliferate 
during early larval stages, and pigmentation begins from around 24 hpf (Kimmel et 
al., 1995) but the embryo is still mostly transparent before 30 hpf (compare the 
pigmentation in the template images in Section 5.2.1). This reduces the ability of the 
detection program (which uses interruption of a light beam) to ‘see’ younger embryos 
and correctly match them to a template image. As discussed in Section 5.2.1, several 




of embryos, which also reduced the speed per embryo processed by the VAST. 
Overall, a theoretical highest rate of 144 embryos per screening afternoon (48 wells 
with 3 embryos per well) by the VAST is higher than manual mounting and imaging, 
although the attrition rate meant that this theoretical upper limit was never reached. 
The attrition rate described (Table 5.2) leads to a final proportion of usable images at 
54% of the starting population. To mount and image 144 embryos manually would 
take 7 hours 12 minutes, assuming 1 minute to mount each embryo and 2 minutes to 
image each embryo with a confocal. 54% of this time would be 3 hours 53 minutes, 
which would approach the time taken by the VAST to process the embryos. Although 
a relatively low percentage of success, this initial attrition has been consequently 
improved in other screens performed by colleagues (data not shown) to around 75% 
or more. Software updates from Union Biometrica and other minor adjustments have 
been applied by others using the platform, which has improved the proportion of 
embryos that pass through the platform without damage. 
 
5.3.1.2 - The timescale of treatment and imaging may have caveats for its 
translation into human patients 
 
The timescale of treatment and then imaging was designed from a number of factors. 
Previous drug treatments in zebrafish screens were applied from 6 hpf onwards 
(Wishart et al., 2014), and the 26-30 hpf imaging window was chosen for its 
phenotypic relevance to the chodl -/- mutant. The 6 hpf stage is after gastrulation, but 
before the differentiation of motor neurons. When IOX1 and UNC0642, our putative 
hits, were applied at a later stage (16 hpf, just before axons exit the spinal cord), but 
the rescue was abolished (Section 5.2.6). This suggests that both compounds rescue 
the chodl -/- phenotype by a mechanism involving gene expression during motor 
neuron differentiation. The mechanism of action cannot be during axon growth stages 
only, as the rescue is completely lost. This may indicate that the axonal outgrowth is 
determined by factors that also influence the differentiation on the motor neuron. For 
translating this finding into humans, zebrafish develop ex utero, and thus are easily 
accessible to drug solution, while humans are not. Pre-natal testing for SMA could be 
applied to high-risk pregnancies to identify SMA patients before birth. Then, a small 
molecule compound which pass the placenta would be an important therapeutic, 
compared with ASOs like nusinersen that must be delivered post-natally via 





5.3.1.3 - The hit rate after screening the Epigenetic Probes Collection was 
2.6% 
 
After screening the 38 compounds in the Epigenetic Probes Collection library, we 
found two putative hits (IOX1 and UNC0642) using the axon passing scores (Section 
5.2.3). However, due to the lack of axon length improvement, the UNC0642 will not 
be taken forward (Section 5.2.5). This leaves us with a hit rate of 1/38, 2.6%. This is 
similar to other library screens in the zebrafish. For example, when screening wild-
type larvae to find compounds which increase oligodendrocyte number, 4/146 
compounds caused a significant increase, a hit rate of 2.7% (Early et al., 2018). In the 
morpholino-based screen against a SOD1 model of ALS, 13/303 morpholinos showed 
significant rescue of the axonal phenotype, a hit rate of 4.29% (Van Hoecke et al., 
2012). 
After validating the screening protocol using the Epigenetic Probes as a pilot library, 
further libraries have been screened in the chodl -/- embryos by colleagues in the 
group. As of writing, approximately 650 compounds have been screened in these 
mutants, using the same experimental settings as described above. From these 
compounds, 6 compounds passed both an initial thresholding and also a rescreening 
round. This translates to to 6/650, or a 0.92% hit rate, similar to several previously 
published zebrafish compound screens. A screen for compounds which alleviate 
seizures found 4 hits out of 320, or 1.25% (Baraban, Dinday and Hortopan, 2013). A 
screen for inhibitors of fin regeneration found 17/2000 compounds, 0.85% (Mathew 
et al., 2007) 
 
 
5.3.1.4 - The use of chodl -/- mutants over smn knockdown streamlined 
screening of the drug library 
 
I chose to use the chondrolectin mutants instead of morpholino-derived smn 
knockdown. Breeding a set of homozygous mutants generates several hundred eggs 
and is less labour intensive than injecting the same number of eggs with morpholino. 




estimate that manual mounting and imaging of 144 embryos would likely take 7 hours, 
if mounting and imaging took 3 minutes per embryo. Although the attrition rate in my 
screen was 54%, this has been improved with changes to the VAST software, to 
around 75% or higher, which gives an advantage over manual processing. 
As discussed in the Introduction, the chodl -/- phenotype is more easily scored 
compared to the smn knockdown phenotype. We also only had access to morpholino 
knockdown of smn, and not the genetic zebrafish models of SMA which exist 
(discussed below). Injection of each egg with a morpholino dose would have greatly 
increased the workload and time needed to screen the compound library, hence our 
choice to use the chodl -/- mutant. However, the main flaw in this screening is that 
chondrolectin is linked to SMA but is not the causative gene. Rather than working 
directly with smn knockdown, we are using a mutant in a gene whose expression is 
dysregulated in SMA models (Bäumer et al., 2009). This means that the screen results 
are already one stage removed from the SMA disease context. However, the purpose 
of this screen was not to directly find compounds to treat SMA. Instead, we hoped to 
triage and thus filter potentially useful axon-stabilising compounds from a larger 
population of compounds, to refine a small number of drug compounds to screen in 
SMA models.   
Although I did not have access to them during my project, there are several zebrafish 
genetic models of SMA, mostly generated by the Beattie group, and recapitulate many 
of the phenotypes seen in the MO knockdown. The first genetic models of SMA in 
zebrafish selected three mutants from an ENU screen, of which had two premature 
stop codons, and one had an amino acid change, all of which resulted in loss of 
function (Boon et al., 2009). These homozygote mutants were able to survive until 
around 2 weeks of age due to maternal deposition of mRNA into the eggs from the 
heterozygote smn +/- females. There is no widespread axonal phenotype observed 
in the smn mutant embryo, unlike in the morpholino knockdown, as the maternally 
deposited mRNA is translated and is sufficient for early development. However, at 
larval stages as the amount of Smn protein decreases, there is an observable change 
to the pre-synaptic puncta. There is no way to separate these mutants from their 
maternally deposited mRNA, as the homozygotes do not survive long enough to 
breed. 
An improved genetic model of SMA in zebrafish was later developed to overcome the 




RFP cassette, under a heat-shock promoter, was introduced into one of the previously 
described smn premature stop mutant lines. A slight leakiness of the SMN2-RFP 
transgene extended the non-heat-shocked larvae lifespan by around 2 days. 
Periodically heat-shocking these larvae allowed their survival until adulthood, to 
generate of breeding adults which would not be able to deposit smn RNA into their 
offspring. These offspring then recapitulated the motor axonal phenotypes observed 
in the morpholino-induced knockdown (Hao et al., 2013).  
Using these genetic models directly for the drug screening or to test the IOX1 
compound would be highly useful, as they directly model the reduction in Smn protein 
and do not require individual injection such as the MO knockdown does. The SMA 
model zebrafish which is zsmn -/-;hsp:hSMN2-RFP also expresses the human SMN2 
gene, so can be used to model treatments which alter the Smn2 splicing, which is an 




5.3.2 – Discussion of the properties and target of the hit 
compound IOX1 
 
IOX1, 5-Carboxy-8-hydroxyquinoline, was identified as an inhibitor of the 2-
oxoglutarate-dependent (2OG) Jumonji C domain (JmjC) (Hopkinson et al., 2013). 
The JmjC family act as histone lysine demethylases (KDMs), modifying the histone 
and chromatin assemblies in the nucleus to activate and silence gene expression. 
Methylation of histones was originally thought to be irreversible due to the large 
thermodynamic cost to remove a stable methyl group. The JmjC-domain proteins can 
demethylate histones by oxygenating the methyl group in a 2-oxoglutarate- and iron- 
dependent mechanism, reducing the stability of the bond. Although its specificity is 
highest in inhibiting JmjC-containing KDMs, IOX1 is also known to inhibit other 2OG 
oxygenases, meaning it has a broad spectrum of activity across multiple targets 
(Hopkinson et al., 2013). A list of targets that IOX1 is able to inhibit, as well as their 
function, is found further in this section as Table 5.3. Other compounds whose targets 




The 2OG oxygenase family has been also been found to catalyse protein 
hydroxylation, which is implicated in multiple cancer models (Ploumakis and 
Coleman, 2015). The hydroxylation of proline and lysine residues by these 
oxygenases is required for collagen biosynthesis. Asparagine and proline 
hydroxylation is also required to activate many hypoxia-inducible factors (Markolovic, 
Wilkins and Schofield, 2015). In all cases, the 2OG-dependent proteins are ferrous 
proteins, and the IOX1 binds with the iron atom in crystal structures of the IOX1-
protein complex. Solved crystal structures of KDM JMJD2A and IOX1 in complex 
demonstrate that IOX1 is able to dislodge the metal ion when it binds, interfering with 









Name of Compound Specific Target 
IOX1 pan-2-OG oxygenases 
IOX2 PHD2 
GSK-J1 JMJD3, UTX, JARID1B 
GSK-LSD1 LSD1 
Table 5.3: Lysine demethylase inhibitors (KDMs) present in the SGC Epigenetic 
Probes Collection and their specific enzymatic targets. (Source:  
https://www.thesgc.org/chemical-probes/epigenetics) 
Figure 5.13: The chemical structure of IOX1 and IOX2, two structurally related 






IOX1 and IOX2 share structural similarity (Figure 5.13) and have some overlapping 
targets, but IOX2 was unable to rescue the chodl -/- axon phenotype. Although both 
compounds target 2OG oxygenases, IOX2 binds specifically to PHD2. PHD2 (Prolyl 
hydroxylase 2) catalyses the degradation of hypoxia-inducible transcription factor α 
(HIF-α) by ubiquitination/proteosomal degradation and acts as an oxygen sensor as 
it requires oxygen as a cofactor. Inhibition of PHD2 therefore leads to an increased 
hypoxic response, and transcription of genes to mitigate low oxygen levels in the cell 
(Chowdhury et al., 2013). Given the lack of rescue with IOX2 treatment, it seems that 
inhibiting PHD2, and thus reducing the degradation of HIF-α has no effect in axon 
growth. 
The other KDM inhibitors in the SGC probe library are shown above (Table 5.3). 
Neither GSK-J1 or GSK-LSD1 showed rescue of the chodl -/- axonal phenotype. 
Compared to the average score of 26.79% ±5.74 (n=7) by the DMSO control group, 
GSK-J1 showed a very similar score of 25% ±7.22 (n=3), as did the GSK-LSD1 
treatment, with a score of 33.33% ±11.02 (n=3). Because of the lack of rescue by 
these compounds, we can also eliminate their targets as the mechanism by which 
IOX1 rescues the chodl -/- phenotype. As well as LSD1, UTX, JARID1B, this also 
eliminates the JmjC-domain protein JMJD3. It is known that IOX1 inhibits JMJD3 with 
an IC50 of 0.14 µM and UTX with an IC50 of 1.1 µM (Hopkinson et al., 2013). After 
eliminating these potential targets that IOX1 is able to bind, the potential mechanism 
by which IOX1 increases axon growth in the chodl -/- embryo must be one of the 





As for the mechanism by which IOX1 rescues the chodl -/- phenotype, the best way 
to determine this would be to compare the gene expression profile of IOX1-treated 
and DMSO-treated chodl -/- embryos and identify differentially-expressed genes. 
Confirmation of the gene expression change responsible for the axon rescue could 
be confirmed using either morpholino or mRNA injection to knock down or over-
express these genes. In the chodl -/- embryo, analysis of the axons for phenotypic 
rescue would be sought, while in wild-type embryos we would expect to phenocopy 



















JMJD2A KDM 0.2  
JMJD2C KDM 0.6  
JMJD2D KDM 0.2  
JMJD2E KDM 0.3  
JMJD1A KDM 0.17  
JMJD3 KDM 0.14 GSK-J1 – does not rescue 
UTX KDM 1.1 GSK-J1 – does not rescue 
FBXL11 KDM 15.4  
PHF8 KDM 15  
JARID1C KDM 25  
Table 5.4: IOX1 is a pan-2-OG oxygenase inhibitor. Tabulated are the targets of 
IOX1, their catalytic function, and the IC50 of IOX1 inhibition, as well as any other 
compounds from the SGC library which also inhibit the same target. (Taken from 




5.3.3 – Outlook for future experiments 
5.3.3.1 - Testing hit compounds in SMA disease models 
 
From these results, there are several further avenues of investigation that could be 
pursued in future projects. Colleagues in the group are continuing the screen in chodl 
-/- embryos using other commercially-available libraries. Rescue of SMA models, 
such as smn knockdown in zebrafish, are then key to determine if the hit compounds 
can rescue the disease model. The axonal phenotype of the smn knockdown in 
zebrafish is more variable than the chodl -/- embryo, with missing truncated, and 
branched axons (McWhorter et al., 2003; Sleigh et al., 2014; Wishart et al., 2014), of 
which there are several ways to quantify the severity of the phenotype. However, even 
partial rescue of one aspect could be measured and represents a potentially useful 
treatment. IOX1 treatment was performed in smn morphant zebrafish but was not able 
to rescue the axonal phenotype (unpublished data, Dr Oprişoreanu). This 
demonstrates that IOX1, although increasing axonal growth in the chodl -/- embryo, 
does not improve the axonal defects caused by smn knockdown. 
These compounds could also be tested in human Induced Pluripotent Stem Cells 
(hIPSCs) to increase both the speed of throughput and the relevance to humans. 
hIPSCs derived from patients and their isogenic controls (i.e. the patient sample 
mutagenised to correct the SMN2 splicing defect) have been generated for SMA (Corti 
et al., 2012). SMA patient-derived IPSCs show similar genetic changes as mouse 
models, such as UBA1 disruption in IPSCs differentiated into motor neurons (Fuller 
et al., 2016), demonstrating similarity and thus physiological relevance. These IPSCs 
can be differentiated into other cell types, including neurons or glia, for analysis of 
expression after treatment with compounds such as IOX1.  
 
5.3.3.2 – Testing the hit compounds for synaptic phenotype rescue as well as 
axonal rescue in the chodl -/- embryos 
 
The hit compounds IOX1 and UNC0642 were selected due to their ability to rescue 
the axon length in the chodl -/- embryos. As has been demonstrated in Chapter Four 
of this thesis, as well as an axonal growth deficit there are widespread synaptic 
defects in the mutant at both embryonic and larval stages. I also suggest that the 




larvae, motor axon branching is almost always associated with synaptic puncta at the 
branching point (data presented in Chapter Four). It would therefore be useful to 
analyse the synapses in chodl -/- mutants treated with IOX1 and determine if the axon 
growth rescue also correlates with a rescue of the synaptic puncta. Changes to the 
neuromuscular junction has also been extensively reviewed in mouse and zebrafish 
models of SMA (Boon et al., 2009; Murray, Talbot and Gillingwater, 2010; Boido and 
Vercelli, 2016; Boyd and Gillingwater, 2016). This means that examination of the 
synapses in compound-treated mutants may again be useful, as stabilising the NMJ 





Chapter Six – Conclusions 
 
6.1 – Summary of novel findings in this thesis 
 
In this thesis, I have demonstrated the cell-autonomous mechanism of chondrolectin 
in motor neurons, which is required for axon growth. The protein level of Chodl is 
tightly regulated, with both insufficiency and over-expression causing axonal growth 
defects. I have also established the functional domains in the protein, determining that 
both the C-type lectin domain and intracellular domain are required for correct protein 
function. To further develop this, I have demonstrated that there is a phosphorylation 
requirement of the intracellular domain to allow the correct function of chondrolectin. 
This synergises with data in our group which shows that chondrolectin binds 
collagen19a1 in the ECM. I also utilised the chodl -/- phenotype as a tool for screening 
small molecule libraries to find axon-stabilising compounds. I have shown that 
chondrolectin is not necessary for adult survival, as chodl -/- fish grow to adulthood. 
However, I have found novel roles for chondrolectin in synapse stabilisation, which 
leads to a change in behavioural responses in the larval zebrafish. The axonal growth 
defects in the chodl -/- zebrafish phenocopy the morphant (Zhong et al., 2012), but 
the stable mutant allowed much deeper investigation into the mechanism of Chodl. 
The novel synaptic role further links chondrolectin dysfunction and SMA, as the NMJ 
is a focal point in SMA pathology and a therapeutic target (Murray, Talbot and 












6.2 - Chondrolectin as a cell-autonomous 
growth molecule in motor axons 
 
6.2.1 – Chondrolectin is required for primary motor axon 
growth and secondary motor axon branching 
 
Our CRISPR/Cas9 mutant, chodl -/-, shows CaP axon stalling at 28 hpf, with 75% of 
the axons stalled at the HM (Chapter Three Section 3.2.3). At larval stages 
 At 33 hpf the secondary motor axons begin to exit the spinal cord and grow along the 
same pathway as the primaries (Menelaou and McLean, 2012). In the chodl -/- 
embryos, 42.2% of the CaP axons escape the HM and extend beyond this choice 
point by 31 hpf (27/64 axons in 16 embryos, Chapter 4, Section 4.2.2). This means 
that at 31 hpf, 57.8% of the axons in the mutants remain stopped at the HM. We did 
not further investigate if these stopped primary axons ever extend beyond the HM. 
Differential labelling of the primary and secondary motor axons could be performed 
by combining the HB9:GFP transgenic line, which labels both primary and secondary 
neurons, with zn5 staining, which is limited to secondary motor neurons (Menelaou 
and Svoboda, 2009). The axons only labelled with GFP and not the GFP/zn-5 co-
label would be primary axons. 
As previously discussed, the secondary motor axons exit the spinal cord at ~33 hpf. 
Quantification of the motor axon lengths at 48 hpf showed that the chodl -/- axons 
were significantly shorter than controls (Chapter Three, Section 3.2.3). The ventral 
nerve bundle catches up to controls by 72 hpf (Chapter Three, Section 3.2.3). The 
secondary motor axons do not require the primaries to path find correctly, but are 
delayed in their extension when the primary motor neurons are ablated (Pike, 
Melancon and Eisen, 1992). Thus, although the ventral nerve bundle catches up to 
wild-types by 72 hpf, and extends along the mid-segmental pathway, there are 
aberrations to the axonal branching. 
Abnormal branching was observed in both 48 hpf and 72 hpf larvae. At 48 hpf, an 
increased number of branches are observed, potentially due to pathfinding errors as 
the secondary axons extend. The aberrant branching is mostly localised to the ventral 
parts of the trunk, where the secondary axons growth cones would be extending. At 




length but the dendritic branching into the myotome is reduced. This is observed 
qualitatively using the HB9:GFP transgenic line (Chapter Three, Section 3.2.3), and 
was confirmed by the lack of synaptic labelling in Chapter Four, Section 4.2.3. The 
lack of axonal branching and loss of synaptic puncta are closely related in the chodl -
/- larvae. We hypothesised that the deficit in axonal branching is a consequence of 
the synaptic defect and performed branching analysis in wild-type larvae in Chapter 
Four, Section 4.2.4 to demonstrate that branchpoints are almost always associated 
with synaptic sites. This suggests that, as is demonstrated in the Xenopus motor 
axons (Javaherian and Cline, 2005), that stabilisation of axonal branches requires 
synaptic puncta. 
 
6.2.2 – Chondrolectin acts cell-autonomously in motor 
neurons 
 
I demonstrated in Chapter Three, Section 3.2.5 that chondrolectin acts cell-
autonomously in zebrafish. By expressing Chodl-FLAG under the HB9 promoter, the 
expression is specific to the motor neurons, shown by FLAG immunoreactivity. 
Injection of the HB9:Chodl-FLAG plasmid into chodl -/- eggs induced mosaic rescue 
of the axonal phenotype, and the stable transgenic line, once established via back-
crossing into the chodl -/- line, fully rescued the axonal length to wild-type axon 
lengths. The complete rescue of the global knockout by re-expression of 
chondrolectin demonstrates that it acts motor neuron-autonomously in zebrafish.  
This consolidates previous work in the localisation of chondrolectin expression, but I 
have shown functional data which demonstrates the mechanism of the protein. In 
zebrafish, in situ hybridisation of chondrolectin shows detectable expression only in 
the trigeminal ganglion and HB9:GFP-expressing motor neurons (Zhong et al., 2012). 
Expression of chondrolectin is detectable from ~12 hpf, after differentiation of motor 
neurons (Lewis and Eisen, 2003), until at least 24 hpf, when wild-type CaP axons 
have grown beyond the horizontal myoseptum choice point. In the mouse, expression 
of chondrolectin is enriched in fast motor neurons (Enjin et al., 2010) as well as muscle 
tissue, brain, and spleen (Weng, Hübner, et al., 2003). 
From my data, I also suggest that the expression level of chondrolectin must be tightly 




embryos causes acute reduction in the axon length, correlated with the FLAG 
reactivity (Chapter Three, Section 3.5.2). This demonstrates that the over-expression 
of chondrolectin in the motor neurons leads to aberrant axon growth, and it is not an 
artefact due to ectopic expression of the protein. Previously published global over-
expression of chondrolectin, using mRNA, caused similar phenotypes of the motor 
axons, but mRNA expression was not cell type-specific, and so ectopic expression of 
chondrolectin could have caused the axonal phenotype (Zhong et al., 2012).Thus, 
both insufficiency and over-expression of chondrolectin in motor neuron results in 
defects in motor axon growth, demonstrating that Chodl protein levels are tightly 
controlled in motor neurons during axon outgrowth. 
 
6.2.3 – Biochemistry of the chondrolectin protein 
 
The acute rescue experiments using Chodl constructs with structural domains deleted 
(Chapter Three, Section 3.2.6) offer new insights about the mechanism of the 
chondrolectin protein. I first demonstrated that removal of either the C-type lectin 
domain or the intracellular domain of chondrolectin abolished the axonal rescue 
observed when the chodl -/- eggs were injected with full-length chondrolectin-FLAG. 
This supports the hypothesis that chondrolectin is a cell-surface protein, interacting 
with other proteins via its extracellular CTLD and intracellular domain. I further 
demonstrated that the intracellular domain requires phosphorylation for its function, 
as mutagenesis of the serine and threonine residues to alanine also abolishes the 
rescue of the chondrolectin mutant zebrafish. Phosphorylation of the ID is necessary 
for signal transduction, although the putative kinase and any intracellular binding 
partners are still unknown. 
This data is further supported by the in vitro data gained by Dr Oprişoreanu in HEK 
cells (unpublished data in the group, shown in Chapter Three Section 3.3.3). The HEK 
cells localise chondrolectin to the plasma membrane, demonstrating that its 
endogenous signal peptide will traffic and cause insertion into the membrane. This is 
different from the mostly perinuclear localisation observed in the earliest studies into 
chondrolectin (Weng et al., 2002), although punctate signalling in the membrane was 
also observed in this staining. In zebrafish, the HB9 promoter causes expression of 
the Chodl-FLAG in both cytoplasm and membrane, and the immunohistochemistry of 




as Zn12 (HNK-1, Nourizadeh-Lillabadi et al., 2010) could be used to confirm that the 
Chodl-FLAG in zebrafish is trafficked to the plasma membrane. However, transfection 
of chondrolectin-FLAG into HEK cells does show highly enriched FLAG 
immunoreactivity in the HEK cell membranes.  
The putative ligand Collagen19a1 was hypothesised to bind Chodl previously to this 
thesis, due to the phenotypic similarity between the stumpy collagen19a1 mutants 
and the chondrolectin morphants. Unpublished data by Dr Zhong discussed in 
Chapter Three, Section 3.3.3 also demonstrated the genetic interactions between the 
two genes, where sub-threshold doses of both morpholinos synergistically generate 
the phenotype. The chondrolectin mutant generated during this thesis phenocopies 
both the chondrolectin morpholino and stumpy, and binding between chondrolectin 
and collagen19a1 was confirmed in binding assays from proteins produced in HEK 
cells. We therefore proposed that Chodl, trafficked to the membrane, projects its C-
type lectin domain onto the surface of the axon, and binds Col19a1 localised in the 
ECM. This is supported both by my in vivo rescue experiments demonstrated in the 
zebrafish (Chapter Three, Section 3.2.6), where deletion of the C-type lectin domain 
abolishes the function, and the HEK cell binding assays, where Col19a1 added as 
supernatant is bound only onto cells transfected with Chodl constructs containing the 
C-type lectin domain (Chapter Three, Section 3.3.3).  
Overall, this data suggests that chondrolectin acts as a cell-signalling molecule on the 
motor axon surface, but there are still further avenues for investigation. There may be 
other proteins complexed with chondrolectin, either in the motor axon cytoplasm or in 
the ECM. The mechanism and kinase which phosphorylates the intracellular domain 
of Chodl is also unknown, as is the order of collagen binding and phosphorylation of 
the intracellular domain. Future experimental approaches are discussed in Section 
6.5 of this chapter. 
 
6.3 – Chondrolectin has a novel role in synapse 
stabilisation 
 
Previous investigation into chondrolectin focused mostly on its role in axonal growth. 
In this thesis, I have proposed that chondrolectin also affects synaptic development, 




motor axons, and a reduction of synaptic puncta number at 3 dpf, affecting the 
secondary motor axons. 
At 28 hpf, the number of pre-synapse clusters at the HM are reduced, labelled with 
SV2 (Chapter Four, Section 4.2.1). This analysis, repeated by a colleague using 
synaptotagmin labelling, also confirms this phenotype, suggesting that the pre-
synapse generally is affected, and it is not limited to SV2 (data not shown, Dr 
Oprişoreanu). The post-synapse was unaffected in my initial images, although using 
different batches of α-AChR antibody and different secondary antibodies, it also 
showed fewer clusters (Chapter Four, Section 4.2.1, Dr Oprişoreanu). This suggests 
a failure of synaptic remodelling, where the pre- and post-synaptic clusters become 
more condensed over time (Panzer et al., 2005). The pre-synaptic defects measured 
in the primary motor axons were independent of axon length, as ‘escapees’ which 
have extended beyond the HM at 31 hpf have persistent pre-synaptic enlargement 
(Chapter Four, Section 4.2.2).  
The 3 dpf phenotype, after the secondary motor axons have branched to innervate 
the myotome, exhibited a large reduction in synaptic puncta number and no changes 
in puncta size in the chodl -/- larvae compared to wild-types (Chapter Four, Section 
4.2.3). This supports the hypothesis that the axonal branches fail to establish and are 
retracted due to a lack of synapse sites that stabilise them. This has previously been 
demonstrated in Xenopus motor axons (Javaherian and Cline, 2005). By analysing 3 
dpf wild-type larvae, I observed that 96.8% of the axonal branchpoints contain pre- 
and post-synaptic sites, suggesting a similar mechanism (Chapter Four, Section 
4.2.4). 
The larval phenotype of reduced puncta number is partially rescued by expression of 
HB9:chodl-FLAG, although this also leads to an enlargement of the average puncta 
size (Chapter Four, Section 4.2.3). However, this partial rescue is sufficient to rescue 
the behavioural phenotype observed in the mutants (Chapter Four, Section 4.2.5). 
Although the distance swum by the larvae to escape a tail touch is unchanged 
between the controls and mutants, there is a turning deficit in the chodl  -/- larvae after 
a head tap. This means that the synapse loss affects the normal actions of the larvae, 
even though the mutants can successfully grow to adulthood without gross 
behavioural abnormalities. It also demonstrates that loss of function of chondrolectin 




have normal survival, the reduction in turning response could weaken its ability to 
survive predation in the wild.  
 
6.4 – The chondrolectin mutant as a drug 
screening tool 
 
In this thesis, I have established a small-molecule screening protocol utilising the 
axonal phenotype in the chodl -/- embryo (Chapter Five, Section 5.2.1). This also 
represents the first use of embryos in the VAST BioImager, which recommends larvae 
of 48 hpf or older (Pardo-Martin et al., 2010). As extensively discussed, chondrolectin 
is a key gene of interest due to both its requirement for motor axon growth and due to 
its link with Spinal Muscular Atrophy. It is down-regulated in spinal cord samples of 
SMA mice (Zhang et al., 2008). It is also mis-spliced in pre-symptomatic time points 
in SMA mice, suggesting that chondrolectin dysfunction may be a contributing factor 
in SMA pathology (Bäumer et al., 2009). In zebrafish, over-expression of 
chondrolectin partially rescues the axonal phenotype observed in zebrafish with 
knocked-down smn (Sleigh et al., 2014). 
I performed a small pilot screen using a 40-compound library, and using both scoring 
and axonal length measurements, I demonstrated that treatment by IOX1 rescues the 
motor axon growth in chodl -/- embryos in a dose-dependent manner (Chapter Five, 
5.2.4). Although the compound does not rescue the axons knockdown of smn (data 
not shown, Dr Oprişoreanu), the screening protocol has now been established for use 
with more compound libraries.  
 
 
6.5 – Future directions 
 
An excellent future direction would be to perform live imaging in the zebrafish, to 
confirm several hypotheses that cannot be confirmed in fixed immunohistochemistry. 




of both synapse stabilisation and axonal growth, and I will discuss some of these 
future directions in the following section. 
Injection of constructs encoding pre-synaptic proteins such as synaptophysin-GFP 
(Meyer and Smith, 2006; Ruthazer, Li and Cline, 2006) and imaging both wild-type 
and mutant larvae would offer insight into the mechanism of axonal branching. Firstly, 
imaging the wild-type would confirm that motor axons preferentially branch from 
synaptic sites. In the chodl -/- larvae, live imaging would allow analysis of 
synaptogenesis dynamics. The data presented in Chapter Four demonstrates 
changes to the pre-synapse in the embryo, and defects in the pre- and post-synapses 
in larvae, but the static preparations do not give functional information about how the 
deficits occur. The dynamics of extension and retraction of the axonal branches in the 
mutants compared to controls are not possible to determine except through live 
imaging. 
We further hypothesise that the filopodial stability is impaired in the motor axons of 
chodl -/- embryos. This may be dependent or independent from the synaptic 
stabilisation of the dendritic branches. Filopodial lifespan is reduced in SMA model 
zebrafish (Hao et al., 2013). If filopodial defects lead to impaired axonal growth, we 
would thus anticipate the filopodia to be impaired in the chodl -/- motor axons. The 
filopodia can be visualised using LifeAct-GFP, a construct which labels F-actin with 
GFP, and was used in Hao et al., 2013 to image the filopodial dynamics. 
Collagen19a1 has been demonstrated to bind the ECM-projected C-type lectin 
domain of chondrolectin, and we have presented evidence that the protein’s 
intracellular domain likely acts through a mechanism involving phosphorylation. 
However, the precise kinase which phosphorylates the intracellular domain is 
unidentified, or any adaptor proteins which also interact with the intracellular domain. 
There may be other ECM ligands besides collagen19a1. With the establishment of 
the chodl -/-;HB9:chodl-FLAG stable transgenic line, the Chodl protein could be 
isolated using the FLAG tag, and bound ligands could be identified by mass 
spectrometry. Further mutagenesis of the intracellular domain to remove each Ser/Thr 
residue individually would also identify how many residues spared would re-establish 
rescue of the phenotype, if any. Also, use of phosphomimetic residues (Dephoure et 
al., 2013) could be used to generate constiutively-active forms of chondrolectin, to 




Finally, the drug screening protocol I designed with the chodl -/- embryos can be 
applied in the future to screen more libraries. Colleagues in the group are continuing 
this work, as well as applying the hit compounds into zebrafish injected with smn 
morpholino. For compounds which rescue the chodl -/- phenotype, independent of the 
effect in zebrafish with smn knockdown, further investigation into the pathways which 
leads to axonal rescue can be performed. By comparing the expression profiles of 
compound-treated and vehicle-treated chodl -/- embryos, the genes differentially 
expressed in the compound-treated embryos can be used to elucidate chondrolectin’s 
potential signalling pathways. With the axonal rescue from hit compound application, 
it would also be worthwhile to stain for synaptic proteins and determine if the synaptic 
phenotype in the chodl -/- embryo is also rescued. If true, this would also support the 
hypothesis that the axonal growth phenotype is caused by a failure in synaptic 
organisation. 
In summary, this thesis demonstrates novel roles for chondrolectin in synapse 
development, and its requirement for correct motor axon growth and branching. The 
novel role in synapse development opens up exciting further investigations, including 
live imaging of synapse formation. I have also performed the first functional assays 
on the mechanism of the protein, showing which domains are necessary for function, 
although the full pathway is yet to be elucidated. Overall, this thesis shows the vital 
role of chondrolectin for correct motor axon development in the zebrafish, which 
potentially has translational prospects into Spinal Muscular Atrophy in humans. 
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